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Abstract
Drug addiction is a ubiquitous phenomenon worldwide that places treme-
ndous financial and psychological burden on societies, families and the in-
dividual. Interestingly, only a small percentage of individuals (∼20%), re-
gardless their drug of choice, go on to develop the compulsive behaviours
that define drug addiction. Clinical studies have shown that there is a
subset of the population with a genetically determined reduction in the
serotonin transporter that may increase vulnerability to developing a va-
riety of psychiatric disorders like depression, anxiety and drug addiction.
To investigate the influence of reduced serotonin transporter function
in the laboratory we studied the effects of MDMA (‘ecstasy’) and heroin
in a genetically altered animal model: the serotonin transporter (SERT)
knockout rat. Homozygous (HOM) animals lack SERT function completely
while heterozygous (HET) have about 50% SERT function compared to
the wild type (WT). Groups of HOM, HET and WT animals completed
MDMA or heroin self-administration experiments. A robust genotype ef-
fect emerged for animals self-administering MDMA; facilitation of MDMA
self-administration was inversely related to SERT function. HOM ani-
mals, without exception, reached acquisition criterion significantly faster
than the HET animals; HET animals then showed higher acquisition rates
compared to the WT animals. In contrast, there were no differences be-
tween the genotypes when animals self-administered heroin. To inves-
tigate the driving force behind facilitated MDMA self-administration in
animals with reduced SERT function locomotor activity and conditioned
taste aversion experiments were undertaken. In contrast to the drug self-
administration experiments, MDMA induced hyperactivity was positively
related to SERT function. Thus, it was significantly reduced in HOM and
HET animals compared to the WT. Again, heroin treatment did not pro-
duce differences in locomotion between the genotypes. MDMA induced
conditioned taste aversion revealed only a main effect of dose with robust
conditioned taste aversion for both drug doses, although a trend indicated
that HOM animals may have heightened sensitivity to MDMA. However,
heroin treatment failed to produce a conditioned taste aversion effect in
any of the groups regardless of dose. Beyond the aforementioned be-
havioural experiments striatal brain tissue from the animals that had pre-
viously self-administered MDMA or heroin was analysed via quantitative
reverse transcription polymerase chain reaction; five targets were evalu-
ated to quantify drug induced changes in brain derived neurotrophic fac-
tor gene expression (BDNF). Several BDNF isoforms (total BDNF, BDNF
III and BDNF IV) were significantly increased in animals that had self-
administered MDMA; this effect was true across HOM, HET and WT sub-
jects. Comparatively, animals that had self-administered heroin did not
show a difference in BDNF expression compared to untreated control ani-
mals.
This suite of experiments provides insight into the influence of a com-
promised serotonergic system on the development of drug addiction. That
is, while reduced SERT function does not appear to augment the addictive
properties of drugs like heroin there is reason to suspect that it does con-
fer additional susceptibility to developing addiction to drugs like MDMA,
highlighting the hypothesis that different classes of addictive substances
act through different neurobiological pathways.
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Chapter 1
General Introduction
1.1 Drug Addiction
When you can stop you don’t want to, and when you want to
stop, you can’t... -Luke Davies
The development of addictive behaviours in response to psychoac-
tive drugs is characterised by a variety of behavioural and physiological
changes in the individual. In basic terms drug addiction is a chronic re-
lapsing psychiatric disorder. It is important to note that many individuals
who use drugs of abuse do not go on to develop the compulsive behaviour
that defines drug addiction. However, there is a subset of individuals
who make that “transition to addiction” and manifest the constellation
of symptoms set forth in the Diagnostic and Statistical Manual of Mental Dis-
orders (DSM-5) (American Psychiatric Association, 2013). A better under-
standing of this group of individuals represents an incredibly important
area of research that will serve as a foundation for developing future cu-
rative treatments for humans.
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2 CHAPTER 1. GENERAL INTRODUCTION
1.1.1 Costs Associated with Drug Addiction
Drug addiction represents a considerable burden for families, society and
the individual. In addition to an impact on welfare, like disruptions in
family relationships and vocational pursuits, drug addiction comes at a
high financial cost to those affected by it. According to the World Drug
Report 2014, of the 243 million people (adults) who use drugs of abuse,
about 11% or 27 million represent “addicts”. And of these problem drug
users only one in six seeks out treatment each year. However, a change
in treatment demand is emerging worldwide; for example, the number of
individuals seeking treatment for cannabis use is on the rise around the
world. Whereas effective opioid treatment is being sought in Eastern Eu-
rope and parts of Asia and treatment demand for amphetamine like stim-
ulant use is increasing in Oceania. Despite these changes there remains a
vast number of individuals who do not receive the help that they need and
consequently there is considerable drug related loss of life. Loss of life, pri-
marily due to drug overdose, numbers approximately 183,000 individuals
annually. And while often left unreported there exists a group of individ-
uals who survives one or more drug overdoses and is left with lifelong
disability and compromised health (United Nations Office on Drugs and
Crime, 2014). Premature death and reduced quality of life due to disability
where evaluated in a 2013 study that assessed the global disease burden
associated with drug addiction. They found that, worldwide, drug ad-
diction led to a loss of 3.6 million years of life due to premature death
(Degenhardt et al., 2013). Additionally, 16.4 million years of life were lost
due to disability associated with drug addiction.
In New Zealand alone the welfare costs, including loss of life due to
premature death and reduced quality of life associated with disability, to-
tal NZD $2 billion with total costs of drug addiction reaching NZD $6.5
billion annually. This figure is staggering as it approximates the gross do-
mestic product of the New Zealand agricultural or finance industry (NZD
$6.7 and NZD $ 7.0 billion, respectively) (Slack, Nana, Webster, Stokes, &
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Wu, 2009).
1.1.2 Terminology
The term “drug addiction” is specified as substance use disorder in the
DSM-5 (formerly, substance dependence). For purposes of clarity, through-
out the whole of this thesis, I will use the term “addiction” or “drug addic-
tion” to refer to the symptoms that are defined as substance use disorder
by the DSM-5. While many researchers argue the appropriateness and ac-
curacy of these terms I will use “addiction” or “drug addiction” because
they are less likely to be confused with physical dependence that can result
when individuals use drugs of abuse (Koob & Volkow, 2010). Importantly,
physical dependence is not necessarily a hallmark of drug addiction and
therefore I will avoid using the word “dependence” in this document.
1.1.3 Behavioural Changes that Define Drug Addiction
The behavioural changes that accompany drug addiction, according to the
DSM-5, include difficulty in limiting use of the drug. That is, even a well-
intentioned individual tends to fail when attempts are made to decrease
drug intake. This, in turn, leads an individual to use the substance for
longer periods of time than he/she originally intended. Over time individ-
uals are increasingly motivated to obtain the drug and put in a consider-
able amount of time and financial resources in order to obtain it. This moti-
vation is manifested when addicted individuals prioritise his/her pursuit
of the drug while sacrificing important personal and vocational respon-
sibilities. Additionally, individuals continue to use the drug despite neg-
ative consequences; therefore, even if an individual knows that his/her
drug use is detrimental to mental and physical health this information is
not sufficient to deter the individual from using. While the definition of
drug addiction has evolved over many years tolerance and withdrawal
remain an important part of how this disorder is characterised. Tolerance
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develops over time as an individual consumes increasing amounts of the
drug and whereby the subjective effects begin to wane. Withdrawal oc-
curs when an individual ceases to take the drug and experiences a cas-
cade of deleterious effects that differ depending on the type of substance
taken (American Psychiatric Association, 2013; West, 1994). In addition,
even though relapse is not part of the aforementioned formal definition
is it perhaps the most serious issue surrounding drug addiction. That is,
individuals are at high risk for relapse even after relatively long periods,
months or years, of abstinence from the drug (Deroche-Gamonet & Piazza,
2010; Koob, Lloyd, & Mason, 2009; Milton & Everitt, 2012).
1.1.4 Neurochemical Effects that Coincide with Behavioural
Changes
While drug addiction can technically be defined in terms of behavioural
changes there exists an equally important series of neurochemical effects
that occur as an individual develops addictive behaviour (Nestler, 2001).
The neurochemical basis of addiction is contingent upon activation of the
mesolimbic dopamine system; dopamine release is generally thought to
underlie the rewarding properties of drugs of abuse (Badiani, Belin, Ep-
stein, Calu, & Shaham, 2011; Haber & Knutson, 2010; Koob et al., 2009).
The mesolimbic dopamine system constitutes a major projection that
connects the midbrain with the more rostral limbic and forebrain struc-
tures. Projections from the ventral tegmental area (midbrain) terminate
in the nucleus accumbens, frontal cortex, amygdala and hippocampus (all
structures located in the forebrain) (see Figure 1.1 (Kruk & Pycock, 1993b))
(Haber & Knutson, 2010; Iversen & Iversen, 2007; Koob, Sanna, & Bloom,
1998; Koob & Volkow, 2010; Meyer, 2005).
Consequently, when dopaminergic neurons in the ventral tegmental
area are stimulated dopamine is released in the target structures (e.g. nu-
cleus accumbens) (Pettit & Justice, 1989). The ventral tegmental bundle
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Figure 1.1: The dopaminergic system.
and its forebrain projections represent an important component of the re-
ward system. Early work investigating the mechanisms of reward demon-
strated that rats implanted with electrodes actively pressed a lever to de-
liver electrical current directly into this portion of the brain (Crow, 1972;
Olds & Milner, 1954). These seminal studies and a plethora of additional
research since then have supported the overarching idea that dopamine
represents a part of the chemical substrate that underlies the initial re-
sponse to drugs of abuse (Everitt et al., 2008; Koob et al., 1998; Koob &
Volkow, 2010; Nestler, 1996, 2001).
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While a dopamine-mediated “reward circuit” is widely accepted re-
cent research has demonstrated the integral role of the neurotransmitter
serotonin (5-HT) in reward and the development and maintenance of ad-
dictive behaviours (Hayes & Greenshaw, 2011; Kirby, Zeeb, & Winstanley,
2011; Mueller & Homberg, 2015; Nonkes, Van Bussel, Verheij, & Homberg,
2011; Sora et al., 2001).
The serotonergic system originates in the rostral and caudal raphe nu-
clei located in the midbrain and brainstem, respectively. The rostral bun-
dle comprises the caudal linear nucleus as well as the dorsal and me-
dian raphe nuclei. These neurons send projections to the limbic system as
well as a variety of forebrain structures like the nucleus accumbens, ven-
tral tegmental area, hippocampus, amygdala and prefrontal cortex. The
caudal bundle includes the magnus, pallidus and obscurus raphe nuclei
and sends projections to the spinal cord (see Figure 1.2 (Kruk & Pycock,
1993a)) (Gaspar & Lillesaar, 2012; Hayes & Greenshaw, 2011; Hornung,
2003; Kranz, Kasper, & Lanzenberger, 2010; Tork, 1990).
To date there is a multitude of studies investigating the disrupted sero-
tonergic neurotransmission that accompanies psychiatric disorders like
depression or anxiety (Hayes & Greenshaw, 2011). Disrupted serotonin
neurotransmission is a key factor in the pathology underlying these dis-
orders and they are often treated with pharmaceutical agents that specifi-
cally target serotonergic neurotransmission allowing serotonin additional
time to act on target cells (Reinhold, Mandos, Rickels, & Lohoff, 2011;
Taurines, Gerlach, Warnke, Thome, & Wewetzer, 2011). More recently
focus has shifted to trying to understand the role that serotonin neuro-
transmission plays in the development and maintenance of addictive be-
haviours. Like dopamine, serotonin is an integral player in the neuro-
chemical changes that accompany a diagnosis of drug addiction. For ex-
ample, some drugs of abuse act on the serotonergic system by trigger-
ing release of 5-HT in several brain regions but inhibit 5-HT release when
an individual is experiencing withdrawal; this contributes to the negative
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Figure 1.2: The serotonergic system.
withdrawal symptoms and can lead to escalated intake or relapse (Kirby
et al., 2011; Nonkes et al., 2011).
1.1.5 Transition to Drug Addiction
Interestingly, only a small percentage (15-35%) of individuals who use
drugs of abuse go on to develop the compulsive behaviour that defines
drug addiction (Badiani et al., 2011; Deroche-Gamonet & Piazza, 2010;
United Nations Office on Drugs and Crime, 2014). This suggests that there
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is a difference between individuals who go on to develop addictive be-
haviour and those that do not. Researchers refer to this difference am-
ong drug users as a “transition to addiction”. Drug users begin using the
substance and continue to do so initially because it possesses rewarding
properties; dopaminergic activation in the ventral portions of the striatum
including the nucleus accumbens underlie these enjoyable subjective ex-
periences. Described in terms of behaviour drug use initially can be seen
as an action and the outcome that follows it; therefore, individuals ini-
tially continue taking a drug because they are pursuing the outcome (i.e.
“high”) that follows drug intake. However, after continued use the drug
influences neural plasticity; it does this by first shifting dopaminergic ac-
tivation from the ventral to more dorsal portions of the striatum. Second,
a critical change occurs within the dorsal striatum itself; control mediated
by the dorsomedial striatum is ultimately shifted more laterally within
the structure. These changes underlie the transition from pursuing an out-
come (“high”) to a largely automatic habitual pattern of drug taking. And
this is why individuals diagnosed with drug addiction continue to use the
drug long after the enjoyable subjective experiences have waned due to
the development of tolerance (Everitt, 2014; Everitt et al., 2008). Addition-
ally, while initial drug use is associated with transient changes in synaptic
plasticity (long term depression) in the nucleus accumbens these changes
become permanent as drug use increases. This inflexibility in the neural
connections in the dopaminergic pathways may underlie the “transition to
addiction” (Kasanetz et al., 2010). These neural changes represent an inte-
gral component in the “transition to addiction” and constitute the biolog-
ical substrate that underlies the behavioural changes seen in individuals
given a diagnosis of drug addiction (Ahmed, 1998).
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1.1.6 Theories of Drug Addiction
Theories of drug addiction posit that changes in drug effects may explain
why some individuals take drugs compulsively. Some research suggests
that addictive behaviour is driven by changes in the effect of drugs; that
is, compulsive drug use is driven by the rewarding properties of drugs of
abuse. Additional research posits that individuals continue to take drugs
in order to avoid the negative consequences of withdrawal. That is, indi-
viduals may develop increased sensitivity to either the positive properties
of drugs of abuse or to the negative effects and this sensitivity underlies
compulsive drug taking behaviour.
The incentive-sensitisation theory put forth by Robinson and Berridge
(1993) proposes that compulsive drug intake produces a sensitised neural
“reward” network where the reinforcing effects of the drug are patholog-
ically enhanced. This sensitisation enhances the salience of drug related
stimuli making them more attractive and increasing the likelihood that the
user will consume the drug. With a heightened drug effect and increas-
ingly powerful salience of drug related stimuli drug taking behaviour is
increasingly reinforced (Robinson & Berridge, 1993, 2001). While there is
compelling support for incentive-sensitisation it is important to acknowl-
edge research findings from other groups that have investigated sensiti-
sation to drugs of abuse. In both conditioned place preference and drug
self-administration paradigms researchers have demonstrated a dissocia-
tion between sensitisation and subsequent addictive behaviours (Ahmed,
2010; Brown, Short, & Lawrence, 2010).
In contrast to incentive-sensitisation others argue that individuals make
the transition to addiction because the negative consequences associated
with drug withdrawal increase over time. Koob et al. (2009) suggested
that initially drug taking is driven by the desire to experience the positive
subjective effects of the drug (e.g. euphoria). However, after continued
use and concurrent with the transition to drug addiction the negative con-
sequences of withdrawal (e.g. anxiety, irritability and dysphoria) increase
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driving an escalation in drug taking. This view is supported by the fact
that individuals take increasing amounts of drug over time and exhibit
neurobiological changes as drug intake continues (Koob, 1992; Koob et al.,
2009, 1998).
Both explanations suggest that there are inherent differences within in-
dividuals themselves. That is, because only a small percentage of indi-
viduals who use drugs of abuse go on to develop addictive behaviours
this has led researchers to ask the question: Are there genetic differences
amongst individuals that might represent risk factors in the development
of drug addiction? (Deroche-Gamonet & Piazza, 2010). Studies in ani-
mals demonstrate similar patterns; that is, in groups of rats only a small
percentage (∼20%) develop addictive like behaviours (Deroche-Gamonet,
Belin, & Piazza, 2004; Pelloux, Dilleen, Economidou, Theobald, & Everitt,
2012). Historical research has focused on understanding addiction in light
of its influences on drug effects as well as understanding the role of ge-
netic vulnerability. More recent research has shifted focus to evaluating
the contribution of specific genes in the development of drug addiction.
1.2 Individual Differences
As mentioned above researchers have started to investigate individual ge-
netic differences to understand why some individuals who use a drug of
abuse become addicted while others do not (Deroche-Gamonet & Piazza,
2010; Lesch & Gutknecht, 2005). One type of genetic variation, that is a
polymorphism in the promoter region of the serotonin transporter gene,
has been implicated in the development of drug addiction and may repre-
sent an important point of focus in understanding how genetic variability
influences the probability of developing addictive behaviours (Lesch &
Gutknecht, 2005; Murphy et al., 2001).
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1.2.1 The Serotonin Transporter (SERT)
The serotonin transporter (SERT) is a presynaptic protein located on, am-
ong others, cerebral serotonin neurons. When a serotonergic neuron is
stimulated it releases serotonin into the synaptic cleft where it acts on
the 5-HT receptors of adjacent cells. The vast majority of the serotonin
left in the synapse is taken back up into the presynaptic terminal via the
SERT. The serotonin is then repackaged and can be used at a later time. It
is important to note that serotonin reuptake via the SERT is the primary
mechanism that stops serotonin action in the synapse and therefore plays
a crucial role in overall serotonin neurotransmission in the brain (Kenna
et al., 2012; Lesch et al., 1996). Additionally, the SERT represents a target
for certain anxiolytic and antidepressant medications; they block the SERT
allowing serotonin to remain in the synaptic space where it will continue
to interact with adjacent cells (Kenna et al., 2012; Reinhold et al., 2011; Tau-
rines et al., 2011).
1.2.2 The Serotonin Transporter Gene (SLC64A) and Pro-
moter Region
The gene that codes for the SERT, SLC6A4, located on chromosome 17 in
humans, is regulated by an upstream promoter region. A genetic poly-
morphism or variation in the DNA sequence, in the promoter region, 5-
HTTLPR, influences transcription of the SERT protein. Specifically, the
polymorphism consists of a 44 base pair insertion or deletion which in
turn yields a long (16 base pair element repeats) or short (14 base pair ele-
ment repeats) allele. The long allele promotes standard protein transcrip-
tion and consequently does not disrupt serotonergic neurotransmission in
the brain. Conversely, the short allele results in reduced protein transcrip-
tion which leads to a decreased number of SERT proteins on serotonergic
neurons. With fewer SERT proteins to remove serotonin from the synapse
extracellular levels of serotonin increase (Kenna et al., 2012; Lesch et al.,
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1996; Su et al., 2009; Watanabe et al., 2011).
As humans have two sets of chromosomes, inheriting a single chro-
mosome from each parent, an individual may be homozygous for the l
allele (l/l), homozygous for the s allele (s/s) or heterozygous (l/s). Fol-
lowing the description above individuals who are homozygous for the l
allele (l/l) represent those with undisrupted serotonergic reuptake as they
have the greatest amount of SERT protein (100%) compared to the other
allelic combinations. Conversely, those homozygous for the s allele (s/s)
have reduced serotonergic reuptake because they only have half as much
SERT protein (50%) compared to those with the l/l genotype. Lastly, those
that are heterozygous (l/s) have about 75% of the SERT protein (Kenna et
al., 2012; Lesch et al., 1996; Lesch & Gutknecht, 2005).
To appreciate the impact of the SERT polymorphism it is important to
understand how often it occurs within various population groups. Impor-
tantly, the incidence of the SERT polymorphism varies widely between
ethnic groups. As outlined in a comprehensive meta-analysis the inci-
dence of the L allele is highest in those of European and African descent
(57% and 62%, respectively). Indiviuals of Mexican or Asian descent have
the lowest incidences in populations studied thus far (46% and 27%, re-
spectively) (Cao, Hudziak, & Li, 2013).
1.2.3 Human Studies of the SERT
Study of this functional polymorphism is widespread and covers topics
including its relationship with anxiety and mood disorders as well as its
influence on the development and maintenance of addictive behaviours
(Cao et al., 2013; Caspi et al., 2003; Gorwood, Batel, Ades, Hamon, & Boni,
2000; Kenna et al., 2012; Laucht et al., 2009; Lesch et al., 1996; Merenakk et
al., 2011).
1.2. INDIVIDUAL DIFFERENCES 13
SERT and Depression and Anxiety
Researchers have shown that individuals who have reduced SERT func-
tion (one or two s alleles) tend to show greater susceptibility to developing
depression (Cervilla et al., 2006; Lesch & Gutknecht, 2005; Murphy et al.,
2001).
Other groups have described the relationship between reduced SERT
function and the development of anxiety indicators using a variety of per-
sonality assessments based on the five factor model of personality, Cattels
personality inventory as well as a biosocial model that classifies variation
in temperament. The finding that individuals with one or two copies of
the s allele reported higher levels of anxiety than those homozygous for
the l allele was consistent across these measures (Lesch et al., 1996).
Additionally, research investigating the neurological substrate under-
lying anxiety suggests that there is a relationship between the SERT poly-
morphism and activity in the amygdala. That is, individuals with reduced
SERT function show higher levels of neuronal activity in the amygdala
(where fear is processed) than individuals with intact SERT function. This
over activation of the amygdala occurs only with fearful, not neutral or
positive, stimuli and is considered an abnormal fear response. With that
said individuals with one or two s alleles may be more likely to develop
anxious symptoms due to an overactive amygdala leaving them vulnera-
ble when confronted with fearful environmental stimuli (Hariri et al., 2002;
Heinz et al., 2005).
It is also important to note that many research groups have focused on
illuminating the complex interplay between environmental factors (e.g.
stress) and the SERT polymorphism (Caspi & Moffitt, 2006). For example,
Caspi et al. (2003) investigated the relationship between stress and the de-
velopment of depression. What they found was a significant moderation
by the SERT polymorphism; individuals with reduced SERT function (one
or two copies of the s allele) were more likely to develop depression than
those who were homozygous for the l allele. These findings implicate dis-
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rupted serotonergic neurotransmission, which occurs when an individual
carries one or two s alleles, with the development of depression (Karg,
Burmeister, Shedden, & Sen, 2011; Mann, 1999).
Interestingly, van ijzendoorn et al. (2012) demonstrated that individu-
als who carry the s/s and s/l genotypes are more susceptible to the influ-
ence of negative environments (e.g. one study investigated the relation-
ship between family risk and depression) compared to those with the l/l
genotype. They also determined that individuals who were heterozygous
or homozygous for the s allele were more “open” to the influence that a
positive environment might have (e.g. one study looked at the effects of
responsive parenting on positive development in their children). Whereas
most studies focus on the negative outcomes that may result for those with
reduced SERT function this study introduces the idea that these individu-
als may benefit more readily from positive experiences than those with the
l/l genotype. This suggests that individuals with one or two copies of the
s allele may be, more or less, equally open to the influence of positive and
negative environmental situations (van Ijzendoorn, Belsky, & Bakermans-
Kranenburg, 2012).
SERT and Drug Addiction
As discussed above there is a plethora of research to support the connec-
tion between reduced SERT function and anxiety and mood disorders. In-
terestingly, there is high comorbidity between anxiety and mood disorders
and drug addiction (Grant et al., 2004; Kilpatrick et al., 2003; Regier et al.,
1990). Therefore, there may be a relationship between serotonergic dys-
function (reduced SERT function) and the development of drug addiction.
The following section will briefly outline the relevant research findings
regarding this relationship. Please see Table 1.1 for a list of the studies dis-
cussed. They are divided into two categories: first, studies that provide
support for vulnerability to engage in drug taking behaviour and the s al-
lele and, second, those that implicate the l allele in drug taking behaviour.
1.2. INDIVIDUAL DIFFERENCES 15
Drug(s) Participant Allele Reference
Alcohol, heroin, cocaine Addict s Enoch et al. 2011
Heroin Addict s Gerra et al. 2004
Alcohol, tobacco Healthy s Merenakk et al. 2011
Nicotine Healthy s Nilsson et al. 2009
Alcohol Healthy s Kaufman et al. 2007
Nicotine Healthy s Gerra et al. 2005
Alcohol and illegal drugs Healthy s Gerra et al. 2005
Alcohol Healthy s Herman et al. 2003
Alcohol Healthy s Herman et al. 2005
Alcohol Addict l Ait-Daoud et al. 2009
Alcohol Addict l Kweon et al. 2005
Alcohol Healthy l Laucht et al. 2009
Nicotine Healthy l Ishkawa et al. 1999
Nicotine Healthy l Kremer et al. 2005
Table 1.1: Human Studies of SERT and Drug Addiction.
Interestingly, a portion of these studies demonstrates that reduced SERT
function may confer susceptibility where individuals carrying the s allele
are more likely to engage in drug taking behaviour than those that carry
the l allele. However, other studies suggest that the l allele may represent
a risk factor in the development of drug addiction instead of the s allele
(see Table 1.1).
The aforementioned mixed results beg the question: Are there factors
that can account for the discrepancies so that scientists can collate the en-
tire body of research to inform the general topic of the SERT polymor-
phism and its relationship to drug addiction? While this is no straightfor-
ward task I will describe three factors that may contribute to the difficultly
in understanding this complex relationship between genes and behaviour:
differences in ethnicity, allelic variation and the types of drugs of abuse
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that are used.
The ethnicity of an individual may influence his/her susceptibility to
develop addictive behaviours. For example, as mentioned above van Ijzen-
doorn et al. (2012) showed that individuals, across all ethnicities, who
carry the s/s and s/l genotypes are more susceptible to the influence of
negative environments compared to those with the l/l genotype. Interest-
ingly, they also determined that, in a Caucasian sample, individuals who
were homozygous or heterozygous for the s allele were more “open” to
the influence that a positive environment might have compared to Cau-
casian individuals who were homozygous for the l allele (van Ijzendoorn
et al., 2012). This may suggest that the combination of certain ethnicities
with specific environmental conditions could represent a risk factor in the
development of addictive behaviours.
It is also important to note that across geographic regions the percent-
age of individuals carrying any of the allelic combinations (s/s, l/s, l/l)
can vary significantly (Chiao & Blizinsky, 2010). Specifically, Gelernter
at al. (1997) showed that when Japanese and European American sam-
ple groups were compared those carrying the s allele comprised a much
larger percentage (70-80%) of the Japanese group compared to the Euro-
pean American group (40-45%) (Gelernter, Kranzler, & Cubells, 1997). Ad-
ditionally, Noskova et al. (2008) showed that even among an all-European
sample (comprised of Croats, Russians, Tatars and Bashkirs) there were
significant allelic differences among the subgroups. Individuals from the
Croat sample group were more likely to carry the s/s genotype than those
from the other groups (Noskova et al., 2008).
The second major consideration to be addressed is the inherent com-
plexity of human allelic variation. That is, most studies analyse genetic
material from participants and place them into various subgroups: s or
l allele, or the allelic combinations s/s, l/s and l/l. In truth, this is the
simplest way to approach the SERT polymorphism because the variation
extends beyond the s and l alleles. Kenna et al. (2012) made this point
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when discussing the complexity of the polymorphism. They discuss that
the l allele can contain a single nucleotide polymorphism that results in an
LA or an LG allele. These alleles then reflect differences in the transcrip-
tional activity of the gene where the LG has similar functionality to the s
allele (Kenna et al., 2012).
Previous research has described the well-known s and l allelic differ-
ences, that comprise 14 and 16 base pair element repeats (Heils et al., 1996;
Mortensen, Thomassen, Larsen, Whittemore, & Wiborg, 1999). However,
there has been subsequent research to back the identification of three ad-
ditional alleles (18, 19, and 20 base pair element repeats) (Delbruck et al.,
1997; Kunugi et al., 1997; Michaelovsky et al., 1999). Extending these stud-
ies Nakamura et al. (2000) delineated ten novel allelic variants to give a
combined total of fourteen different possible human alleles (Nakamura,
Ueno, Sano, & Tanabe, 2000).
Lastly, there is a wide variety of drugs of abuse and this variability un-
doubtedly complicates the relationship between the SERT polymorphism
and the development of drug addiction. Drugs of abuse can be separated
into different groups depending on their mechanism of action. For exam-
ple, when drugs like alcohol or heroin are taken they indirectly stimulate
dopamine release whereas stimulant drugs directly target the dopamin-
ergic transporter which prolongs dopamine action. Conversely, “ecstasy”
(MDMA) has a different mechanism of action; MDMA blocks the SERT
and moves 5-HT out of the presynaptic neuron by reverse transport in ad-
dition to acting on the dopamine transporter. Therefore, depending on
a variety of individual differences as well as different drug mechanisms
the relationship between the SERT polymorphism and drug addiction is
highly complex (Green, Mechan, Elliott, O’Shea, & Colado, 2003; Kreek et
al., 2012).
Taken together these studies outline some of the potential issues sur-
rounding the interpretation of research results from human studies inves-
tigating the relationship between the SERT polymorphism and the devel-
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opment of drug addiction. Therefore, to clarify some of these issues it
would be worthwhile to measure SERT activity directly. This is made
possible by using animal models, specifically rats and mice, that have a
targeted reduction in the SERT.
1.3 Modelling Individual Differences in the Lab-
oratory
The SERT polymorphism represents a genetic mutation of great interest to
researchers who are investigating the role of genes in the development of
a variety of psychiatric disorders including addiction to drugs of abuse.
Because the neurochemical and behavioural changes that accompany ad-
dictive behaviours are highly complex it is essential that researchers utilise
a viable and sustainable laboratory model. Like many complex physio-
logical processes these behavioural and neurochemical changes cannot be
successfully studied in vitro or directly in humans due to ethical issues
surrounding use of humans in laboratory research. Therefore, a “middle
ground” of sorts, animal models, is widely used in drug addiction research
to investigate the complex behavioural and neurochemical changes that
accompany drug intake.
1.3.1 Serotonin Transporter Knockout Preclinical Model
Initially, in an effort to study a reduction in the SERT in the laboratory a
serotonin transporter knockout (SERT KO) mouse model was developed
(Lira et al., 2003). These animals were created using a homologous recom-
bination technique yielding homozygotes with 0% SERT function. Their
behavioural phenotype has been characterised with SERT KO mice show-
ing heightened levels of anxious and depressive behaviours when evalu-
ated with a variety of behavioural paradigms (Fox et al., 2007; Lira et al.,
2003). Additionally, several research groups have investigated the impact
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of disrupted SERT function on brain physiology as well as in relation to the
development of drug addiction (Fabre et al., 2000; Fox et al., 2007; Trigo et
al., 2007).
Since then researchers have developed a genetically altered rat model:
the serotonin transporter knockout rat (SERT KO). Smits et al. (2006) in-
vestigated the effectivity of a super mutagen, N-ethyl-N-nitrosourea, or
ENU, to alter the genetic material of Wistar rats. Male Wister rats were
treated once a week for three weeks with ENU and then mated with wild
type females. The resulting offspring were processed via mutation screen-
ing to determine what point mutations had occurred in the animals. Those
that had a mutation of interest were then backcrossed with wild type ani-
mals to effectively isolate the mutation (Smits et al., 2006).
1.3.2 Point Mutation in the SLC6A4 Gene
Of the various point mutations that resulted, six of these produced a pre-
mature stop codon leading to a truncated polypeptide chain. The prema-
ture stop codon is identified by a specific biological process that breaks
down the messenger RNA and subsequently no protein is formed (Smits
et al., 2006).
One of the mutations produced a premature stop codon in the gene
that codes for the serotonin transporter protein, SLC6A4. In Wild type
(SERT+/+) animals neither allele contains a premature stop codon and this
promotes standard protein synthesis (100% SERT protein). Conversely,
both alleles in homozygous (SERT-/-) animals contain a premature stop
codon and lead to no protein synthesis (0% SERT protein). Lastly, het-
erozygous (SERT+/-) animals have a premature stop codon in one of the
two alleles; this combination promotes reduced protein synthesis (50%
SERT protein) (Homberg et al., 2007).
It is important to note that these rat genotypes do not match those of
humans exactly. To our knowledge there are no humans who lack the
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SERT completely but for those who are homozygous for the s allele they
would be similar to rats that are heterozygous as both of these groups
have 50% of the standard amount of SERT protein. Of course, the humans
with the allelic combination l/l and the wild type rats represent those with
standard serotonergic neurotransmission and can serve as an important
comparison to those with reduced SERT function.
As the SERT has been implicated in a variety of psychiatric disorders
the serotonin transporter knockout rat model provides a unique opportu-
nity to systematically study a reduction in the SERT and how it might be
related to the development of drug addiction. This particular model ele-
gantly mimics reduction in the SERT that happens naturally in humans.
Other laboratory models have investigated the relationship between sero-
tonergic function and drug addiction by lesioning serotonergic neurons;
however, these manipulations were conducted in adult animals (Bradbury
& Schenk, 2011). The SERT KO model animals, like humans with reduced
SERT function, are born with an altered serotonergic system. This pro-
vides a more precise way to evaluate the development of drug addiction
within a system that has been compromised from conception.
1.4 Drugs of Abuse
While it is widely accepted that drugs of abuse activate the mesolimbic
dopamine system the specific mechanism of action as well as additional
neurotransmitter systems involved can differ substantially between dis-
parate classes of drugs (see Table 1.2 for a summary of the fundamental
differences) (Badiani et al., 2011). To highlight the differential mechanisms
of drug action the following sections will compare and contrast the psy-
chostimulant, 3,4-methylenedioxymethamphetamine (MDMA) and the opi-
oid, heroin.
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Differential Aspects of Psychostimulants (PS) and Opioids (OP)
Impulsivity Greater impulse control and cognitive flexibility
deficits for PS vs OP
References Ersche et al. 2005, 2006; Winstanley et al. 2009; McNa-
mara et al. 2010
Mechanism of Action PS target monoamine transporters; OP target µ-opioid
receptors
References Harris & Baldessarini, 1973; Gyling & Wang, 1983;
Johnson & North, 1992
Neuronal Subpopulations PS and OP stimulate different neuronal populations in
the NAc and mPFC
References Carelli & King, 1993; Chang et al. 1997, 1998
Serotonergic interactions Differential implication of 5-HT receptors in PS and OP
addiction
References Carboni et al. 1989; Porras et al. 2002, 2002a
Synaptic Plasticity PS withdrawal promotes LTP in the mPFC, OP with-
drawal does not
References Huang et al. 2007; Van den Oever et al. 2008; Lu et al.
2010
Structural Plasticity PS increases dendrite branching and density in NAc,
mPFC neurons, OP decreases dendrite complexity
References Robinson & Kolb, 1997; Robinson & Kolb, 2004
Behavioural Drug Effects PS increases approach avoidance (appetitive/aversive
state), whereas OP increases approach behaviour (ap-
petitive)
References Ettenberg, 2004; Ettenberg & Geist, 1993; Ettenberg et
al. 1999; Geist & Ettenberg, 1997
Compulsive Drug Use PS produce binge drug taking, whereas OP produce a
gradual increase in drug intake
References Pickens & Harris, 1968; Weeks & Collins, 1968
Relapse PS reinstatement is driven by few brain regions (VTA,
dorsal mPFC, NAc core) compared to OP
References McFarland and Laivas, 2001; Rogers and See, 2008
Setting of drug taking Enhanced PS effects in “non-resident” environment,
enhanced OP effects in “home” environment
References Caprioli et al. 2007, 2008, 2009; Spagnolo et al. 2011
Table 1.2: Differential aspects of psychostimulants and opioids.
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1.4.1 3,4-methylenedioxymethamphetamine, MDMA, “Ec-
stasy”
MDMA is a ring substituted synthetic drug that belongs to the ampheta-
mine family; before 1985 it was not officially considered a drug of abuse
nor was it included in the Schedule 1 list of substances that are deemed
illegal. In 1985 the Food and Drug Administration of the United States
decided that MDMA had sufficient abuse liability and therefore should
be given Schedule 1 status. Before this it was a widely held belief that
MDMA was inherently different from other drugs of abuse; that it was
less addictive and therefore less dangerous than other highly addictive
drugs like cocaine (Green et al., 2003; McDowell & Kleber, 1994; Schenk,
2011).
Acute Effects of MDMA
When queried about the acute subjective effects experienced when tak-
ing MDMA users describe an overall feeling of “warmth”, “closeness” or
“connection” to those around them. MDMA has become known for this ef-
fect and was termed “ecstasy”. Interestingly, the Los Angeles drug dealer
who named MDMA “ecstasy” originally wanted to name it “empathy”
but decided against it for fear that people wouldn‘t understand the term.
Regardless, MDMA is now known as “ecstasy” and consistently produces
feelings of warmth and connection in those who use it (McDowell & Kle-
ber, 1994). The positive subjective effects of “closeness” to others is said
to be the result of MDMA‘s action on the serotonergic system. That is,
MDMA blocks the SERT and moves serotonin into the synapse via reverse
transport; the serotonin remains there because the SERT cannot move it
back into the presynaptic cell and therefore prolongs its action on adjacent
cells (Rattray, 1991).
In addition to the empathetic feelings described above MDMA also
produces an overall increase in motor activity as well as increased heart
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rate and blood pressure. Other acute subjective effects of MDMA include
hyperthermia, nausea, chills, bruxism (jaw clenching) and increased sex-
ual arousal although some users report difficulty reaching orgasm (Green
et al., 2003; McDowell & Kleber, 1994; Parrott, 2002; Schenk, 2011). This
constellation of symptoms has been termed “serotonin syndrome” which
is directly precipitated by increased levels of extracellular serotonin that
result when MDMA acts on serotonin neurons. Gillman (1999) argues that
“serotonin syndrome” represents a continuum where symptoms may vary
due to individual differences, drug dose and poly drug use. With increas-
ing serotonin syndrome severity comes increased risk of death (Gillman,
1999).
Chronic Effects of MDMA
With increasing use of MDMA serotonin stores are repeatedly depleted
and this leads to the development of tolerance. Where initially a smaller
amount of drug was needed to induce the positive subjective effects de-
scribed above after repeated use serotonin is depleted and individuals
need more of the drug to achieve the “high” experienced at the onset of
drug use (McDowell & Kleber, 1994).
There is a myriad of research to support the idea that MDMA use
may lead to serotonergic neuronal toxicity (Green et al., 2003; McCann
& Ricaurte, 1993; Parrott, 2002; Schenk, 2011). This toxicity involves the
degradation of serotonin neuron axon terminals and is caused by the in-
creased formation of free radicals. Free radicals are unstable groups of
atoms or molecules that damage biological tissue in humans and animals;
in this case the MDMA facilitates free radical damage in serotonin neu-
rons leading to a downregulation of serotonin in several regions of the
brain (e.g. forebrain and hippocampus) (Colado, O’Shea, Granados, Mur-
ray, & Green, 1997; Fischer, Hatzidimitriou, Wlos, Katz, & Ricaurte, 1995;
Ohearn, Battaglia, Desouza, Kuhar, & Molliver, 1988; Sharkey, McBean, &
Kelly, 1991).
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It is important to note that MDMA induced hyperthermia may influ-
ence the level of neurotoxicity and is considered a hallmark of chronic
MDMA use; with increased hyperthermia comes more extreme changes
in neuroregulation. Malberg and Seiden (1998) investigated the effect of
varying ambient temperature on MDMA induced neurotoxicity and found
that rats exposed to higher temperatures also had more severe deficits in
serotonin levels compared to those that had been exposed to MDMA but
at lower temperatures (Malberg & Seiden, 1998).
To complement and extend studies done in laboratory animals research-
ers have started to investigate the potentially deleterious effects of MDMA
in humans. There are several studies that may support the idea that MD-
MA causes changes in neuroregulation in humans comparable to that seen
in laboratory animals. For example, even though initially MDMA was
seen as a “non-addictive” substance there is now evidence to demonstrate
that some users consume amounts of the drug comparable to what can
cause neurotoxicity in non-human primates (Ricaurte, Delanney, Irwin, &
Langston, 1988). Additionally, Ricaurte et al. (2000) demonstrated that
exposure to MDMA in non-human primates caused a permanent loss in
specific serotonin neuron populations (Ricaurte, Yuan, & McCann, 2000).
Ricaurte et al. (1990) investigated changes in the concentration of 5-
hydroxyindoleeactic acid (5-HIAA), a serotonin metabolite, in cerebro-
spinal fluid (CSF) of human participants. The measurement of 5-HIAA
is often used as a determinant of serotonin neuron function with reduced
function indicating a disruption in serotonin neurotransmission. This study
revealed that the 5-HIAA levels in MDMA users were significantly (26%)
lower than in control participants (Ricaurte, Finnegan, Irwin, & Langston,
1990).
Semple et al. (1999) also investigated MDMA induced effects in hu-
man using single photon emission computed tomography (SPECT) cou-
pled with a SERT ligand that binds to SERT proteins. After binding to
the SERT the ligand emits gamma radiation that is detected by the scan-
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ner. This technique shows the density of SERT proteins as they are iden-
tified by the ligand in various areas of the brain. The study demonstrated
a reduced number of SERT proteins in MDMA users compared to con-
trol participants which may be evidence of a downregulation in serotoner-
gic neurotransmission (Semple, Ebmeier, Glabus, O’Carroll, & Johnstone,
1999). In a similar study McCann et al. (1998) used positron emission to-
mography (PET) coupled with a SERT ligand. They found that MDMA
users had significantly lower densities of SERT proteins compared to con-
trol participants (McCann, Szabo, Scheffel, Dannals, & Ricaurte, 1998). By
investigating the living, human brain these latter two studies suggest that
MDMA can induce long term changes in the serotonergic system.
Taken together these human and non-human primate studies demon-
strate that MDMA may have a damaging effect on the serotonergic system.
This is evidenced by the permanent loss of certain serotonin neuron popu-
lations; in addition, MDMA users show reduced levels of 5-HIAA in CSF
and number of SERT proteins in the brain.
MDMA Mechanism of Action
Like other drugs of abuse MDMA increases activity in the mesolimbic
dopamine pathway. However, it is important to note that MDMA also
influences the serotonergic and noradrenergic neurotransmitter systems.
Specifically, when MDMA is taken up by the body, usually via oral con-
sumption of pills, it binds to the dopamine, serotonin and noradrenaline
transporters (DAT, SERT and NET, respectively) and inhibits them from
removing their respective neurotransmitters from of the synaptic space
and effectively stopping their action. It also stimulates release of these
neurotransmitters into the synapse via reverse transport; that is, the neu-
rotransmitter that is being held in the terminal buttons is transported out
of the cell through its respective transporter. While this leads to an in-
crease in extracellular dopamine, noradrenaline and serotonin MDMA has
the highest affinity for the SERT and therefore influences the serotonergic
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system more so than the other systems (Han & Gu, 2006). This contrast
is readily apparent when considering the mechanism of action in other
drugs of abuse like cocaine and methamphetamine (see Table 1.3) (Han &
Gu, 2006; Rothman & Baumann, 2003).
Drug SERT Affinity NET Affinity DAT Affinity
MDMA 238±13 462±18 1572±59
Cocaine 304±102 779±30 478±25
Methamphetamine 2137±98 48±5.1 114±11
Table 1.3: Relative drug affinity for monoamine transporters given as Ki
(inhibition constant in nM) where lower values reflect greater inhibition.
Drug SERT Reversal NET Reversal DAT Reversal
MDMA 56.6±2.1 77.4±3.4 1572±59
Cocaine >10,000 >10,000 >10,000
Methamphetamine 736± 12.3±0.7 24.5±2.1
Table 1.4: Relative reverse transport for monoamine transporters given as
CG50 (intercellular adhesion molecule-3 level in nM) where lower values
reflect greater neurotransmitter release.
Additionally, SERT blockade and reverse transport of MDMA also dis-
rupt the synthesis of serotonin by inhibiting tryptophan hydroxylase (a
crucial player in serotonin synthesis) (see Table 1.4).
1.4.2 (5α,6α)-7,8-Didehydro-4,5epoxy-17-methylmorphinan-
3,6-diol diacetate (ester), Heroin, diamorphine
Heroin is a powerful narcotic, inducing drowsiness when consumed via
ingestion, smoking or injection. Along with morphine, codeine, oxycodone
and hydrocodone heroin is a member of the opioid family. Opium comes
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from the poppy plant, Papaver somniferum, and has been used for cen-
turies to alleviate pain. In the early 1800s morphine was isolated and
was generously prescribed for the treatment a myriad of health maladies.
Widespread use of morphine during the nineteenth century led to a grow-
ing concern regarding its abuse liability. Then in 1870 the hypodermic nee-
dle was introduced and initially was perceived as a boon in the medical
community because it allowed heightened precision of morphine admin-
istration. Interestingly, just four years later heroin was synthesised from
morphine and its name was coined soon after. It was heralded as a safe,
non-addicting, alternative to morphine. This along with a variety of fac-
tors, including ease of access, over prescription, and injection of opioids,
led to an increase in heroin use, abuse and subsequent addiction. Finally,
in 1970, under the Controlled Substances Act, heroin was added to the list
of Schedule 1 substances due to its high abuse liability, lack of official med-
ical utility and safety (Dhawan et al., 1996; Hughes, Barker, Crawford, &
Jaffe, 1972; Musto, 1991; Strang, Griffiths, & Gossop, 1997).
Acute Effects of Heroin
Intravenous injection is a common method of heroin administration al-
though it can be preceded by subcutaneous injection or uptake through
the nasal mucosa. Upon injection heroin is quickly taken up into the brain
where it is perceived as a “rush-flash”. Heroin leads to the depression of
overall central nervous system function and is perceived as a feeling of
warmth, drowsiness and euphoria. Dangerously, higher doses of heroin
can depress respiration, heart rate and blood pressure to very low levels.
Additionally, the individual may feel abdominal contractions caused by
spasms between the stomach and small intestine; however, the cough re-
flex in inhibited and can lead to aspiration into the lungs if the individual
vomits. Other acute affects coinciding with heroin administration include
injection site vessel and tissue damage, injuries to skeletal muscles that can
occur if the individual is unconscious for long periods of time as well as
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constipation (Kendall & Latter, 2003; Louria, Hensle, & Rose, 1967; Rook,
Huitema, van den Brink, van Ree, & Beijnen, 2006).
Chronic Effects of Heroin
The continued use of heroin can quickly lead to tolerance, that is a larger
amount of the drug is needed to regain a previously experienced “high”.
Additionally, due to the prohibitive cost of heroin, if the individual is not
able to acquire the substance he/she will begin to experience a series of
withdrawal symptoms. Some of these include feelings of anxiety and ir-
ritability in addition to a myriad of somatic symptoms: sweating, mus-
cle aches, fever chills, vomiting, excessive tear production and nasal dis-
charge. Increased heart rate, respiration and body temperature also char-
acterise opioid withdrawal (Louria et al., 1967; Musto, 1991).
It has been proposed that the anhedonia described above is related to
decreased mesolimbic dopamine transmission when there is a gap in drug
taking. Consequently, in an attempt to avoid these negative consequences,
individuals may then relapse and begin taking the drug to regain previ-
ously enhanced dopamine neurotransmission (De Vries & Shippenberg,
2002). A study was undertaken to evaluate dopaminergic and serotoner-
gic markers in human heroin addicts; compared to age matched controls
addicts had slightly lower dopaminergic activity. This suggests that in-
creased levels of dopamine neurotransmission due to heroin intake may
lead to a down regulation of dopamine, as well as its metabolites and
transporter. No differences were detected between controls and addicts
when serotonin levels were evaluated (Kish et al., 2001).
Several research groups have investigated the neural mechanisms that
underlie the changes that occur with prolonged opioid use. For example,
like humans, rats show a suite of withdrawal symptoms upon cessation of
heroin intake; these include weight loss, writhing, paw tremor and teeth
chattering (Dai, Corrigall, Coen, & Kalant, 1989; Doherty & Frantz, 2013).
Other labs have elucidated the specific areas in the brain that change dur-
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ing opioid administration. Nestler et al. (1996) evaluated the role of the
locus coeruleus in opioid withdrawal; chronic opioid administration in-
hibits activity in this brain structure and over time it develops tolerance to
the effects of the drug. Then when the drug is removed activity in the lo-
cus coeruleus greatly increases beyond baseline measures suggesting this
disrupted activation drives opioid withdrawal; this effect was replicated
by the same group in subsequent years (Nestler, 1996, 2004).
Additionally, specific neuroadaptations have been cited as the under-
lying cause to explain why changes in the brain after chronic opioid ad-
ministration are long lasting. Jacobs et al. (2002) evaluated long term gene
expression in two groups of rats: one had been given heroin passively and
the other had self-administered heroin. The animals that were given he-
roin passively did not show any changes in long term gene expression.
Conversely, the animals that had self-administered heroin showed a sig-
nificant decrease in nucleus accumbens long term gene expression sug-
gesting that the repeated behaviour of self-administration is necessary to
initiate changes in gene expression (Jacobs et al., 2002).
Taken together these studies highlight the consequences of chronic he-
roin intake. Animal studies have provided a useful way to evaluate and
understand the chronic effects of heroin. Delineating underlying neural
mechanisms may provide the foundation for developing curative treat-
ments for humans.
Heroin Mechanism of Action
While heroin has a very similar chemical structure to morphine it has
higher lipid solubility and this allows for more efficient, that is faster,
transmission through the blood brain barrier. After entering the brain he-
roin is then converted into a metabolite, 6-monoacetylmorphine, and then
into morphine (Oldendor, Oldendor, Braun, & Hyman, 1972; Pardridge,
2012). It is morphine that then binds to three types of opioid peptide
receptors: mu, delta and kappa (Dhawan et al., 1996). Upon binding to
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mu-opioid receptors morphine triggers a series of events: first, inhibitory
interneurons that influence dopaminergic activity in the mesolimbic “re-
ward” pathway (ventral tegmental area) become hyperpolarised. Second,
hyperpolarised interneurons do not provide inhibition to dopamine neu-
rons and this leads to increased dopaminergic activity (Johnson & North,
1992; Kreek et al., 2012; Nestler, 2004).
It is important to remember that while all drugs of abuse influence the
release of dopamine the mechanisms of action by which they do this vary
greatly between classes of drugs. As outlined in the previous sections
MDMA acts on the serotonin, dopamine and norepinephrine transporters
having the greatest impact on the SERT. Conversely, heroin acts indirectly
to release dopamine through opioid receptors and interneurons that influ-
ence the dopaminergic system.
1.5 Molecular Analysis
Drug addiction, or substance use disorder, is technically defined in terms
of behavioural changes in the individual. However, there is a large body
of research to support the idea that drug addiction facilitates long term
changes in the way the brain functions. As discussed earlier research-
ers have hypothesised that drug addiction represents changes in synaptic
plasticity (i.e. learning); where neural connections in the dopaminergic
system become inflexible leading to habitual drug intake.
While synaptic plasticity encompasses a variety of processes in differ-
ent structures throughout the brain a family of proteins, neurotrophic fac-
tors, play an important role in synaptic plasticity that underlies learning
and memory (Binder & Scharfman, 2004).
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1.5.1 Brain Derived Neurotrophic Factor (BDNF)
One protein of interest is brain derived neurotrophic factor (BDNF); as a
member of the neurotrophic factor family it influences the development
of the brain by promoting survival and growth of neurons. Additionally,
BDNF has been implicated in synaptic transmission, neurogenesis and im-
portantly, the synaptic plasticity that coincides with learning (Binder &
Scharfman, 2004; Conner, Lauterborn, Yan, Gall, & Varon, 1997). Found
widely throughout the central nervous system BDNF binds to the tropom-
yosin related kinase B receptor (trkB).
1.5.2 BDNF and Neuropsychiatric Illness
BDNF plays a crucial role in neurological basis for psychiatric illness like
depression. Research has demonstrated that decreased BDNF levels co-
incide with depression and stress. However, antidepressants have been
shown to be effective in eliminating these effects; over a course of treat-
ment BDNF levels return to normal. While many current antidepressants
work by inhibiting reuptake of serotonin this research suggests that reg-
ulating levels of BDNF is also important for the treatment of depression
(Duman & Monteggia, 2006; Kozisek, Middlemas, & Bylund, 2008).
Whereas decreased levels of BDNF contribute to the neurological chan-
ges associated with depression there is evidence to suggest that increased
BDNF may linked to drug addiction. For example, several research groups
have demonstrated that BDNF messenger RNA (mRNA) levels in rats
were increased in several brain structures (e.g. striatum, nucleus accum-
bens) after a single injection of cocaine (Berglind et al., 2007; Le Foll, Diaz,
& Sokoloff, 2005; Liu et al., 2006). Additional research has demonstrated
that when BDNF levels were increased in rats so did their self-administr-
ation of cocaine (Graham et al., 2007; McGinty, Whitfield, & Berglind, 2010).
Interestingly, in both human and rodent studies researchers have deter-
mined that a reduction in the SERT may influence baseline mRNA levels of
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specific coding regions (isoforms) in the BDNF gene. Specifically, mRNA
levels of isoforms III, IV, VI and IXa were decreased in rats with a reduction
in the SERT (Molteni et al., 2010). The same group then investigated the
effects of the antidepressant, duloxetine, which targets the SERT and the
norepinephrine transporter (NET) prolonging 5-HT and norepinephrine
action in the synapse. After treating HOM and WT animals they found
that mRNA levels for total BDNF were increased in the hippocampus, the
prefrontal cortex and the frontal cortex. They also investigated changes
in specific BDNF isoforms and found that BDNF III mRNA levels were
increased in the hippocampus in both genotypes. Interestingly, they also
saw increased mRNA levels for BDNF transcripts IV and VI in the HOM
animals but not the WT (Calabrese et al., 2010). In addition, studies have
shown that treatment with cocaine can lead to differential mRNA level
changes across isoforms. For example, Liu et al. (2006) demonstrated
that mRNA levels of BDNF isoform IV were significantly increased in the
striatum after cocaine administration. Similarly, research has shown that
cocaine exposure facilitates brain region specific increases in mRNA levels
of BDNF isoforms (e.g. increased BDNF isoform IV in the medial pre-
frontal cortex) (Sadri-Vakili et al., 2010; H. D. Schmidt et al., 2012). These
studies suggest a specific role for BDNF in the neurological changes that
accompany drug addiction. Therefore, investigating changes in BDNF will
add valuable insight into the specific drug induced neuroadaptations that
occur in individuals with altered serotonergic function.
1.6 Brief Outline of Behavioural and Molecular
Experiments
The suite of current experiments seeks to elucidate the complex interac-
tion between genetic risk, a reduction in the serotonin transporter, and the
development of drug addiction. In other words: Is the serotonin trans-
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porter a risk factor in the development of drug addiction? To investigate
this question in the laboratory the first two experiments evaluated the be-
haviour of SERT-/- (HOM), SERT+/- (HET), and SERT+/+(WT) rats when
completing drug self-administration with MDMA and with heroin. The
drug self-administration behavioural paradigm has become the accepted
“gold standard” for studying drug addiction pre-clinically and has many
advantages. Some of these include the ability to monitor the exact amount
of drug intake as animals are implanted with indwelling catheters for drug
delivery. Additionally, drug self-administration allows the investigator to
scrutinise various stages of drug taking behaviour (e.g. maintenance re-
sponding shows how animals regulate drug intake to maintain a specific
level of drug consumption or responding on a progressive ratio sched-
ule can demonstrate motivation to pursue additional infusions of drug).
In modelling various aspects of drug taking behaviour it is a powerful
tool not only for understanding drug addiction but for screening poten-
tial pharmacological treatments (Panlilio & Goldberg, 2007; Richardson &
Roberts, 1996).
Because drug addiction is often comorbid with other psychiatric ill-
nesses like anxiety all animals completed a novelty suppressed feeding
paradigm before they underwent surgery for the drug self-administration
experiments. This test measured latency to begin eating a food pellet set in
the middle of an open field apparatus where longer latency corresponds
with a higher level of anxiety. Drug self-administration behaviour was
then evaluated against latency to begin feeding to determine if a correla-
tion existed (Lira et al., 2003; Olivier et al., 2008).
Following the drug self-administration experiments a set of locomotor
activity experiments were completed. Groups of homozygous (SERT-/-,
HOM), heterozygous (SERT+/-, HET), and wild type (SERT+/+, WT) were
treated with MDMA (or vehicle) and ambulatory counts were measured.
A second identical experiment was conducted with heroin. These exper-
iments provided an opportunity to evaluate the acute effects of multiple
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doses of MDMA and heroin on locomotion. Additionally, locomotor ac-
tivity has been linked to the rewarding properties of drugs of abuse; that
is, dopaminergic transmission within the mesolimbic system has been im-
plicated as a mechanism for both rewarding drug effects and locomotion
(Beninger, 1983; Pijnenburg & van Rossum, 1973). Therefore, these exper-
iments served to identify any differences between the genotypes for both
drugs.
Lastly, to complement the locomotor activity experiments, the poten-
tially negative consequences of MDMA and heroin were evaluated with
two conditioned taste aversion experiments. Conditioned taste aversion
is elicited when a drug, in this case either MDMA or heroin, is paired with
a novel sucrose solution; when given a choice between sucrose and water
animals will cease to drink the sucrose. This reduced intake suggests that
the sucrose solution has been devalued as a reinforcer and consequently
the animal will choose to drink water (Goudie, 1979; Hunt & Amit, 1987).
Therefore, these experiments served to identify any differences between
the genotypes for both drugs.
Finally, in addition to the behavioural experiments outlined above the
striatal brain region of the animals that completed the drug self-adminis-
tration experiments was analysed with quantitative reverse transcription
polymerase chain reaction (qRT-PCR). This technique has become widely
used since its advent 32 years ago and is a relatively straightforward way
to evaluate changes in gene expression. It also allows for a more in depth
understanding of the molecular changes that accompany drug addiction
and serves as a useful complement to the behavioural changes investi-
gated in the drug self-administration experiments described earlier (Bustin,
Benes, Nolan, & Pfaffl, 2005; VanGuilder, Vrana, & Freeman, 2008).
Overall, it is predicted that a reduction in the serotonin transporter will
confer susceptibility to the development of drug addiction as measured
by the suite of experiments described above. Specific predictions for each
experiment are given in the following chapters.
Chapter 2
Novelty Suppressed Feeding and
Drug Self-Administration
2.1 Introduction
Addiction to drugs of abuse is a ubiquitous, worldwide, phenomenon that
places a tremendous financial and psychological burden on society, fam-
ilies and the individual. The DSM-5 defines drug addiction as a series of
behavioural changes: that is, over time individuals have difficulty in lim-
iting their drug use, they are extremely motivated to obtain the drug and
are willing to pursue it even despite negative consequences (American
Psychiatric Association, 2013). Currently, only about 1 in 6 “addicts” seek
help in the clinic and, sadly, many do not achieve a successful outcome
from their treatment regimen. This fact has led research groups to con-
tinue studying the complex interplay of behavioural and neurochemical
changes that accompany drug addiction in an effort to better inform treat-
ment programs for humans (United Nations Office on Drugs and Crime,
2014).
Interestingly, only a small percentage of individuals (∼20%) who use
drugs of abuse actually go on to develop the compulsive behaviours that
define addiction (Deroche-Gamonet & Piazza, 2010). Clinical studies have
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shown that there is a subset of the population with a genetically deter-
mined reduction in the serotonin transporter protein (SERT) that may in-
crease vulnerability for developing psychiatric disorders like anxiety, de-
pression and drug addiction (Lesch et al., 1996; Lesch & Gutknecht, 2005;
Murphy et al., 2001). It should be noted that the polymorphism in the
promotor region of the SLC64A gene is not the only molecular alteration
implicated in the development of drug addiction. However, due to the
relatively common incidence of this polymorphism and its relationship to
other psychiatric illnesses it may represent an important avenue for un-
derstanding why some individuals develop addiction to drugs of abuse
while others do not.
Therefore, to systematically investigate the influence of reduced sero-
tonin transporter function in the laboratory we studied the behaviour of a
genetically altered animal model: the serotonin transporter (SERT) knock-
out rat. Homozygous (SERT-/-, HOM) animals lack SERT function com-
pletely while heterozygous (SERT+/-, HET) have about 50% SERT function
compared to the wild type (SERT+/+, WT) (Smits et al., 2006).
It is important to note that all drugs of abuse lead to the stimulation
of dopamine release and this is thought to underlie the initial rewarding
effects of drugs of abuse (Everitt et al., 2008; Koob et al., 1998; Koob &
Volkow, 2010; Nestler, 1996, 2001). However, the precise mechanism of ac-
tion varies widely between different classes of drugs. For example, while
MDMA, a psychostimulant, directly stimulates the release of dopamine its
primary action targets the serotonin transporter (Green et al., 2003) (Han
& Gu, 2006; Rothman & Baumann, 2003). Studies investigating this com-
plex mechanism of action have shown that MDMA induced 5-HT release
may inhibit dopamine neurotransmission (Alex & Pehek, 2007; Rothman
& Baumann, 2006). Unlike MDMA, the opioid heroin, stimulates indirect
dopamine release via action on the µ-opioid receptor (Johnson & North,
1992; Kreek et al., 2012; Nestler, 2004). Taken together it is possible that
reduced SERT function and consequently reduced 5-HT release, may lead
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to a sensitised dopaminergic response to drugs of abuse.
To understand the interaction between reduced SERT function and the
development of addictive behaviours groups of HOM, HET and WT rats
completed a drug self-administration behavioural paradigm. Drug self-
administration is regarded as the “gold standard” for evaluating drug
addiction in the laboratory as it allows for precise measurement of how
much drug is taken. Additionally, it mirrors some of the hallmarks of
drug addiction as outlined in the DMS-5; for example, you can evaluate
how motivated an animal is to receive a drug infusion by requiring addi-
tional “work” (lever presses) in order to earn it (Panlilio & Goldberg, 2007;
Richardson & Roberts, 1996).
Drug self-administration behaviour was evaluated in animals taking
either MDMA or heroin to determine if disrupted serotonergic transmis-
sion interacts with the class of drug being self-administered. Prior to this
suite of experiments another research group had repeatedly demonstrated
that in rats with normal SERT function only about 50% of those animals
acquire MDMA self-administration (Schenk, 2009, 2011; Schenk, Colussi-
Mas, Do, & Bird, 2012). This result is in line with the idea that MDMA
induced 5-HT release may produce inhibition on dopamine neurotrans-
mission and subsequently lead to reduced MDMA self-administration. It
is important to note that these experiments were carried out in Sprague-
Dawley (SD) rats; however, the SERT KO rats have a Wistar background.
Therefore, it was of interest to determine if SERT WT animals, with in-
tact SERT function, would respond similarly to the SD animals that had
self-administered MDMA.
Lastly, since a reduction in the SERT has been implicated in a variety of
psychiatric illnesses, like anxiety and mood disorders, and these are often
comorbid with drug addiction, it was important to evaluate levels of anxi-
ety before drug self-administration (Lesch et al., 1996; Lesch & Gutknecht,
2005; Murphy et al., 2001). Therefore, all animals completed a novelty
suppressed feeding paradigm to measure anxiety. Any genotype differ-
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ences could then be compared to the subsequent drug self-administration
behaviour.
2.1.1 Predictions
Prediction 1: In the novelty suppressed feeding paradigm higher lev-
els of anxiety will be inversely related to SERT function (HOM >
HET > WT).
Prediction 2: As MDMA targets the SERT and because 5-HT release
may inhibit dopamine neurotransmission, it is predicted that MDMA
self-administration will be inversely related to SERT function (HOM
> HET > WT).
Prediction 3: As heroin, like MDMA, stimulates dopamine release
(albeit indirectly) it is predicted that heroin self-administration will
be inversely related to SERT function (HOM > HET > WT).
2.2 Methods
2.2.1 Novelty Suppressed Feeding
Subjects
All experimental procedures were approved by the Animal Ethics Com-
mittee at Victoria University of Wellington. Subjects were male Wistar rats
(HOM, HET and WT). Breeding occurred in the vivarium at Victoria Uni-
versity of Wellington and animals were housed in groups until they under-
went novelty suppressed feeding testing. Before testing animals were iso-
lated and housed individually in a temperature (19-21 ◦C) and humidity
(55%) controlled room that was maintained on a 12 hour light-dark phase
with lights on at 0700. Testing occurred during the light phase beginning
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each day at 0800. Water was available ad libitum but food availability was
restricted as described in the procedure below.
Apparatus
The novelty suppressed feeding experimental procedure was conducted
as previously described (Lira et al., 2003; Olivier et al., 2008). Subjects
were food deprived for 24 hours prior to testing. Testing began one hour
after subjects had been transferred to the experimental room in their home
cages. Then, under dim light, animals were observed individually in a
circular open field apparatus. Clean bedding covered the floor of the open
field and was replaced between subjects. A single food pellet was placed
on a small piece of circular paper (6.25 cm) in the centre of the open field.
Testing Schedule
Testing commenced when subjects were placed in a preselected “start” lo-
cation, adjacent to the wall, in the open field. Latency to begin feeding was
recorded with a maximum value of 10 min (600 seconds). After a subject
began feeding or 10 min had elapsed the subject was removed from the
open field and placed back into its home cage. All subjects were returned
to the housing room after the conclusion of the experiment and given free
access to food.
2.2.2 Drug Self-Administration
Subjects
After the completion of novelty suppressed feeding testing subjects re-
mained individually housed and underwent the surgical procedure de-
scribed below. Subjects weighed 280-380 g at the time of surgery. Testing
occurred during the light phase beginning each day at 0700 when animals
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were transferred from their home cages to the experimental room. Food
and water was available ad libitum except during testing.
Surgery
Groups of 13-18 animals, per genotype, underwent surgery. Subjects were
anesthetised with ketamine (90 mg kg−1) and xylazine (9 mg kg−1) via an
intraperitoneal (i.p.) injection and an indwelling catheter was implanted
in the right jugular vein. The analgesic carprofen (5.0 mg kg−1) was ad-
ministered via subcutaneous (s.c.) injection immediately before surgery
and the subjects eyes were swabbed with Lacrilube. The area over the
right jugular vein was shaved and cleansed with ethanol and iodine. Thr-
ough an incision in the upper right chest quadrant the jugular vein was
isolated and tied off. A length of tubing was inserted through a small cut
made in the vein. The distal portion of the tubing was passed subcuta-
neously to an exposed portion of the skull where it was connected to a 2
cm length of 22 ga stainless steel tubing. The tubing was then secured to
the skull with four jeweller‘s screws and acrylic dental paste. All incisions
were treated topically with Terramycin and electrolytes were administered
(s.c.). Postoperatively, subjects were treated with carprofen (5.0 mg kg−1)
(s.c.) for two days and their catheters were flushed daily with 0.2 mL of
a sterile solution containing heparin (30 IU mL−1) and penicillin G potas-
sium (250,000 IU mL−1) to prevent infection and the formation of clots.
Subjects recovered for 5-7 days after surgery before they commenced drug
self-administration testing.
Apparatus
Before each session rats were weighed and flushed with 0.2 mL of a ster-
ile solution containing heparin (30 IU mL−1) and penicillin G potassium
(250,000 IU mL−1) before being transported to the testing room. Drug self-
administration was carried out in Med Associates test chambers that were
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housed in sound attenuating boxes. The testing room was temperature
(19-21 ◦C) and humidity (55%) controlled. Each box was equipped with
two levers; depression of the active lever delivered an infusion of the drug
while depression of the inactive lever was counted but produced no other
consequence. During each drug infusion 0.1 mL solution (MDMA) was
delivered to the subject over 12 seconds via a Razel pump equipped with
a 20 mL syringe. With each infusion a light located above the active lever
was illuminated (for the duration of the infusion). Each training session
began when the subject was placed in the chamber, connected to the line
and the experimenter delivered a single infusion (primer, uncounted, light
illuminated) of the drug.
A slightly modified procedure was used for heroin self-administration.
Upon depression of the active lever 0.025 mL of heroin drug solution was
delivered to the subject over 3 seconds via a Razel pump equipped with
a 20 mL syringe. The smaller volume, 0.025 mL, was used to ensure that
animals were not taking drug too quickly. In addition, a 30 second time out
was added after each infusion where no infusion could be earned despite
presses on the active lever. These procedures are common practice with
narcotic drugs like heroin (Dai et al., 1989; Doherty & Frantz, 2012).
Testing Schedule
For MDMA self-administration subjects were placed in the testing cham-
bers on an FR1 (fixed ratio; where 1 active lever press delivers 1 infusion)
schedule for daily two hour self-administration sessions (1.0 mg kg−1 per
infusion MDMA). Acquisition of MDMA self-administration occurred af-
ter 85-90 total presses on the active lever within 25 test sessions. When sub-
jects met this criterion the dose was then halved (0.5 mg kg−1 per infusion
MDMA). After responding had stabilised animals were placed on an FR2
(fixed ratio; where 2 active lever presses deliver 1 infusion) schedule and
finally on an FR5 schedule. Stable responding was defined as three con-
secutive days where total active lever presses varied less than 20%. Next,
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subjects underwent progressive ratio testing where the number of lever
presses for each subsequent infusion increased systematically (i.e. 1, 2, 4,
6, 9, 12 etc.) (Richardson & Roberts, 1996). Progressive ratio testing was
completed for three counterbalanced doses of MDMA: 0.25 mg kg−1 per
infusion, 0.5 mg kg−1 per infusion and 1.0 mg kg−1 per infusion. Between
progressive ratio doses subjects were placed back on FR5 until responding
returned to their previous level of FR5 responding (at least one session was
completed). After the last progressive ratio dose animals completed one
additional day on the FR5 schedule to resume normal responding. The
next day subjects were euthanised via CO2 asphyxiation and brains were
extracted and frozen immediately at -80 ◦C.
For heroin self-administration subjects were placed in the testing cham-
bers on an FR1 (fixed ratio; where 1 active lever press delivers 1 infusion)
schedule for daily two hour self-administration sessions (0.05 mg kg−1 per
infusion heroin). Subjects completed 15 self-administration sessions; then
the dose was doubled (0.1 mg kg−1 per infusion heroin) until responding
was stable (at least three consecutive days). When subjects met this crite-
rion they were placed on an FR2 (fixed ratio; where 2 active lever presses
deliver 1 infusion) schedule and finally on an FR5 schedule. Next, sub-
jects underwent progressive ratio testing where the number of presses
for each subsequent infusion increased systematically (i.e. 1, 2, 4, 6, 9,
12 etc.) (Richardson & Roberts, 1996). This schedule was slightly mod-
ified: four breakpoints (2, 4, 9 and 12) at the beginning of the sched-
ule were eliminated to decrease over-sedation at the start of the session
(Smith & Aston-Jones, 2012). Progressive ratio testing was completed for
three doses of heroin: 0.05 mg kg−1 per infusion, 0.1 mg kg−1 per infusion
and 0.2 mg kg−1 per infusion. After the last progressive ratio dose animals
completed one additional day on the FR5 schedule to resume normal re-
sponding. The next day subjects were euthanised via CO2 asphyxiation
and brains were extracted and frozen immediately at -80 ◦C.
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Drugs
Drug solutions for infusion were prepared by mixing 3,4-methylenedioxy-
methamphetamine (MDMA) or Heroin HCl (BDG Synthesis, Wellington,
New Zealand), in powder form, with heparinised saline. Before use intra-
venous drug solutions were clarified of impurities using hypophilic Minis-
art syringe filters and placed directly into sterile 20 mL syringes. Syringes
were labelled with the type of drug and corresponding “weight class”.
Weight classes were calculated to account for rats of differing weights; it
was not uncommon for rats to weigh 280-400 g (with rats gaining weight,
up to 400 g, throughout the experiment). Therefore, rats were divided into
three weight classes: featherweight 300 g (280-320 g), welterweight 340 g
(320-360 g), and heavyweight 380 g (360-400 g) with drug solutions pre-
pared according to these weights. When an animal reached a boundary
between two weight classes he would start the following testing day with
the solution for the next weight class.
2.3 Results
2.3.1 MDMA
Novelty Suppressed Feeding
Before drug self-administration surgery and testing was conducted sub-
jects completed a novelty suppressed feeding paradigm. Latency to begin
feeding was recorded and compared across groups of HOM, HET and WT
subjects. A one-way ANOVA revealed no significant difference between
the genotypes, F(2, 47) = .62, p = .55 (see Figure 2.1).
Drug Self-Administration
After recovery from surgery subjects began MDMA self-administration
testing. Due to a small number of unsuccessful surgeries or early loss of
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Figure 2.1: Average (+SEM) latency to begin feeding for HOM (n = 16),
HET (n = 18) and WT (n = 16) subjects.
Figure 2.2: Acquisition responding for MDMA self-administration for
HOM (n=8), HET (n=9) and WT (n=12) groups.
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catheter patency while subjects were recovering from surgery the group
sizes were slightly reduced from those described for novelty suppressed
feeding. Subjects completed MDMA self-administration until they reached
acquisition criteria: 85-90 total presses on the active lever. Upon reach-
ing this criterion they then began the first schedule of Maintenance test-
ing. If subjects did not meet this criterion in the first 25 test sessions they
were removed from the study. Kaplan-Meier survival analysis revealed
a significant genotype effect (χ 2 = 13.83, p=.001). Acquisition of MDMA
self-administration is given in Figure 2.2; after 25 test sessions 100% of
HOM subjects had acquired MDMA self-administration with the HET and
WT groups reaching 89% and 50%, respectively. Post hoc comparisons re-
vealed a significant difference between the HOM and both the HET and
WT groups; however, the comparison between the HET and WT groups
did not reach significance but it may indicate a trend toward an effect (see
Table 2.1).
p value
HOM - HET 0.03*
HOM - WT 0.002*
HET - WT 0.06
Table 2.1: Acquisition responding for MDMA self-administration: Post
hoc comparisons. *Denotes statistical significance.
The day after reaching acquisition criterion subjects remained on an
FR1 schedule but administered a half dose (0.5 mg kg−1 per infusion) un-
til responding was stable (at least three consecutive days). Then subjects
completed FR2 and FR5 schedules of responding.
A repeated measures ANOVA revealed a significant main effect of geno-
type F(2, 15) = 4.82, p = .02, and fixed ratio schedule F(2,30) = 8.64, p = .001
on lever presses. The genotype*fixed ratio schedule interaction did not
reach significance but it may indicate a trend toward an effect F(4,30) =
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2.34, p = .08.
One-way ANOVA post hoc analysis of FR1 responding demonstrated
a significant difference among the genotypes, F(2, 15) = 6.87, p = .008)
with HOM subjects showing significantly higher responding compared
to HET and WT subjects. However, there was no significant difference
between HET and WT groups. Similarly, post hoc analysis of FR2 re-
sponding showed a significant difference between the genotypes, F(2, 15)
= 4.06, p = .04, where HOM subjects had higher responding than HET how-
ever both the HOM/WT and HET/WT comparisons failed to reach signif-
icance. Lastly, when FR5 responding was analysed differences between
the groups did not reach significance but may indicate a trend toward an
effect (p = .07) (see Figure 2.3 and Table 2.2).
Figure 2.3: Maintenance responding for MDMA self-administration. Av-
erage (+SEM) responding across varying fixed ratio schedules for HOM (n
= 7), HET (n = 7) and WT (n = 4) subjects.
Upon further investigation within each genotype across the fixed ratio
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FR1 FR2 FR5 HOM HET WT
HOM - HET 0.009* 0.04* 0.133 FR1 - FR2 0.78 0.29 0.47
HOM - WT 0.04* 0.165 0.1 FR2 - FR5 0.05 0.01* 0.96
HET - WT 0.97 0.92 0.88 FR1 - FR5 0.01* 0.001* 0.34
Table 2.2: Maintenance responding for MDMA self-administration: Post
hoc comparisons. *Denotes statistical significance.
schedules HOM subjects showed a significant difference among fixed ratio
schedules, F(2, 18) = 5.70, p = .012, with significantly lower responding
on FR1 and FR2 fixed ratio schedules compared to FR5. The FR1/FR2
comparison failed to reach significance. Like the HOM the HET group
showed a significant difference between fixed ratio schedules, F(2, 18) =
12.67, p < .001, with significantly lower responding on FR1 and FR2 fixed
ratio schedules compared to FR5. The FR1/FR2 comparison failed to reach
significance. Finally, the WT group revealed no difference across the fixed
ratio schedules, F(2, 9) = 1.27, p = .33 (see Table 2.2).
After maintenance responding subjects completed a progressive ra-
tio schedule with three doses of MDMA: 0.25 mg kg−1, 0.5 mg kg−1 and
1.0 mg kg−1. A repeated measures ANOVA revealed a significant main ef-
fect of dose, F(2, 20) = 6.78, p = .006, on the number of infusions; however,
the main effect of genotype did not reach significance but may indicate a
trend toward an effect F(2, 10) = 3.62, p = .07). The dose*genotype interac-
tion failed to reach significance, F(4, 20) = 1.55, p = .23.
One-way ANOVA post hoc analysis of the 0.25 mg kg−1 and 0.5 mg kg−1
doses revealed no difference between genotypes. However, although an
effect among the genotypes when responding on the 1.0 mg kg−1 dose did
not reach significance it may indicate a trend toward an effect F(2, 10) =
3.46, p = .07 (see Figure 2.4 and Table 2.3).
Upon further investigation within each genotype HOM subjects show-
ed a significant difference between the doses, F(2, 6) = 4.98, p = .05. They
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Figure 2.4: Progressive Ratio responding for MDMA self-administration.
Average (+SEM) responding across varying MDMA doses on a progres-
sive ratio schedule for HOM (n = 3), HET (n = 7) and WT (n = 3) subjects.
MDMA 0.25 MDMA 0.5 MDMA 1.0
HOM - HET 0.53 0.67 0.8
HOM - WT 0.18 0.2 0.26
HET - WT 0.5 0.4 0.06
HOM HET WT
MDMA 0.25 - 0.5 0.05 .06 0.77
MDMA 0.25 - 1.0 0.21 0.01* 0.99
MDMA 0.5 - 1.0 0.5 0.56 0.84
Table 2.3: Progressive ratio responding for MDMA self-administration:
Post hoc comparisons. *Denotes statistical significance.
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demonstrated significantly lower responding for the 0.25 mg kg−1 dose
compared to the 0.5 mg kg−1 dose. The 0.25 mg kg−1/1.0 mg kg−1 and 0.5 -
mg kg−1/1.0 mg kg−1 comparisons failed to reach significance. Similarly,
HET subjects showed a significant difference in progressive ratio respond-
ing, F(2, 18) = 6.39, p = .008. They showed significantly lower respond-
ing on the 0.25 mg kg−1 dose compared to the 1.0 mg kg−1 dose; a differ-
ence between responding on the 0.25 mg kg−1 and 0.5 mg kg−1 doses did
not reach significance but may indicate a trend toward an effect. The
0.5 mg kg−1/1.0 mg kg−1 comparison failed to reach significance. Lastly,
comparing WT responding across doses revealed no significant difference,
F(2, 6) = .28, p = .76 (see Table 2.3). It should be noted that due the lengthy
nature of drug self-administration experiments some subjects lost catheter
patency before completing the entire experiment; therefore, the sample
sizes decreased as the experiment progressed.
2.3.2 Heroin
Novelty Suppressed Feeding
Before drug self-administration surgery and testing was conducted sub-
jects completed a novelty suppressed feeding paradigm. Latency to begin
feeding was recorded and compared across groups of HOM, HET and WT
subjects. A one-way ANOVA did not reach significance but may indicate
a trend toward an effect between the genotypes, F(2, 38) = 3.34, p = .05 (see
Figure 2.5). Post hoc analysis did not reach significance but may indicate
a trend toward an effect when both the HOM and HET were compared to
the WT group. The difference between HOM and HET groups failed to
reach significance (see Table 2.4).
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Figure 2.5: Average (+SEM) latency to begin feeding for HOM (n = 13),
HET (n = 15) and WT (n = 13) subjects.
p value
HOM - HET 0.99
HOM - WT 0.07
HET - WT 0.08
Table 2.4: Novelty Suppressed Feeding: Post hoc comparisons.
Drug Self-Administration
After recovery from surgery subjects began heroin self-administration test-
ing. Due to a small number of unsuccessful surgeries or early loss of
catheter patency while subjects were recovering from surgery the group
sizes were slightly reduced from those described for novelty suppressed
feeding. Subjects completed self-administration for 15 days (0.05 mg kg−1
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per infusion heroin). Upon completing this initial phase they then began
the first schedule of Maintenance testing.
Figure 2.6: Initial drug intake for Heroin self-administration for HOM
(n=8), HET (n=7) and WT (n=10) groups.
When evaluating drug intake over this period a one-way ANOVA re-
vealed no differences between the genotypes F(2, 22) = .645, p = .53. How-
ever, analysis comparing Days 1-7 to Days 8 -15 revealed a significant main
effect of day F(2, 22) = 36.7, p < .001, indicating an increase in responding
during Days 8-15 compared to Days 1-7 (see Figure 2.6). The main effect of
genotype, F(2, 22) = .653, p = .53, and the days*genotype interaction, F(2,
22) = 1.80, p =.19, failed to reach significance.
On Day 16 subjects remained on an FR1 schedule but administered a
double dose (0.1 mg kg−1 per infusion heroin) until responding was stable
(at least three consecutive days). The animals were then moved to FR2 and
FR5 (using the same procedure for stable responding).
To compare maintenance responding on fixed ratio schedules, FR1, FR2
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Figure 2.7: Maintenance responding for heroin self-administration across
varying fixed ratio schedules for HOM (n = 6), HET (n = 5) and WT (n = 7)
subjects.
and FR5, a repeated measures ANOVA was conducted but failed to reveal
a significant main effect of genotype F(2, 15) = 1.026, p = .38, or fixed ratio
schedule F(2,30) = .952, p = .40 on lever presses. Additionally, the geno-
type*fixed ratio schedule interaction failed to reach significance F(4,30) =
1.491, p = .23. (see Figure 2.7).
After maintenance responding subjects completed a progressive ra-
tio schedule with three doses of heroin: 0.05 mg kg−1, 0.1 mg kg−1 and
0.2 mg kg−1. A repeated measures ANOVA failed to reveal a significant
main effect of genotype F(2, 13) = 1.345, p = .30, or dose F(2,26) = .56,
p = .58 on infusions. Additionally, the genotype*dose interaction failed
to reach significance F(4,26) = 1.33, p = .29 (see Figure 2.8). It should be
noted that due the lengthy nature of drug self-administration experiments
some subjects lost catheter patency before completing the entire experi-
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ment; therefore, the sample sizes decreased as the experiment progressed.
Figure 2.8: Average (+SEM) responding across varying MDMA doses on
a progressive ratio schedule for HOM (n = 4), HET (n = 5) and WT (n = 7)
subjects.
As described above latency to begin feeding was measured to eval-
uate anxiety before animals began drug self-administration. Correlation
analysis was conducted to compare latency to begin feeding with average
heroin self-administration maintenance and progressive ratio responding.
Neither analysis revealed a significant correlation between latency to be-
gin feeding and heroin self-administration maintenance or progressive ra-
tio responding, r(15) = -.09, p = .74, and r(14) = .38, p = .15, respectively
(see Figures 2.9 and 2.10).
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Figure 2.9: Latency to begin feeding (min) plotted against average main-
tenance responding (infusions).
Figure 2.10: Latency to begin feeding (min) plotted against average pro-
gressive ratio responding (infusions).
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2.4 Discussion
Evaluation of latency in the novelty suppressed feeding paradigm pro-
vided a measure of anxiety; however, for the animals that underwent this
testing before MDMA drug self-administration comparison of group aver-
ages did not reveal a difference between the genotypes. This result differs
from previous research where significantly greater anxiety was correlated
with reduction in the serotonin transporter (Olivier et al., 2008). Disagree-
ment between these two studies may be due to slight differences in the
experimental procedure. Prior to commencing the current novelty sup-
pressed feeding experiment a pilot study was undertaken to provide fa-
miliarity with the experimental logistics before running the large cohort of
animals that would go on to drug self-administration. In the pilot study,
utilising a brightly lit open field to evaluate latency to begin feeding as
specified in Olivier et al. (2008), none of the animals commenced feed-
ing when presented with a food pellet within the duration of the test (10
minutes). Therefore, a slight procedural variation was included where the
animals were moved into the experimental room 1 hour prior to begin-
ning of the experiment. Additionally, the lights in the room were dimmed
throughout the entirety of the experiment. This slight difference may pro-
vide an explanation as to the differing result between the two experiments.
For animals that underwent novelty suppressed feeding before heroin
drug self-administration a nonsignificant trend emerged in latency to be-
gin feeding amongst the genotypes. That is, the HOM and HET groups
showed greater latency to begin feeding compared to the WT group. This
does follow previous research (Olivier et al., 2008) however it should be
noted that the post hoc comparisons failed to reach statistical significance.
Considering very similar methods were used to run the novelty suppressed
feeding experiments this differential result was not expected and may be
due to natural variation between discrete groups of animals. Alterna-
tively, minor changes in the experimental conditions may have increased
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the variability in the measured response; regardless the direction of the
effect was the same in both novelty suppressed feeding experiments. This
also suggests that levels of anxiety, at least as measured by novelty sup-
pressed feeding, may not be a particularly robust read-out parameter.
To further investigate the relationship between levels of anxiety and
heroin self-administration novelty suppressed feeding latency was com-
pared with both maintenance and progressive ratio responding. Corre-
lation analysis failed to revealed a significant relationship between levels
of anxiety (increased latency) and either maintenance or progressive ratio
responding for heroin.
Importantly, the groups of animals that completed MDMA drug self-
administration did not show differences in anxiety but demonstrated ro-
bust differences in MDMA drug self-administration. The animals that
completed heroin drug self-administration showed a nonsignificant trend
towards an increase in anxiety however there were no corresponding dif-
ferences in heroin drug self-administration. If higher levels of anxiety, as
demonstrated by HOM (and sometimes HET) subjects, were driving drug
self-administration behaviour then these subjects would have shown fa-
cilitated drug self-administration for both MDMA and heroin. In fact
when subjects self-administered heroin no differences emerged between
the genotypes.
Regarding acquisition of MDMA self-administration a genotype effect
emerged with HOM subjects acquiring MDMA drug self-administration
significantly faster than both the HET and WT groups. Percentage of ac-
quisition followed the predicted pattern with 100% of HOM subjects com-
pared to 89% of HET subjects and only 50% of WT subjects. These re-
sults mirror findings from a pilot study conducted by our group where
HOM and WT animals showed a similar pattern of responding when self-
administering MDMA (Oakly, Brox, Schenk, & Ellenbroek, 2014). Addi-
tionally, with only half of WT subjects acquiring MDMA self-administr-
ation this result aligns with previous research where “normal” animals
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(those with intact serotonergic function) only acquire MDMA drug self-
administration about half of the time (Schenk et al., 2012). Importantly,
the current result extends this pattern of responding, previously demon-
strated in Sprague-Dawley rats, to a Wistar strain (SERT KO). While the
comparison between the HET and WT groups did not technically reach
significance the pattern of responding suggests that HET, like HOM, an-
imals are more sensitive to the effects of MDMA as is reflected in their
increased responding.
Beyond MDMA acquisition when animals were tested on FR1, FR2
and FR5 schedules of reinforcement the HOM group was more willing to
increase their responding for additional drug infusions across FR sched-
ules compared to both the HET and WT groups. When the genotypes
were evaluated individually both the HOM and HET groups significantly
increased their responding on a FR5 schedule; however, the WT group
did not show a difference in responding across the FR schedules. Af-
ter MDMA maintenance animals were effectively asked, “How hard are
you willing to work for another drug infusion?” with a progressive ra-
tio schedule of responding; however analysis only revealed a main effect
of dose. Evaluation of each genotype across the drug doses revealed that
both HOM and HET groups showed higher responding as dose increased
while there were no differences for the WT group. These results suggest
that a disrupted serotonergic function plays a role in increased responding
for MDMA.
Taken together, the MDMA self-administration results suggest that a
reduction in the SERT plays an important role in the acquisition, mainte-
nance and progressive ratio responding for MDMA. Both HOM and HET
groups consistently self-administered more MDMA compared with the
WT group over a variety of FR schedules suggesting that these groups
are more sensitive to the effects of MDMA and this sensitivity is driv-
ing their increased responding. Genotype differences for MDMA self-
administration are likely mediated by the complex interaction of serotonin
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and dopamine. That is, for animals with intact SERT function (WT) when
MDMA is self-administered it acts on the SERT by blocking reuptake and
facilitating reverse transport. This leads to increased levels of 5-HT in the
synapse. In addition to action on the SERT MDMA also targets the dop-
amine transporter (DAT) (to a lesser degree). With previous research to
support the idea that 5-HT release can have an inhibitory effect on dopa-
mine neurotransmission this may explain why only about half of WT an-
imals go on to acquire MDMA drug self-administration (Alex & Pehek,
2007; Baumann et al., 2011; Di Matteo, De Blasi, Di Giulio, & Esposito,
2001; Rothman & Baumann, 2006). Conversely, for HOM subjects that
completely lack the SERT when MDMA is self-administered there is no
protein for MDMA to target and facilitate reverse transport of 5-HT back
into the synapse. For this reason MDMA targets the DAT producing DA
release into the synapse. As described earlier HOM animals, because they
lack the SERT, have increased basal levels of 5-HT in specific brain regions
that lead to 5-HT receptor downregulation. Therefore, in HOM animals
MDMA may lead a tonic increase in 5-HT compared to the rapid phasic in-
crease seen in WT animals. This result is consistent with a study where 5-
HT neurotransmission was disrupted via neurotoxic lesions (5,7 dihydrox-
ytryptamine) in Sprague Dawley rats; MDMA self-administration was fa-
cilitated in these animals and coincided with a reduced 5-HT phasic re-
sponse (Bradbury et al., 2014).
It should be noted that MDMA self-administration has been investi-
gated in mice with reduced SERT function; WT animals self-administer
MDMA reliably however SERT KO mice fail to demonstrate responding
for MDMA above saline levels (Trigo et al., 2007). It has been suggested
that this may be due to differences in the pharmacological targets of MD-
MA between the two species. As described earlier MDMA facilitates 5-HT
release in rats and humans; however, in mice MDMA influences levels
of 5-HT to a lesser degree. Instead, MDMA increases dopamine neuro-
transmission in mice and these elevated levels can lead to dopamine neu-
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rotoxicity (Easton & Marsden, 2006). Unfortunately, this explanation is
insufficient in describing why rats and mice with reduced SERT show dif-
ferential patterns of MDMA self-administration. Interestingly, mice with
reduced SERT demonstrate cocaine self-administration similar to WT an-
imals (Thomsen, Hall, Uhl, & Caine, 2009); if elevated dopamine release
was inhibiting MDMA self-administration in SERT KO mice it would be
expected to have the same effect on cocaine self-administration. Addi-
tional studies have investigated the influence of both serotonergic and
dopaminergic disruption on cocaine reward and have indicated that there
may be a complex relationship between the serotonin and dopamine neu-
rotransmitter systems. That is, mice with reduced SERT or dopamine
transporter (DAT) function both demonstrate cocaine induced conditioned
place preference (CPP); these results suggest that the 5-HT and DA sys-
tems may play a compensatory role in the lifelong absence of the other
transporter (Hagino et al., 2011; Sora et al., 1998). It is only with a dou-
ble knockout that has neither SERT nor DAT function that cocaine CPP is
effectively eliminated (Sora et al., 2001). It has been suggested that dif-
ferences in MDMA self-administration between SERT rats and mice may
be due to potentiated dopaminergic effects. That is, in rats these lead to
enhanced MDMA self-administration but in mice they lead to dopamine
neurotoxicity which inhibits self-administration behaviour. Interestingly,
research has elegantly demonstrated that SERT mice (HOM and WT) show
similar increases in dopamine in the nucleus accumbens when evaluated
via microdialysis (Trigo et al., 2007). This result directly opposes the idea
that MDMA leads to dopamine neurotoxicity in mice leading to dimin-
ished MDMA self-administration behaviour. Considering these findings
as a whole it is possible that there are inherent differences in the sero-
tonergic systems of rats and mice with a reduction in the SERT; studies
indicate that specific serotonin receptor density varies between the two
species (Fabre et al., 2000; Shanahan et al., 2009). Additionally, there may
be fundamental differences in MDMA effects between rats and mice with
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reduced SERT; for example, HOM mice show spontaneous serotonin syn-
drome behaviours (Straub tail, tremors, tics) whereas HOM rats do not
(Kalueff, LaPorte, & Murphy, 2008). This finding is interesting considering
both HOM rats and mice show elevated levels of extracellular 5-HT after
MDMA treatment. At this time, even with current and historical data, we
are unable to fully explain the differential effect between SERT rats and
mice when they self-administer MDMA.
When HOM, HET and WT groups began heroin drug self-administrati-
on there were no significant differences between the genotypes over the
first 15 testing sessions. However, when the data was evaluated for the
first half of that period (Days 1-7) compared to the second half (Days
8-15) a significant main effect of Session emerged. Regardless of geno-
type, animals increased their responding over sessions. On maintenance
schedules, FR1, FR2 and FR5, there were no significant differences in re-
sponding between the genotypes. Additionally, there was no difference
between the genotypes when responding on a progressive ratio schedule
across several drug doses. It was hypothesised that reduced SERT function
leads to a sensitised dopaminergic response to drugs of abuse. However,
if this were true then HOM, and most likely HET, subjects would have
demonstrated greater heroin self-administration compared to the WT. In-
stead, no genotype differences emerged throughout the whole of heroin
self-administration including varying doses and schedules of responding.
Therefore, the theory that animals with reduced SERT function have a sen-
sitised dopaminergic system may not be true. However, it is important to
note that, compared to MDMA, heroin is a powerful drug and it is possi-
ble that potential genotype differences may be difficult to detect with such
a potent reinforcer. Cocaine self-administration in rats with reduced SERT
function is facilitated similarly to the MDMA self-administration results
presented in this chapter. Considering cocaine and MDMA target both the
SERT and DAT it is possible that this direct stimulation of the dopaminer-
gic system then drives their respective self-administration. Alternatively,
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the heroin mechanism of action is inherently different as it acts indirectly
to stimulate dopamine release.
Regarding the drug self-administration experiments as a whole it is
readily apparent that reduction in the SERT influences drug self-admini-
stration behaviour very differently depending on the type of drug that is
self-administered. MDMA drug self-administration was facilitated in ani-
mals with reduced SERT function whereas heroin drug self-administration
did not differ between the genotypes. This result is in line with previous
research that demonstrated facilitated cocaine self-administration in sub-
jects with reduced SERT function; specifically, the desensitisation of a spe-
cific serotonergic autoreceptor (5-HT1A) leading to facilitated cocaine self-
administration (Homberg et al., 2008). Another study in rats with reduced
SERT function demonstrated that cocaine facilitated a significantly smaller
increase in extracellular 5-HT in the nucleus accumbens and hippocam-
pus compared to WT animals. This study also demonstrated that cocaine
treatment did not lead to differing levels of dopamine and norepinephrine
between HOM and WT animals (Verheij, Karel, Cools, & Homberg, 2014).
Together with the current results this research points to the existence of a
complex relationship between the serotonin, dopamine and norepinephri-
ne neurotransmitter systems which in turn drives drug self-administration
in animals with reduced SERT.
These studies provide insight into how reduced SERT function may
influence the development of drug addiction. That is, because reduction
in the SERT has been linked to other psychiatric disorders it was initially
posited that a reduction in the SERT would constitute a risk factor in the
development of drug addiction to all drugs of abuse. However, the results
of this suite of experiments provide evidence counter to this argument.
Namely, that a reduction in the SERT facilitates the self-administration of
MDMA but not for heroin. As described in the General Introduction there
is growing evidence to implicate a reduction in the SERT in the develop-
ment of drug addiction. The current MDMA self-administration data pro-
62
CHAPTER 2. NOVELTY SUPPRESSED FEEDING AND
DRUG SELF-ADMINISTRATION
vides support for this theory. Conversely, the heroin self-administration
data suggests that a reduction in the SERT does not contribute to the de-
velopment of opioid addiction. Interestingly, a portion of the human clini-
cal research into heroin addiction supports the idea that a reduction in the
SERT confers susceptibility to developing addictive behaviours (Gerra et
al., 2004; Saiz et al., 2008; Tan, Yeo, Ho, Tay, & Tan, 1999; Yang, Kavi, Wang,
Wu, & Hao, 2012); other research shows no such relationship (Kotler et al.,
1999; T. Li et al., 2002; Saiz et al., 2009). A review of these studies sug-
gests that these mixed results may be due to small sample sizes, variations
in the SERT polymorphism between different ethnic groups and the fact
that there are relatively few studies investigating the specific relationship
between reduced SERT function and heroin addiction (Cao et al., 2013).
Therefore, the current preclinical data fit with a portion of the human data
where a reduction in the SERT does not appear to be a risk factor when
it comes to heroin addiction. Only additional research in larger and more
diverse groups of humans will elucidate this relationship.
Overall, this series of experiments provided an opportunity for eval-
uating the effect of disrupted serotonergic neurotransmission on anxiety
and drug self-administration. Interestingly, animals with reduced SERT
function showed facilitated MDMA, but not heroin, drug self-administrati-
on compared to those with intact SERT function. While these results are
interesting they beg the question: “Why do animals with reduced SERT
function show increased MDMA self-administration?”. The incentive-sen-
sitisation theory of drug addiction suggests that increased drug taking re-
sults from a sensitised “reward” network where the behaviour is increas-
ingly reinforced; that is drug taking escalates due to the “positive” rein-
forcing properties the drug (Robinson & Berridge, 1993, 2001). Conversely,
others have posited that increased drug taking is related to the “negative”
effects of the withdrawal syndrome that increase over time. This the-
ory is supported by the fact that individuals continue to take increasing
amounts of the drug and this may postpone experience of the withdrawal
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syndrome (Koob, 1992; Koob et al., 2009, 1998). In an effort to determine
which theory of drug addiction is applicable groups of HOM, HET and
WT animals completed a series of locomotor activity and conditioned taste
aversion experiments. These two paradigms have been widely used to as-
sess aspects of drug addiction including reinforcing properties and nega-
tive effects. They are described fully in Chapter 3.
64
CHAPTER 2. NOVELTY SUPPRESSED FEEDING AND
DRUG SELF-ADMINISTRATION
Chapter 3
Locomotor Activity and
Conditioned Taste Aversion
3.1 Introduction
The drug self-administration experiments described in Chapter 2 demon-
strated a strong genotype effect with MDMA, but not heroin, begging
the question,“What is driving the effect?”. Are the HOM and HET ani-
mals self-administering significantly more MDMA compared to the WT
because of the positive, reinforcing effects of the drug? Or do they take
more to stave off the negative consequences that can accompany the with-
drawal syndrome? To investigate these questions a series of experiments
was conducted. Specifically, groups of HOM, HET and WT animals were
treated with MDMA or heroin and their locomotor activity or conditioned
taste aversion was measured.
Assessing locomotion in experimental animals has become a hallmark
in preclinical research especially when evaluating drug effects (Walsh &
Cummins, 1976). It allows a rapid and precise measure of how the drug
influences motor movement and provides a behavioural correlate to drug
induced neurochemical changes in the brain (Beninger, 1983; Pijnenburg
& van Rossum, 1973). It is widely posited that drug induced locomotor
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activity is driven by activation of the mesolimbic dopamine pathway. This
is evidenced by several studies that have demonstrated increased locomo-
tion after treatment with DA stimulating substances like D-amphetmaine,
cocaine and apomorphine (Fray, Sahakian, Robbins, Koob, & Iversen, 1980;
Isaacson, Yongue, & Mcclearn, 1978; Lyon & Robbins, 1975). Additionally,
other studies have shown that DA antagonists or lesions created with 6-
hydroxydopamine (6-OHDA) reliably decrease psychostimulant induced
locomotor activity in laboratory animals (Anden, Butcher, Corrodi, Fuxe,
& Ungerstedt, 1970; Carlsson, Lindqvist, Magnusson, & Waldeck, 1958;
Ungerstedt, 1979). This is also true for MDMA; several studies have demon-
strated that dopamine receptor antagonists decrease locomotor activity
(Ball, Budreau, & Rebec, 2003; Daniela, Brennan, Gittings, Hely, & Schenk,
2004). Additionally, treatment with opioids like heroin and morphine ac-
tivate the mesolimbic dopamine pathway and facilitate dose dependent
locomotor activity (Kalivas & Duffy, 1987; Ranaldi, Egan, Kest, Fein, & De-
lamater, 2009; Vanderschuren & Kalivas, 2000). As described in the Gen-
eral Introduction dopaminergic activity in this same pathway is thought
to underlie the initially rewarding properties of drugs of abuse (Everitt
et al., 2008; Koob et al., 1998; Koob & Volkow, 2010; Nestler, 1996, 2001;
Robbins & Everitt, 1996). Therefore, in order to determine if animals with
reduced SERT are more sensitive to the reinforcing properties of drugs of
abuse locomotor activity was measured after MDMA or heroin treatment.
Conversely, to assess sensitivity to the negative effects of drugs of abuse
groups of animals were tested in a conditioned taste aversion paradigm.
Conditioned taste aversion develops when a drug of abuse is delivered
systemically after an animal has had access to a novel, palatable sucrose
solution. Under normal circumstances animals will readily drink sucrose
when given the opportunity. However, when paired with a drug of abuse
animals will reliably avoid the sucrose solution when given a choice be-
tween it and water (Cappell & LeBlanc, 1977; Goudie, 1979). Previous
research suggests that this phenomena demonstrates that drugs of abuse
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may possess both positive and negative effects. This is evidenced by the
fact that drugs that are readily self-administered by animals also cause
conditioned taste aversion when paired with a desirable solution like su-
crose (Hunt & Amit, 1987). Therefore, to evaluate the influence of negative
drug effects development of conditioned taste aversion was evaluated af-
ter MDMA or heroin treatment.
3.1.1 Predictions
Prediction 1: As subjects with reduced SERT appear to have height-
ened sensitivity to MDMA drug effects (i.e. facilitated MDMA self-
administration described in Chapter 2) it is predicted that MDMA
induced locomotor activity will be inversely related to SERT func-
tion (HOM > HET > WT).
Prediction 2: As subjects with reduced SERT appear to have height-
ened sensitivity to MDMA drug effects (i.e. facilitated MDMA self-
administration described in Chapter 2) it is predicted that MDMA
induced conditioned taste aversion will be inversely related to SERT
function (HOM > HET > WT).
Prediction 3: As heroin self-administration behaviour was similar
across genotypes (Chapter 2) it is predicted that heroin induced lo-
comotor activity will not differ between HOM, HET and WT groups.
Prediction 4: As heroin self-administration behaviour was similar
across genotypes (Chapter 2) it is predicted that heroin induced con-
ditioned taste aversion will not differ between HOM, HET and WT
groups.
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3.2 Methods
3.2.1 Locomotor Activity
Subjects
All experimental procedures were approved by the Animal Ethics Com-
mittee at Victoria University of Wellington. Subjects were male Wistar
rats, homozygous (SERT-/-, HOM), heterozygous (SERT+/-, HET) and wild
type (SERT+/+, WT), weighing 300-400 g at the time of the experiments de-
scribed below. Breeding occurred in the vivarium at Victoria University of
Wellington and animals were housed in groups of 3-4 until five days prior
to the commencement of testing. During testing animals were housed in
pairs (same genotype) in a temperature (19-21 ◦C) and humidity (55%)
controlled room that was maintained on a 12 hour light-dark cycle with
lights on at 0700. Testing occurred during the light phase beginning each
day at 0800. Food and water was available ad libitum except during testing.
Apparatus
Locomotor activity testing was conducted as previously described (Brad-
bury, Gittings, & Schenk, 2012). Data were collected using sixteen clear
Plexiglas open field chambers, 42x42x30 cm, (Med Associates Inc., USA;
model ENV-515) housed in sound attenuating boxes. Each chamber was
equipped with four sets of sixteen infrared sensors, at two different heights,
that created a lattice of beams dividing the space into squares measuring
25x25 mm. Ambulatory counts were recorded where the interruption of
three consecutive, adjacent beams defined one “ambulatory count”. Dur-
ing testing a white noise generator was utilised to mask any noise outside
the boxes.
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Testing Schedule
Animals were transferred to the testing room in their home cages. Weight
was recorded for each animal. With the white noise generator on they
were placed into the locomotor activity chambers. After thirty minutes
subjects were injected with either drug or saline and placed back into the
chambers for 60 min. After the experiment animals were placed back into
their home cages and returned to the housing room.
Groups of 8 animals per genotype were counterbalanced across cham-
bers where each animal used the same chamber for all sessions. Using a
within subjects design (1 dose per week) locomotor activity was measured
for four counterbalanced doses of MDMA: 0.0 mg kg−1 (saline), 2.5 mg kg−1,
5.0 mg kg−1 and 10.0 mg kg−1. Identical testing procedures were used for
three counterbalanced doses of heroin: 0.0 mg kg−1 (saline), 0.5 mg kg−1
and 1.0 mg kg−1.
Drugs
Drug solutions were prepared by mixing 3,4-methylenedioxymethamphe-
tamine or heroin HCl (BDG Synthesis, Wellington, New Zealand), in pow-
der form, with saline. Both MDMA and heroin were administered subcu-
taneously (s.c.) in a volume of 1.0 mg kg−1.
3.2.2 Conditioned Taste Aversion
Subjects
All experimental procedures were approved by the Animal Ethics Com-
mittee at Victoria University of Wellington. Subjects were male Wistar
rats, homozygous (SERT-/-, HOM), heterozygous (SERT+/-, HET) and wild
type (SERT+/+, WT), weighing 300-450 g at the time of the experiments.
Breeding occurred in the vivarium at Victoria University of Wellington
and animals were housed in groups until they underwent the experimen-
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tal paradigm described below. Animals were transferred to individual
cages housed in a temperature (19-21 ◦C) and humidity (55%) controlled
room that was maintained on a 12 hour light-dark phase with lights on
at 0700. Testing occurred during the light phase beginning each day at
0900. Food was available ad libitum but water availability was restricted
according to the procedure described below.
Apparatus
Two days before the experiment began subjects were transferred to indi-
vidual home cages where they remained for the duration of experimental
testing. They were then water deprived for 24 hours before beginning the
six day testing period.
Testing Schedule
The experimental methods follow a procedure described previously (Fenu,
Cadoni, & Di Chiara, 2010). The testing period consisted of three phases:
training, conditioning and testing. First, subjects underwent training for
three days (Days 1, 2 and 3). Each day animals were given access to a wa-
ter bottle for 30 min. Water bottles were weighed before and after drinking
to calculate intake and ensure that animals were drinking water when it
was available. Second, subjects completed the conditioning phase for two
days (Days 4 and 5). Before testing subjects were weighed and then given
access to a bottle containing a 5% sucrose solution for 30 min. After 30 min
had elapsed subjects were injected with MDMA or saline. Finally, testing
was conducted on Day 6. Subjects were given access to both a bottle filled
with water and one filled with 5% sucrose solution. All water and sucrose
bottles were counterbalanced across the left and right sides of the cage
throughout the experiment. Conditioned taste aversion was calculated as
the intake of sucrose divided by total fluid intake (sucrose + water).
Groups of 8 animals per genotype were randomly assigned to a treat-
3.3. RESULTS 71
ment condition; conditioned taste aversion was measured for three doses
of MDMA: 0.0 mg kg−1 (saline), 2.5 mg kg−1 and 5.0 mg kg−1. Identical
testing procedures were used for used for three counterbalanced doses of
heroin: 0.0 mg kg−1 (saline), 0.5 mg kg−1 and 1.0 mg kg−1.
Drugs
Drug solutions were prepared by mixing 3,4-methylenedioxymethamphe-
tamine or heroin HCl (BDG Synthesis, Wellington, New Zealand), in pow-
der form, with saline. Both MDMA and heroin were administered via
intraperitoneal (i.p.) injection in a volume of 1 mg kg−1.
3.3 Results
3.3.1 Locomotor Activity
MDMA
Levels of basal locomotor activity were inversely related to SERT function
(HOM > HET > WT) reflecting increased exploratory behaviour in HOM
subjects (data not shown). Locomotor activity following a drug injection
was recorded over 60 min and is reported as total ambulatory counts. A
repeated measures ANOVA was conducted with dose (saline, MDMA 2.5,
MDMA 5.0 and MDMA 10.0) as a within subjects variable and genotype
(HOM, HET, WT) as a between subjects variable. This analysis revealed a
significant main effect of dose F(3, 63) = 13.81, p < .001, and a significant
main effect of genotype F(2, 21) = 3.69, p = .04. The dose*genotype was
also significant F(6, 63) = 4.48, p = .001 (see Figure 3.1).
Subsequently, one-way ANOVA post hoc analysis of locomotor activ-
ity was conducted for each drug dose. Saline treatment elicited a signifi-
cant difference between the genotypes F(2, 21) = 3.94, p = .04, with HOM
subjects registering more ambulatory counts compared to WT. Analysis of
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Figure 3.1: Average (+SEM) locomotor activity (ambulatory counts) for
HOM (n = 8), HET (n = 8) and WT (n = 8) subjects.
MDMA 2.5 mg kg−1 elicited locomotor activity revealed no differences be-
tween the genotypes, F(2, 21) = .16, p = .86; however, when animals were
treated with MDMA 5.0 mg kg−1 there was a significant difference in am-
bulatory counts between the genotypes F(2, 21) = 4.46, p = .02, with WT an-
imals demonstrating higher ambulatory counts compared to HET. Lastly,
analysis of MDMA 10.0 mg kg−1 elicited locomotor activity revealed a sig-
nificant difference between the genotypes F(2, 21) = 4.4, p = .03; WT an-
imals showed significantly greater locomotor activity when compared to
both HOM and HET groups (see Figure 3.1 and Table 3.1).
Upon further investigation within each genotype HOM subjects failed
to show a significant difference between the doses F(3, 28) = 1.64, p = .20.
However, HET subjects showed a significant difference between doses F(3,
28) = 5.07, p = .006, with significantly greater locomotor activity when
treated with MDMA 10.0 mg kg−1 compared to the other doses. Similarly,
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Saline MDMA 2.5 MDMA 5.0 MDMA 10.0
HOM - HET 0.18 0.89 0.78 0.99
HOM - WT 0.03* 0.87 0.10 0.04*
HET - WT 0.65 1.00 0.02* 0.05
Table 3.1: MDMA locomotor activity: post hoc comparisons. *Denotes
statistical significance.
WT subjects showed a significant difference between the doses F(3, 28) =
8.02, p = .001; like the HET group WT animals showed significantly greater
locomotor activity when treated with MDMA 10.0 mg kg−1 compared to
the other doses (see Table 3.2).
HOM HET WT
Saline - MDMA 2.5 0.97 0.99 0.99
Saline - MDMA 5.0 0.99 0.98 0.79
Saline - MDMA 10.0 0.42 0.01* 0.001*
MDMA 2.5 - MDMA 5.0 1.00 1.00 0.91
MDMA 2.5 - MDMA 10.0 0.22 0.02* 0.002*
MDMA 5.0 - MDMA 10.0 0.29 0.03* 0.01*
Table 3.2: MDMA locomotor activity: Post hoc comparisons. *Denotes
statistical significance.
Heroin
Locomotor activity following a drug injection was recorded over 60 min
and is reported as total ambulatory counts. A repeated measures ANOVA
was conducted with dose (saline, heroin 0.5, and heroin 1.0) as a within
subjects variable and genotype (HOM, HET, WT) as a between subjects
variable. This analysis revealed a significant main effect of dose F(2, 42)
= 6.53, p = .003; however the main effect of genotype, F(2, 21) = 0.58, p =
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.60, and the dose*genotype interaction failed to reach significance F(4, 42)
= 1.45, p = .24 (see Figure 3.2).
Figure 3.2: Average (+SEM) locomotor activity (ambulatory counts) for
HOM (n = 8), HET (n = 8) and WT (n = 8) subjects.
3.3.2 Conditioned Taste Aversion
MDMA
Conditioned taste aversion to a sucrose solution was calculated by divid-
ing sucrose consumption by total consumption (sucrose + water) on the
final day of testing. A two-way ANOVA was conducted with dose (saline,
MDMA 2.5, MDMA 5.0) and genotype (HOM, HET, WT) as between-
subjects variables. This analysis revealed a significant main effect of dose
F(2, 62) = 61.7, p < .001. The main effect of genotype failed to reach sig-
nificance F(2, 62) = .89, p = .42; interestingly the dose*genotype interaction
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did not reach significance but may indicate a trend toward an effect F(4,
62) = 2.17, p = .08 (see Figure 3.3).
Figure 3.3: Average (+SEM) conditioned taste aversion for HOM (n = 23),
HET (n = 24) and WT (n = 24) subjects
Subsequently, one-way ANOVA post hoc analysis of conditioned taste
aversion was conducted for each drug dose. Saline treatment failed to
elicit a difference in conditioned taste aversion between the genotypes F(2,
20) = 1.98, p = .16, nor was the effect seen for animals treated with MDMA
2.5 mg kg−1 F(2, 20) = .86, p = .44. However, analysis revealed a significant
difference between the genotypes treated with MDMA 5.0 mg kg−1 F(2,
20) = 5.09, p = .02; HET animals showed significantly greater conditioned
taste aversion when compared with WT. The HOM/HET and HOM/WT
comparisons both failed to reach significance (see Figure 3.3 and Table 3.3).
Upon further investigation within each genotype HOM subjects show-
ed a significant difference between the doses F(2, 20) = 19.41, p< .001. Rats
showed significantly greater conditioned taste aversion when treated with
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MDMA 2.5 mg kg−1 and MDMA 5.0 mg kg−1 compared to saline. How-
ever, the MDMA 2.5 mg kg−1 and MDMA 5.0 mg kg−1 comparison failed
to reach significance. The same pattern was seen for the HET and the WT
animals (see Table 3.4).
Saline MDMA 2.5 MDMA 5.0
HOM - HET 0.27 0.99 0.69
HOM - WT 0.97 0.47 0.10
HET - WT 0.19 0.54 0.02*
Table 3.3: MDMA Conditioned Taste Aversion: post hoc comparisons.
*Denotes statistical significance.
HOM HET WT
Saline - MDMA 2.5 0.00* 0.00* 0.03*
Saline - MDMA 5.0 0.00* 0.00* 0.01*
MDMA 2.5 - MDMA 5.0 0.94 0.63 0.80
Table 3.4: MDMA Conditioned Taste Aversion: Post hoc drug dose com-
parisons. *Denotes statistical significance.
Heroin
Conditioned taste aversion to a sucrose solution was calculated by divid-
ing sucrose consumption by total consumption (sucrose + water) on the
final day of testing. A two-way ANOVA was conducted with dose (saline,
heroin 0.5, heroin 1.0) and genotype (HOM, HET, WT) as between-subjects
variables. Both dose and genotype main effects failed to reach significance,
F(2, 61) = 1.77, p = .18, and F(2, 61) = .38, p = .69, respectively. Similarly,
the dose*genotype interaction failed to reach significance F(4, 61) = 1.28, p
= .29 (see Figure 3.4).
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Figure 3.4: Average (+SEM) conditioned taste aversion for HOM (n = 22),
HET (n = 24) and WT (n = 24) subjects.
3.4 Discussion
Taken together the locomotor activity results demonstrate that MDMA
differentially influences locomotion amongst the genotypes whereas he-
roin does not. Intriguingly and contrary to our predictions, we found
that MDMA induced locomotor activity was highest in the WT and com-
pletely absent in the HOM rats (see Table 3.2). If heightened locomo-
tion is an indicator of the rewarding properties of drugs of abuse this
pattern of results would suggest that the WT subjects compared to the
other groups are the most sensitive to MDMA. However, this conclusion
is not in line with what was observed when HOM, HET and WT subjects
self-administered MDMA as described in Chapter 2. Considering reduced
SERT function coincided with facilitated MDMA self-administration it ap-
peared that HOM (and HET) subjects were more sensitive to MDMA com-
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pared to the WT. These seemingly contradictory results can be explained
by examining the neurochemical mechanism underlying MDMA induced
locomotor activity. As mentioned above research has demonstrated that
dopamine neurotransmission in the mesolimbic pathway underlies both
the initial rewarding properties of drugs of abuse and locomotor activity.
However, as our data seem to indicate, MDMA induced locomotor ac-
tivity appears to be fundamentally different from other psychostimulants
like amphetamine and cocaine; Homberg et al. (2008) demonstrated that
HOM animals showed elevated locomotor activity after cocaine treatment
(Homberg et al., 2008). Importantly, MDMA induced locomotor activity
is partially driven by 5-HT release and this may explain why WT subjects
show heightened locomotor activity compared to subjects with reduced
SERT function. This result is consistent with several studies that have
implicated serotonin in the behavioural effects associated with MDMA,
demonstrating that MDMA induced locomotor activity is driven by the re-
lease of 5-HT (Callaway & Geyer, 1992; Callaway, Johnson, Gold, Nichols,
& Geyer, 1991; Callaway, Rempel, Peng, & Geyer, 1992; Callaway, Wing, &
Geyer, 1990). More recent research has demonstrated that when SERT KO
and WT rats were treated with MDMA both groups demonstrated higher
levels of locomotor activity compared saline treated controls; interestingly,
SERT KO animals treated with MDMA displayed delayed, lower levels of
locomotor activity compared to those with intact SERT function (Lizarraga
et al., 2014).
If MDMA induced locomotor activity is driven by 5-HT release then
evaluating this behaviour may not provide an accurate measure of the
dopaminergic activity and by extension the rewarding properties of these
particular drugs of abuse. However, evaluation of baseline levels of loco-
motor activity may elucidate an important aspect of dopaminergic neuro-
transmission. That is, baseline levels of locomotor activity reveal signif-
icantly greater locomotion for HOM animals compared to WT; this pat-
tern reflects differences in novelty induced locomotion which is related to
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dopamine release (Bromberg-Martin, Matsumoto, & Hikosaka, 2010; Du-
lawa, Grandy, Low, Paulus, & Geyer, 1999). Baseline comparisons then
suggest that HOM animals, compared to WT, may have increased dop-
amine neurotransmission and this translates to greater levels of locomo-
tor activity. This is consistent with heightened locomotor activity seen in
HOM animals that have been treated with cocaine suggesting increased
dopaminergic sensitivity (Homberg et al., 2008). Taken as a whole these
results suggest that despite increased basal levels of locomotor activity in
HOM animals it is primarily the release of 5-HT that drives MDMA in-
duced locomotor activity.
Regarding heroin induced locomotor activity it was hypothesised that,
considering there were no differences in heroin self-administration, a re-
duction in the SERT may not lead to a differential locomotor response
between the genotypes. As predicted, locomotion was largely consistent
across the doses for HOM, HET and WT groups. That is, animals, re-
gardless of genotype showed low levels of locomotion when treated with
saline. However, when treated with heroin 0.5 mg kg−1 animals showed a
modest increase in locomotor activity; then locomotor activity decreased
when the dose was increased to heroin 1.0 mg kg−1. Upon inspection of the
raw data it became apparent that some subjects, when treated with heroin
1.0 mg kg−1 (the highest dose), showed no locomotor activity in the final
minutes of the session (consecutive ambulatory counts of 0). This suggests
a higher dose of heroin may have induced sedation to the point where lit-
tle, if any, locomotor activity would have been produced. Therefore, it is
unlikely that the lack of genotype effect is the result of an incorrect dose
range but reflects a true null effect between the groups.
The MDMA conditioned taste aversion data are interesting and promis-
ing; they suggest that a genotype difference may exist depending on drug
dose with reduced SERT function influencing a heightened conditioned
taste aversion. It was predicted that reduction in the SERT would be in-
versely related to conditioned taste aversion with HOM subjects showing
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the largest effect. As described above comparisons failed to reach signif-
icance however this trend followed the initial prediction. Both MDMA
doses dramatically decreased sucrose consumption across the genotypes
with the higher dose producing the most dramatic shift in drinking be-
haviour. Considering this trend it would be useful to investigate how a
lower dose (MDMA 1.0 mg kg−1) may influence the development of MD-
MA induced conditioned taste aversion.
Finally, when the development of heroin conditioned taste aversion
was evaluated analysis revealed no differences between the groups. The
HOM, HET and WT groups failed to demonstrate conditioned taste aver-
sion for either drug dose. That is, the animals continued to prefer and
consume the sucrose solution even after it had been paired with heroin.
Initially, this was surprising considering research has demonstrated that
almost all drugs of abuse can initiate the development of conditioned taste
aversion. It is possible that this null effect was due to an insufficient as-
sociation between the sucrose solution and the effect of the drug. He-
roin induced central nervous system inhibition may have disrupted the
process where the drug effect becomes associated with the sucrose solu-
tion. This may explain why when presented with a choice between sucrose
and water the animals, regardless of genotype, continued to drink the su-
crose. Importantly, prior research has demonstrated that conditioned taste
aversion to sucrose failed to develop when animals were given morphine
(Parker, 1995). This effect was then demonstrated again in a study util-
ising morphine to investigate the combination of deprivation state, drug
type and caloric value of the palatable solution. They found that in water
deprived animals morphine failed to elicit a conditioned taste aversion to
a sucrose solution (Grigson, Lyuboslavsky, Tanase, & Wheeler, 1999). It
was suggested that water deprived animals also minimise food intake ef-
fectively leaving them water and food deprived. Considering sucrose has
a caloric value it is possible that continued consumption of the sucrose so-
lution even after morphine administration may have been due to hunger.
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While the current results were produced with heroin and not morphine
these two drugs have a highly similar mechanism of action and follow
a similar pattern suggesting that this particular combination of param-
eters was sufficient to disrupt the effect. It should be noted that other
research has demonstrated conditioned taste aversion to a sweet saccha-
rin solution after the administration of morphine (Arthurs, Lin, Amodeo,
& Reilly, 2012; Fenu et al., 2010). These studies provide a useful com-
parison for conditioned taste aversion developed in response to either
a sucrose or saccharin solution. That is, morphine paired with sucrose
appears to be insufficient to induce conditioned taste aversion whereas
the morphine/saccharin combination produces the predicted effect. Ad-
ditional research has demonstrated that opioid agonists increase feeding
behaviour (Sanger & McCarthy, 1980); specifically opioids potentiate the
natural reward that accompanies palatable foods (K. Evans & Vaccarino,
1990). This may explain why conditioned taste aversion can be detected
when morphine is paired with saccharin but not sucrose; saccharin, un-
like sucrose, has no caloric value. Moreover, it may explain the difference
between heroin and psychostimulant drugs (MDMA included) as the lat-
ter are appetite suppressants (Corwin, Woolverton, Schuster, & Johanson,
1987; S. Evans & Johanson, 1987; Griffiths, Winger, Brady, & Snell, 1976;
Wood & Emmettoglesby, 1988). Consequently, considering the discussion
given above it cannot be concluded that heroin does not produce condi-
tioned taste aversion but depends on the type of appetitive solution that is
paired with the drug. Therefore, it could be useful to evaluate heroin in-
duced conditioned taste aversion when the drug is paired with a saccharin
solution.
Considering the locomotor activity and conditioned taste aversion re-
sults together highlights a differential sensitivity between the genotypes
to MDMA effects but not to those driven by heroin. Locomotor activity
was facilitated for animals with intact SERT function suggesting that the
WT group is more sensitive to the positive rewarding effects of MDMA.
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However, it is posited that locomotor activity for drugs like MDMA may
not provide an accurate measure of the rewarding properties of these par-
ticular drugs. Therefore, from these experiments it cannot be concluded
that subjects with reduced SERT function are more (or less) sensitive to
the positive effects of drugs of abuse. Interestingly, the current data does
suggest that subjects with reduced SERT function may be more sensitive
to the negative effects of MDMA considering HOM animals showed the
greatest conditioned taste aversion of the three groups. Moving forward it
would be very useful to further evaluate these specific drug effects across
the genotypes.
This chapter highlighted differences in genotype when positive and
negative drug effects were evaluated systematically. However, in attempt-
ing to understand the complex phenomena of drug addiction is it essen-
tial to evaluate changes in behaviour as well as changes in brain function.
Through novelty suppressed feeding, drug self-administration, locomo-
tor activity and conditioned taste aversion Chapters 2 and 3 have sought
to understand how reduced SERT function interacts with different types
of drugs and influences different types of behaviour. Moving forward, in
Chapter 4, is a discussion regarding changes in the brain as a result of drug
taking (MDMA or heroin). This represents a very useful neurobiological
correlate to the behavioural data that has been presented thus far.
Chapter 4
Quantitative Reverse
Transcription Polymerase
Chain Reaction
4.1 Introduction
Drug addiction, or substance use disorder, is technically defined in terms
of behavioural changes in the individual. However, there is a huge body
of research to support the idea that drug addiction facilitates long term
changes in the way the brain functions. As discussed earlier research-
ers have hypothesised that drug addiction represents changes in synaptic
plasticity (i.e. learning); where neural connections in the dopaminergic
system become inflexible leading to habitual drug intake.
While synaptic plasticity encompasses a variety of processes in differ-
ent structures throughout the brain a family of proteins, neurotrophic fac-
tors, play an important role in the synaptic plasticity that underlies learn-
ing and memory (Binder & Scharfman, 2004).
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Brain Derived Neurotrophic Factor (BDNF)
One protein of interest is brain derived neurotrophic factor (BDNF); as a
member of the neurotrophic factor family it influences the development
of the brain by promoting the survival and growth of neurons. Addi-
tionally, BDNF has been implicated in synaptic transmission, neurogen-
esis and importantly, the synaptic plasticity that coincides with learning
(Binder & Scharfman, 2004; Conner et al., 1997). Found widely through-
out the central nervous system BDNF binds to the tropomyosin related
kinase B receptor (trkB).
BDNF and Neuropsychiatric Illness
BDNF plays a crucial role in neurological basis of psychiatric illnesses like
depression. Research has demonstrated that decreased BDNF expression
coincides with depression and stress (Igncio, Rus, Abelaira, & Quevedo,
2014). Antidepressants have been shown to be effective in eliminating
these effects; over a course of treatment BDNF levels return to normal.
Importantly, many current antidepressants, with differing mechanisms of
action, have been shown to increase BDNF levels; these studies provide
strong evidence that regulating levels of BDNF is important for the treat-
ment of depression (Duman & Monteggia, 2006; Kozisek et al., 2008). It
should be noted that these previous studies have utilised normal animals;
therefore, additional research using the SERT KO rat was conducted to
determine the influence of a compromised serotonergic system on BDNF
expression. Specifically, in rodent studies researchers have demonstrated
that a reduction in the SERT may influence baseline mRNA levels of to-
tal BDNF; compared to WT, HOM rats showed significantly reduced total
BDNF mRNA expression in both the hippocampus and prefrontal cortex.
Furthermore, studies have investigated changes in baseline mRNA levels
of specic coding regions (isoforms) in the BDNF gene. mRNA levels of
BDNF isoforms III, IV, VI and IXa in the hippocampus were reduced in
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HOM rats compared to WT; BDNF isoforms IV and VI were also reduced
in the prefrontal cortex in HOM animals (Molteni et al., 2010). Additional
research has investigated changes in BDNF expression after the adminis-
tration of the antidepressant, duloxetine, which targets the SERT and the
norepinephrine transporter (NET) prolonging 5-HT and norepinephrine
action in the synapse. After treating HOM and WT animals they found
that in both genotypes total BDNF mRNA levels were increased in the hip-
pocampus, the prefrontal cortex and the frontal cortex. They also investi-
gated changes in specific BDNF isoforms and found that BDNF III and
BDNF IXa mRNA levels were increased in the hippocampus in both geno-
types. Interestingly, they also saw increased mRNA levels in the prefrontal
cortex and hippocampus for BDNF transcripts IV and VI in the HOM ani-
mals but not the WT. Taken together duloxetine treatment restored BDNF
mRNA levels in HOM animals and increased the normal levels of BDNF
mRNA in the WT (Calabrese et al., 2010).
Whereas decreased levels of BDNF contribute to the neurological chan-
ges associated with depression there is evidence to suggest that increased
BDNF may be linked to drug addiction. For example, several research
groups have demonstrated that BDNF mRNA levels in rats were increased
in several brain structures (e.g. striatum, nucleus accumbens) after a sin-
gle injection of cocaine (Berglind et al., 2007; Le Foll et al., 2005). Another
study showed the same effect after a single dose of MDMA was adminis-
tered (Martinez-Turrillas et al., 2006). Subsequent research has determined
that when BDNF levels were increased in rats so did their self-administr-
ation of cocaine (Graham et al., 2007; McGinty et al., 2010). Interestingly,
research has demonstrated that opioid (morphine) exposure initially de-
creases BDNF expression in addition to reducing the physical size of dopa-
mine neurons in the ventral tegmental area (Chu et al., 2007; Sklair-Tavron
et al., 1996). Other studies investigating the role of BDNF in heroin ad-
diction demonstrated that BDNF mRNA was not influenced after heroin
exposure (Theberge et al., 2011, 2012). However, increases in total BDNF
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expression in the medial prefrontal cortex after withdrawal from chronic
opioid exposure have also been demonstrated (Kuntz-Melcavage, Bruck-
lacher, Grigson, Freeman, & Vrana, 2009). Additionally, another study re-
vealed that BDNF mRNA and BDNF protein levels in the ventral tegmen-
tal area were significantly increased in rats experiencing withdrawal from
heroin (Vargas-Perez et al., 2009). Similarly, Grimm et al. (2003) demon-
strated increased BDNF protein levels in the mesolimbic dopamine path-
way (e.g. ventral tegmental area) after withdrawal from cocaine (Grimm et
al., 2003). More recently, a study investigating withdrawal from metham-
phetamine showed that BDNF mRNA levels are significantly increased in
the dorsal striatum (X. Li et al., 2013). The same group also demonstrated
that cocaine withdrawal influenced BDNF expression in the nucleus ac-
cumbens; specifically, BDNF expression in the core increased over days
while the shell only showed increases after withdrawal day 90 (X. Li et al.,
2015). These studies suggest a specific role for BDNF in the incubation of
craving for sevearl different drugs of abuse.
Regarding specific BDNF isoforms studies have demonstrated that treat-
ment with cocaine can lead to differential changes in mRNA levels across
isoforms. For example, Liu et al. (2006) demonstrated that mRNA levels of
BDNF isoform IV were significantly increased in the striatum after cocaine
administration (Liu et al., 2006). Additionally, research has shown that co-
caine abstinence facilitates brain region specific increases in mRNA levels
of BDNF isoforms (e.g. increased BDNF isoform IV in the medial pre-
frontal cortex) (Sadri-Vakili et al., 2010). Furthermore, a follow up study
demonstrated that forced cocaine abstinence resulted in isoform specific
fluctuations in the ventral tegmental area where BDNF transcript I was in-
creased whereas BDNF transcript IV was unaffected (H. D. Schmidt et al.,
2012). These studies suggest a specific role for BDNF in the neurological
changes that accompany drug addiction. Dopaminergic pathways project
to a variety of brains regions (e.g. frontal cortex and striatum); considering
these neurons are influenced by drugs of abuse it would be useful to eval-
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uate BDNF changes in the structures where they terminate. Therefore, the
current set of experiments measured changes in total BDNF and individ-
ual BDNF isoforms (III, IV, VI, and IXa) in the frontal cortex and striatum
to evaluate the specific drug induced neuroadaptations that occur in sub-
jects with altered serotonergic function.
4.1.1 Predictions
Prediction 1: Considering drugs of abuse like cocaine increase BDNF
mRNA levels it is predicted that MDMA treatment will produce an
increase in total BDNF mRNA levels and this increase will be in-
versely related to SERT function (HOM > HET > WT).
Prediction 2: Considering that cocaine differentially influences BDNF
isoforms it is predicted that MDMA treatment will produce an in-
crease in BDNF isoform IV mRNA levels and this increase will be
inversely related to SERT function (HOM > HET > WT).
Prediction 3: Considering that heroin exposure not does appear to
influence BDNF expression it is predicted that heroin treatment will
not produce an overall change in total BDNF mRNA levels nor in-
dividual BDNF isoforms (III, IV, VI and IXa) and this will not differ
between HOM, HET, and WT groups.
4.2 Methods
4.2.1 Quantitative Reverse Transcription Polymerase Chain
Reaction
At the conclusion of the MDMA and heroin self-administration experi-
ments animals were sacrificed and brain tissue was extracted. For com-
parison untreated, matched groups of animals from each genotype were
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included and are designated “clean” or “untreated” below. Selected tissue
sections, the frontal cortex and striatum, were excised; the entire striatum
was taken for this experiment due to the small size of individual subsec-
tions (e.g. ventral, dorsal, dorsomedial or dorsolateral). Relative mRNA
expression was determined via Quantitative Reverse Transcription Poly-
merase Chain Reaction (qRT-PCR). All procedures described below were
carried out in a dedicated facility with precision qRT-PCR equipment.
In short, RNA was rapidly extracted and reverse transcribed into com-
plimentary DNA (cDNA). cDNA was amplified during the qPCR phase
and amplifications were visualised in real time by intercalation of the dye
SYBR Green that shows high fluorescence when bound to double stranded
DNA (and minimal fluorescence when free in solution). In a high effi-
ciency reaction the qPCR products double with each cycle during the ex-
ponential phase of amplification. Cycle threshold values (CT) for each
sample correspond to the cycle number at which the accumulated am-
plification products surpass the threshold for detection. Typically, the
detection threshold is automatically set by Bio-Rad software to be ap-
proximately 10 standard deviations above the baseline fluorescence value
(Nolan, Hands, & Bustin, 2006).
Tissue Dissection
Manipulations were undertaken at 4 ◦C or below and all tubes, pipette
tips and pestles were autoclaved to prevent nuclease degradation of the
RNA. Frozen tissue was sliced into 1.5 mm sections using a chilled alu-
minium brain cutting block according to a method described previously
(Heffner, Hartman, & Seiden, 1980). Each section was placed on a glass
dish set in ice where the frontal cortex and striatum were rapidly dis-
sected and placed individually into sterile 1.5 ml Eppendorf tubes. TRIzol
reagent was pipetted into each tube as per the manufacturer’s instructions:
1 ml TRIzol reagent per 50-100 mg of tissue. Individual samples weighed
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less than 50 mg; therefore, 0.5 ml TRIzol reagent was added to each tube.
With a sterile plastic pestle each sample was immediately homogenised
and then frozen at -80 ◦C until further use. The analysis below describes
changes in the striatal tissue only.
RNA Extraction
As described in Sargeant (2008) samples stored in TRIzol were thawed and
centrifuged at 13,000 x g at 4 ◦C for 15 min to remove cell debris. The su-
pernatant was transferred to a new micro centrifuge tube and the RNA
was extracted from the TRIzol solution as described in the manufacturer’s
instructions. Briefly, chloroform (50 µl) was added to the 0.5 ml TRIzol ex-
tract and centrifuged at 13000 x g for 10 min to recover the upper aqueous
phase containing the RNA. The aqueous phase was transferred to a new
micro centrifuge tube where it was mixed with 0.5 volumes of absolute
ethanol. A modification to the TRIzol extraction instructions was utilised
where additional purification was achieved with an RNA Isolation Kit
(GeneJet RNA Cleanup and Concentration Micro Kit, ISO9001/ISO14001,
K0842). In short, the aqueous TRIzol phase was mixed with equal volumes
of absolute ethanol and applied to a micro centrifuge column. Under high
ethanol concentration RNA binds to the column where it can be washed
and eluted by following the manufacturer’s instructions. The column was
washed with supplied wash buffers (wash buffer 1, 00115362; wash buffer
2, 00115356, prepared as directed). Each wash was achieved by applying a
volume of 700 µl and centrifuging for 1 minute at 14,000 x g. The RNA was
then eluted in 12 µl of ddH2O and captured in a new micro centrifuge tube.
RNA yield, quantity and quality were assessed by UV spectroscopy using
a ND-1000 “Nanodrop” spectrophotometer (Nanodrop, Wilmington, DE)
to record A260, A280 and A230 absorbance. A A260/280 absorbance ratio
for each sample was calculated where ∼2.0 is the accepted standard for
“pure” RNA (Sargeant, 2008).
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Reverse Transcription
Reverse transcriptions were performed using the Superscript III kit and
components (Invitrogen, 18080-044). Reactions were prepared in two stage-
s (see Table 4.1). First, Oligo dT20, RNA, deoxynucleotides (dNTPs) and
ddH2O were added to achieve a total volume of 26 µl and the mixture
was heated to 65 ◦C for 5 minutes then snap chilled. Second, the follow-
ing components were added: 5x First-Strand Buffer, dithiothreitol (DTT),
RNaseOUT and Superscript III to a total overall volume of 40 µl. The RT
reaction was heated in a water bath at 50 ◦C for 60 minutes and terminated
by heating to 75 ◦C for 15 minutes.
Stage 1
Component Concentration Volume
Oligo dT20 2.5 µM 2 µl
dNTP 10 µM 2 µl
RNA 1-3 µg 7.5 µl
ddH2O - 14.5 µl
Stage 2
Component Concentration Volume
DTT 0.1 M 2 µl
RNaseOUT 40 U/µl 2 µl
Superscript III 200 U/µl 2 µl
5x First-Strand Buffer 250 mM Tris-HCl 8 µl
375 mM KCl
15 mM MgCl2
Table 4.1: Reverse transcription reaction information: Component concen-
trations and volumes.
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Quantitative Reverse Transcription Polymerase Chain Reaction
Amplifications were performed in triplicate in final volume of 25 µl. Mas-
ter mixes containing Platinum SYBR Green qRT-PCR SuperMix-UDG (2x
concentration, SMPF-212G), cDNA (1 µl of the heat activated RT mixture)
and water were prepared and added to each primer set (0.2 µM forward
and reverse primers indicated in Table 4.2).
Control reactions were included with each amplification. A no re-
verse transcription control (NRT) was prepared for each sample where
the cDNA template was replaced with sample RNA; amplification in a
NRT reaction would indicate the presence of contaminating genomic DNA
in the sample. Additionally, a no template control (NTC) was prepared
where the cDNA template was replaced with water (one per 96 well plate);
amplification in a NTC reaction may indicate contamination during the
qRT-PCR setup (e.g. pipette tips, tubes).
qRT-PCR cycling conditions were as previously described (Calabrese
et al., 2010; Molteni et al., 2009). Samples were heated to 50 ◦C for 2 min
then to 95 ◦C for 10 min followed by 40 cycles of denaturation at 95 ◦C (15
s) and annealing/extension at 60 ◦C (1 min). An example of exponential
product amplification for three representative samples is given in Figure
4.1. Melt curve analysis was conducted between 65 and 95 ◦C to confirm
correct amplification of qPCR products. An example of three representa-
tive samples is given in Figure 4.2.
Data Analysis
Five BNDF targets were evaluated: total BDNF, BDNF transcript III, BDNF
transcript IV, BDNF transcript VI and BDNF transcript IXa (see Table 4.2).
Expression relative to two housekeeping genes, Cyclophilin A (Cyc A)
and Hypoxanthine-guanine phosphoribosyltransferase (HPRT), was un-
dertaken. These two housekeeping genes have been used extensively in
similar studies of mRNA expression analysis of brain tissue (Aid, Kazant-
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Figure 4.1: Representative qRT-PCR amplification of mRNA from the
striatum of heroin treated subjects. Amplification targets included: Cy-
clophilin A, HPRT, Total BDNF, and BDNF trasncripts III, IV, VI and IXa.
The detection threshold is indicated by the dash line.
seva, Piirsoo, Palm, & Timmusk, 2007; Sargeant, 2008). As internal control
genes their expression should not vary significantly between genotypes
or treatments. All amplification triplicates were scrutinised and a pat-
tern emerged: the first triplicate consistently differed from the second and
third. As this occured across all samples the second and third triplicate
were averaged and relative gene expression was calculated using the com-
parative cycle threshold (CT) method. For each sample the cycle threshold
value for the housekeeping gene was subtracted from the sample thresh-
old cycle (∆CT = CT target gene - CT housekeeping gene). Then each ∆CT
value was converted into the negative binary log (2−∆CT) prior to statisti-
cal analysis. When the sample threshold cycle exceeded the housekeeping
gene threshold cycle the resulting 2−∆CT value would be <1 indicating a
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Figure 4.2: Representative melt curve analysis with a peak for each ampli-
con consistent with the predicted PCR temperature. Amplification targets
and melting temperatures are as follows: Cyclophilin A (81.5 ◦C), HPRT
(79.5 ◦C), Total BDNF (82 ◦C), BDNF III (79 ◦C), BDNF IV (81.5 ◦C), BDNF
VI (85.5 ◦C) and BDNF IXa (85 ◦C). The threshold filter is indicated by the
dash line.
reduction in gene expression; therefore, by taking the negative inverse of
the binary log (-1/2−∆CT) yielded a fold change reduction for the given
sample (Schmittgen & Livak, 2008).
It should be noted that while evaluating changes in gene expression by
analysing ∆CT values is common practice it may not represent the most
appropriate method. This is due to the fact that a qRT-PCR reaction run-
ning at optimal efficiency (100%) will, with each cycle, produce a doubling
the of the amplification products. Therefore, small ∆CT values may be
deemed insignificant when compared via statistical analysis that does not
take into account the exponential nature of the data points. Additionally,
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Total BDNF
Forward AGCTGAGCGTGTGTGACAGT
Reverse ACCCATGGGATTACACTTGG
Reference Musazzi et al. 2009
BDNF transcript III
Forward ATGCTTCATTGAGCCCAGTT
Reverse GTGGACGTTTGCTTCTTTCA
Reference Calabrese et al. 2010
BDNF transcript IV
Forward TGCGAGTATTACCTCCGCCAT
Reverse TCACGTGCTCAAAAGTGTCAG
Reference Lubin et al. 2008
BDNF transcript VI
Forward TTGGGGCAGACGAGAAAGCGC
Reverse TCACGTGCTCAAAAGTGTCAG
Reference Lubin et al. 2008
BDNF transcript IXa
Forward TGGTGTCCCCAAGAAAGTAA
Reverse CACGTGCTCAAAAGTGTCAG
Reference Calabrese et al. 2010
Table 4.2: Primer sequences used for qRT-PCR analysis.
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it is difficult to interpret varying ∆CT values because they fail to describe
the actual amount of mRNA initially present in the reaction. For exam-
ple, if there is a relatively small amount of input mRNA in the qRT-PCR
reaction it will require additional amplification cycles to generate suffi-
cient product to be detected for both the housekeeping gene as well as the
target gene. So while two samples may yield the same ∆CT value they
may represent vastly different amounts of amplification products. This
can be problematic with particularly high CT values (those approaching
the maximum cycle number, 40) as experimentally generated noise can
become significant. Such amplification has detectable but not quantifiable
amounts of the template. Therefore, in an effort to circumvent these issues
that surround the analysis and interpretation of∆CT values there is grow-
ing support for the use of converted negative binary log values (2−∆CT)
in qRT-PCR statistical analysis (described above). These values represent
increases or decreases in gene expression and more transparently reflect
the fold changes that can be obscured when interpreting ∆CT values. For
these reasons the analysis presented in this chapter utilises converted neg-
ative binary log values (2−∆CT). Please note that for direct comparison the
raw data, with accompanying figures, for both ∆CT and 2−∆CT values are
provided in the Appendix: Supplemental qRT-PCR Analysis.
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4.3 Results
4.3.1 Average Housekeeping Genes
To evaluate the relative expression of the housekeeping genes across geno-
types and treatment groups ∆CT values were calculated for each sample
(∆CT = CT HPRT - CT Cyc A); then each∆CT value was converted into the
negative binary log (2−∆CT) and analysed via two way ANOVA with geno-
type and treatment as between-subjects variables (raw data are provided
in the Appendix: Section 1). Analysis revealed a significant main effect
of treatment, F(2, 35) = 3.73, p = .03; however, neither the main effect of
genotype, F(2, 35) = 1.65, p = .21, nor the treatment*genotype interaction
reached significance, F(4, 35) = .59, p = .67 (see Figure 4.3).
Figure 4.3: Relative housekeeping gene expression across treatment
groups and genotypes.
Post hoc analysis was undertaken and it revealed a significant differ-
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ence within the HOM group between heroin treated and untreated (clean)
subjects; heroin treated subjects showed lower 2−∆CT values compared to
the untreated (clean). Considering this effect was only seen in HOM sub-
jects under one specific treatment regimen it is unlikely that this variation
represents a confounding variable; that is, the effect does not nullify the
selected housekeeping genes as internal references for these experiments.
Therefore, the five BDNF targets listed in Table 4.2 were compared to both
Cyclophilin A and HPRT.
4.3.2 Total BDNF
Cyclophilin A
To evaluate relative gene expression of total BDNF (mRNA) ∆CT values
were calculated for each sample (∆CT = (CT total BDNF) - (CT Cyc A)).
Then each ∆CT value was converted into the negative binary log (2−∆CT).
Individual datum values are provided in the Appendix: Section 2. Data
were analysed via two way ANOVA with genotype and treatment as betw-
een-subjects variables. Comparing clean and MDMA treated samples re-
vealed a significant main effect of treatment, F(1, 24) = 19.91, p< .001, with
MDMA treated samples showing higher converted 2−∆CT values compared
to the clean group. The main effect of genotype and the treatment*genotype
interaction failed to reach significance F(2, 24) = 1.11, p = .35 and F(2, 24) =
1.97, p = .16, respectively. Conversely, comparing clean and heroin treated
samples did not reveal a significant main effect of treatment, F(1, 23) = .15,
p = .7, nor genotype, F(2, 23) = .001, p = 1.0, and the treatment*genotype
interaction failed to reach significance F(2, 23) = .18 p = .83, (see Figure 4.4).
HPRT
To evaluate relative gene expression of total BDNF (mRNA) ∆CT values
were calculated for each sample (∆CT = (CT total BDNF) - (CT HPRT)).
Then each ∆CT value was converted into the negative binary log (2−∆CT).
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Figure 4.4: Converted 2−∆CT values for total BDNF against Cyclophilin A.
Figure 4.5: Converted 2−∆CT values for total BDNF against HPRT.
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Individual datum values are provided in the Appendix: Section 2. Data
were analysed via two way ANOVA with genotype and treatment as betw-
een-subjects variables. Comparing clean and MDMA treated samples re-
vealed a significant main effect of treatment, F(1, 24) = 14.91, p = .001, with
MDMA treated samples showing higher converted 2−∆CT values compared
to the clean group. The main effect of genotype and the treatment*genotype
interaction failed to reach significance F(2, 24) = .23, p = .8 and F(2, 24) =
.28, p = .76, respectively. Conversely, comparing clean and heroin treated
samples did not reveal a significant main effect of treatment, F(1, 23) = 2.79,
p = .11, nor genotype, F(2, 23) = .34, p = .71, and the treatment*genotype
interaction failed to reach significance F(2, 23) = .03, p = .97 (see Figure 4.5).
4.3.3 BDNF transcript III
Cyclophilin A
To evaluate relative gene expression of BDNF transcript III (mRNA) ∆CT
values were calculated for each sample (∆CT = (CT BDNF III) - (CT Cyc
A)). Then each ∆CT value was converted into the negative binary log
(2−∆CT). Individual datum values are provided in the Appendix: Section
3. Data were analysed via two way ANOVA with genotype and treatment
as between-subjects variables. Comparing clean and MDMA treated sam-
ples revealed a significant main effect of treatment, F(1, 24) = 6.44, p =
.02, with MDMA treated samples showing higher converted 2−∆CT values
compared to the clean group. The main effect of genotype and the treat-
ment*genotype interaction failed to reach significance F(2, 24) = .28, p =
.76 and F(2, 24) = .24, p = .79, respectively. Conversely, comparing clean
and heroin treated samples did not reveal a significant main effect of treat-
ment, F(1, 23) = .78, p = .39, nor genotype, F(2, 23) = .11, p = .9, and the
treatment*genotype interaction failed to reach significance F(2, 23) = .29 p
= .75, (see Figure 4.6).
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Figure 4.6: Converted 2−∆CT values for III BDNF against Cyclophilin A.
HPRT
To evaluate relative gene expression of BDNF transcript III (mRNA) ∆CT
values were calculated for each sample (∆CT = (CT BDNF III) - (CT HPRT)).
Then each ∆CT value was converted into the negative binary log (2−∆CT).
Individual datum values are provided in the Appendix: Section 3. Data
were analysed via two way ANOVA with genotype and treatment as betw-
een-subjects variables. Comparing clean and MDMA treated samples re-
vealed a significant main effect of treatment, F(1, 24) = 8.39, p = .008, with
MDMA treated samples showing higher converted 2−∆CT values compared
to the clean group. The main effect of genotype and the treatment*genotype
interaction failed to reach significance F(2, 24) = .57, p = .57 and F(2, 24) =
.43, p = .66, respectively. Conversely, comparing clean and heroin treated
samples did not reveal a significant main effect of treatment, F(1, 23) = 3.63,
p = .07, nor genotype, F(2, 23) = .56, p = .58, and the treatment*genotype
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interaction failed to reach significance F(2, 23) = .30, p = .74 (see Figure 4.7).
Figure 4.7: Converted 2−∆CT values for BDNF III against HPRT.
4.3.4 BDNF transcript IV
Cyclophilin A
To evaluate relative gene expression of BDNF transcript IV (mRNA) ∆CT
values were calculated for each sample (∆CT = (CT BDNF IV) - (CT Cyc
A)). Then each ∆CT value was converted into the negative binary log
(2−∆CT). Individual datum values are provided in the Appendix: Section
4. Data were analysed via two way ANOVA with genotype and treatment
as between-subjects variables. Comparing clean and MDMA treated sam-
ples revealed a significant main effect of treatment, F(1, 24) = 8.93, p =
.006, with MDMA treated samples showing higher converted 2−∆CT val-
ues compared to the clean group. The main effect of genotype and the
treatment*genotype interaction failed to reach significance F(2, 24) = .34, p
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= .71 and F(2, 24) = .31, p = .74, respectively. Conversely, comparing clean
and heroin treated samples did not reveal a significant main effect of treat-
ment, F(1, 23) = .11, p = .75, nor genotype, F(2, 23) = .11, p = .9, and the
treatment*genotype interaction failed to reach significance F(2, 23) = .38 p
= .69, (see Figure 4.8).
Figure 4.8: Converted 2−∆CT values for BDNF IV against Cyclophilin A.
HPRT
To evaluate relative gene expression of BDNF transcript IV (mRNA) ∆CT
values were calculated for each sample (∆CT = (CT BDNF IV) - (CT HPRT)).
Then each ∆CT value was converted into the negative binary log (2−∆CT).
Individual datum values are provided in the Appendix: Section 4. Data
were analysed via two way ANOVA with genotype and treatment as betw-
een-subjects variables. Comparing clean and MDMA treated samples re-
vealed a significant main effect of treatment, F(1, 24) = 10.22, p = .004, with
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MDMA treated samples showing higher converted 2−∆CT values compared
to the clean group. The main effect of genotype and the treatment*genotype
interaction failed to reach significance F(2, 24) = .57, p = .58 and F(2, 24) =
.58, p = .57, respectively. Conversely, comparing clean and heroin treated
samples did not reveal a significant main effect of treatment, F(1, 23) = .84,
p = .37, nor genotype, F(2, 23) = .35, p = .71, and the treatment*genotype
interaction failed to reach significance F(2, 23) = .86, p = .44 (see Figure 4.9).
Figure 4.9: Converted 2−∆CT values for BDNF IV against HPRT.
4.3.5 BDNF transcript VI
Cyclophilin A
To evaluate relative gene expression of BDNF transcript VI (mRNA) ∆CT
values were calculated for each sample (∆CT = (CT BDNF VI) - (CT Cyc
A)). Then each ∆CT value was converted into the negative binary log
(2−∆CT). Individual datum values are provided in the Appendix: Section
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5. Data were analysed via two way ANOVA with genotype and treatment
as between-subjects variables. Comparing clean and MDMA treated sam-
ples did not reveal a significant main effect of treatment, F(1, 24) = 1.41, p =
.25, or genotype, F(2, 24) = .38, p = .69, and the treatment*genotype interac-
tion failed to reach significance F(2, 24) = .73, p = .49. Similarly, comparing
clean and heroin treated samples did not reveal a significant main effect of
treatment, F(1, 23) = .001, p = .97, or genotype, F(2, 23) = .07, p = .93, and
the treatment*genotype interaction failed to reach significance F(2, 23) =
.58, p = .57 (see Figure 4.10).
Figure 4.10: Converted 2−∆CT values for BDNF VI against Cyclophilin A.
HPRT
To evaluate relative gene expression of BDNF transcript VI (mRNA) ∆CT
values were calculated for each sample (∆CT = (CT BDNF VI) - (CT HPRT)).
Then each ∆CT value was converted into the negative binary log (2−∆CT).
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Individual datum values are provided in the Appendix: Section 5. Data
were analysed via two way ANOVA with genotype and treatment as betw-
een-subjects variables. Comparing clean and MDMA treated samples did
not reveal a significant main effect of treatment, F(1, 24) = 2.85, p = .11, or
genotype, F(2, 24) = .14, p = .87, and the treatment*genotype interaction
failed to reach significance F(2, 24) = .15, p = .86. Similarly, comparing
clean and heroin treated samples did not reveal a significant main effect of
treatment, F(1, 23) = 2.00, p = .17, or genotype, F(2, 23) = .62, p = .55, and
the treatment*genotype interaction failed to reach significance F(2, 23) =
.24, p = .79 (see Figure 4.11).
Figure 4.11: Converted 2−∆CT values for BDNF VI against HPRT.
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4.3.6 BDNF transcript IXa
Cyclophilin A
To evaluate relative gene expression of BDNF transcript IXa (mRNA)∆CT
values were calculated for each sample (∆CT = (CT BDNF IXa) - (CT Cyc
A)). Then each ∆CT value was converted into the negative binary log
(2−∆CT). Individual datum values are provided in the Appendix: Section
6. Data were analysed via two way ANOVA with genotype and treatment
as between-subjects variables. Comparing clean and MDMA treated sam-
ples did not reveal a significant main effect of treatment, F(1, 24) = 2.58, p =
.12, or genotype, F(2, 24) = .17, p = .84, and the treatment*genotype interac-
tion failed to reach significance F(2, 24) = .22, p = .80. Similarly, comparing
clean and heroin treated samples did not reveal a significant main effect of
treatment, F(1, 23) = 2.47, p = .13, or genotype, F(2, 23) = .28, p = .76, and
the treatment*genotype interaction failed to reach significance F(2, 23) =
.26, p = .77 (see Figure 4.12).
HPRT
To evaluate relative gene expression of BDNF transcript IXa (mRNA)∆CT
values were calculated for each sample (∆CT = (CT BDNF IXa) - (CT HPRT)).
Then each ∆CT value was converted into the negative binary log (2−∆CT).
Individual datum values are provided in the Appendix: Section 6. Data
were analysed via two way ANOVA with genotype and treatment as betw-
een-subjects variables. Comparing clean and MDMA treated samples did
not reveal a significant main effect of treatment, F(1, 24) = 1.55, p = .23, or
genotype, F(2, 24) = .44, p = .65, and the treatment*genotype interaction
failed to reach significance F(2, 24) = .12, p = .89. Similarly, comparing
clean and heroin treated samples did not reveal a significant main effect of
treatment, F(1, 23) = .1, p = .75, or genotype, F(2, 23) = .03, p = .97, and the
treatment*genotype interaction failed to reach significance F(2, 23) = .14, p
= .87 (see Figure 4.13).
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Figure 4.12: Converted 2−∆CT values for BDNF IXa against Cyclophilin A.
Figure 4.13: Converted 2−∆CT values for BDNF IXa against HPRT.
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Brief Summary of Results
A significant main effect of treatment emerged for total BDNF and BDNF
transcripts III and IV; that is, MDMA treatment increased relative gene
expression in these targets across genotypes. Conversely, no significant
differences emerged when BDNF transcripts VI and IXa were evaluated.
Interestingly, heroin treatment failed to elicit a change in BDNF target ex-
pression compared to subjects that were untreated (clean).
4.4 Discussion
Baseline levels of Cyclophilin A and HPRT were compared to each other
to evaluate relative differences in expression between the two housekeep-
ing genes. Analysis revealed a significant main effect of treatment. This
effect was driven by a significant difference within the HOM subjects that
showed greater 2−∆CT values for the untreated (clean) animals compared
to those treated with heroin. The utility of the comparative CT method is
predicated on the assumption that housekeeping gene expression is stable
across treatment groups; this is essential as the housekeeping gene repre-
sents an internal control to which all target genes are compared. In this ex-
periment a small but significant difference emerged within a single geno-
type (HOM) and between two of the three treatment groups (clean and
heroin). This result may indicate a fundamental difference in the expres-
sion of the housekeeping between genotypes or treatment groups. How-
ever, if the genotypes were interacting with gene expression then it would
be expected that all of the HOM animals, regardless of treatment, would
show consistently altered gene expression. Similarly, if treatment were
interacting with gene expression it would follow that all heroin treated
groups would show this differential expression. Neither of these scenarios
were supported by the current set of findings. Considering the total data
presented in the Results section, a consistent pattern between all of the
4.4. DISCUSSION 109
BDNF targets and both housekeeping genes was demonstrated. Therefore,
this suggests that overall the relative expression of the two housekeeping
genes is stable and that the effect seen here is likely the result of natural
variation between discrete groups of animals.
When the five BDNF targets were compared to both Cyclophilin A and
HPRT a differential pattern emerged between clean and MDMA treated
subjects; a significant main effect of treatment was demonstrated for to-
tal BDNF, BDNF transcript III and BDNF transcript IV. That is, converted
2−∆CT values were significantly greater in the MDMA treated groups com-
pared to those that were untreated (clean) indicating increased BDNF tar-
get gene expression. Conversely, no differences emerged between clean
and MDMA treated subjects when BDNF transcript VI and BDNF tran-
script IXa were evaluated. Despite an MDMA driven increase for total
BDNF, BDNF transcript III and BDNF transcript IV and contrary to the hy-
pothesis given above no genotype differences between clean and MDMA
treated subjects emerged. This lack of effect was not expected considering
the robust differences in MDMA self-administration behaviour exhibited
by these animals. Considering the data carefully it is possible that a geno-
type effect may exist but is being obscured in the current experiment due
to small samples sizes and a degree of variability.
Beyond the initial analysis the data were evaluated for the presence of
outliers via various methods (e.g. outlier labelling rule); however, while
the subsequent reanalysis trended closer to a significant effect it reduced
the already small samples sizes and still failed to reveal a significant in-
teraction or main effect of genotype for any of the BDNF targets. For
this reason the analysis described in this chapter subsumes the entire data
set and the raw data values are given in the Appendix for further inspec-
tion. In addition to evaluating MDMA induced differences in BDNF target
gene expression analysis comparing the clean and heroin treated groups
revealed no differences whatsoever for any of the five BDNF targets.
Taken together these results suggest that MDMA exposure facilitates
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gene expression for total BDNF and it does so equally for the three geno-
types. This effect mirrors previously described research where the admin-
istration of duloxetine led to an increase in BDNF expression in both HOM
and WT animals (Calabrese et al., 2010). Both duloxetine and MDMA tar-
get the SERT and NET and considering HOM animals have no SERT on
which the drugs to act this suggests an important role of the NET in the
MDMA induced changes in BDNF expression although this was not found
in the striatum. The increased BDNF transcript IV expression after MDMA
exposure is consistent with previous research demonstrating that cocaine
facilitated increased expression of this particular BDNF isoform (Liu et al.,
2006). These results are a direct contrast to the lack of effect in any of the
BDNF targets for subjects treated with heroin. Previous research inves-
tigating the relationship between BDNF expression and opioid addiction
has focused on changes associated with drug withdrawal and craving. For
example, one group has demonstrated that total BDNF expression in the
nucleus accumbens did not fluctuate after forced drug abstinence from
heroin (Theberge et al., 2011, 2012); however, other research has demon-
strated that total BDNF expression in the medial prefrontal cortex is in-
creased after forced abstinence from heroin (Kuntz-Melcavage et al., 2009).
It is important to note that the current data came from brain tissue that had
been extracted and snap frozen without the animals experiencing drug
withdrawal. That is, tissue extraction occurred after a single session of
stable FR5 responding that followed the last progressive ratio dose. There-
fore, it is possible that our results differ from others due to BDNF changes
at varying time points during drug taking (immediately after progressive
ratio versus after forced abstinence). Additionally, it should be stated that
these experiments investigated BDNF expression changes in a variety of
brain regions which could be differentially influenced after drug exposure.
For these reasons it would be premature to conclude that heroin does not
influence BDNF expression. Rather changes are likely contingent upon a
variety of factors and these may not have been elucidated fully in the cur-
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rent set of experiments. Nonetheless, the current results show that there
are inherent differences between the changes in striatal BDNF expression
in animals that have self-administered MDMA compared to heroin.
Therefore, given the robust differences in MDMA self-administration
between the genotypes the current qRT-PCR data indicate that changes
in BDNF expression are not explicitly related to the development of drug
addiction (as measured by drug self-administration). However, there are
two important caveats that must be acknowledged. First, the research de-
scribed above investigated changes in BDNF expression after drug with-
drawal (Sadri-Vakili et al., 2010; H. D. Schmidt et al., 2012) whereas the
current experiment did not. Therefore, it is unclear as to the exact role
that BDNF plays in MDMA self-administration. Second, the current ex-
periment only investigated changes in BDNF expression in animals that
had successfully acquired MDMA self-administration (see Figure 2.2). It
is important to remember that only about half of WT animals meet the
acquisition criterion for MDMA self-administration. Therefore, while dif-
ferences exist between the HOM and WT animals (“acquirers”) across var-
ious schedules of responding the differences between the groups are not
as large as those found for the acquisition of MDMA self-administration.
This may explain why the current experiment demonstrated a robust ef-
fect for MDMA treated animals without revealing a difference between
the genotypes.
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Chapter 5
General Discussion
5.1 Rationale
The preceding series of behavioural and molecular experiments aimed to
elucidate how a potential genetic risk factor, a reduction in SERT func-
tion, may influence the development of drug addiction. With only a small
percentage of individuals who use drugs of abuse making the “transition
to addiction” it behoves researchers to investigate the role that individual
differences likely play in the development of drug addiction. Addition-
ally, in order to develop and provide efficacious treatments for the clinic
it is essential to understand the complex interplay between individual ge-
netic differences and the types of drugs being consumed.
5.2 Brief Summary
Utilising the serotonin transporter knockout rat model HOM, HET and
WT animals completed MDMA or heroin drug self-administration exper-
iments. Interestingly, a robust genotype effect emerged for animals self-
administering MDMA; facilitation of MDMA self-administration was in-
versely related to reduced SERT function. HOM animals, without excep-
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tion, reached acquisition criterion significantly faster than the HET ani-
mals; HET animals showed higher acquisition rates compared to the WT
animals. In contrast, there were no differences between the genotypes
when animals self-administered heroin.
MDMA induced locomotor activity was reduced in HOM and HET
animals compared to WT animals. However, heroin treatment did not
produce differences in locomotion between the genotypes.
MDMA induced conditioned taste aversion revealed only a main effect
of dose with robust conditioned taste aversion for both drug doses. How-
ever, heroin treatment failed to produce a conditioned taste aversion effect
in any of the groups regardless of dose.
Lastly, when striatal brain tissue was analysed via qRT-PCR levels in
several BDNF targets were significantly increased in animals that had self-
administered MDMA; this effect was true across genotypes. Compara-
tively, animals that had self-administered heroin did not show a difference
in BDNF expression compared to untreated control animals.
5.3 Experimental Significance
The information gleaned from this series of behavioural and molecular
experiments should be used to inform overall understanding of drug ad-
diction in humans. Utilising the serotonin transporter knockout rat model
was a very useful tool for systematically investigating how a reduction
in the SERT contributes to the development of drug addiction. A major
advantage of this tool is the fact that it effectively models a genetic con-
formation that happens naturally in humans; some individuals are born
with reduced SERT function (s/s or l/s) while others have what would
be considered standard (l/l, not reduced). To our knowledge there are
no humans who completely lack the SERT like the HOM rat genotype.
However, information gleaned from these animals can provide a valuable
theoretical perspective compared to the other genotypes. Reduction in the
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SERT is seen in both humans (s/s) and the HET animals 50% compared to
those with standard SERT function (l/l in humans and WT animals). This
change in the serotonergic system is present from conception in both hu-
mans and the serotonin transporter knockout rat or at least from the time
the serotonergic system and the SERT start to develop. Consequently, it
is reasonable to expect that compensatory mechanisms have occurred in
response to this change.
By definition reduced SERT function does not allow for complete clear-
ance of 5-HT from the synaptic space leaving it to continue acting on ad-
jacent cells. Continually elevated levels of synaptic 5-HT are likely to lead
to down regulation of 5-HT receptors which, in turn, would influence the
entire serotonergic system (Homberg et al., 2008). At this point we do
not fully understand the range, influence and complexity of these adap-
tations. Despite the fact that these changes complicate the understanding
of the entire system they do exist in both humans and the SERT KO rat.
Therefore, the results gleaned from these experiments can be carefully in-
terpreted and inform understanding of human drug addiction. For exam-
ple, the drug self-administration experiments demonstrated that animals
with reduced SERT function are significantly more sensitive to the effects
of MDMA compared to those with intact SERT function. This result sug-
gests that depending on serotonergic function in humans some individu-
als may prove to be more sensitive to the effects of MDMA compared to
others. Comparatively, regardless of genotype heroin self-administration
behaviour was largely the same suggesting that a reduction in the SERT
does not influence addiction to this particular opioid. However, as her-
oin has been well studied for many years it is known to be a powerful
reinforcer and to have high abuse liability (indeed much higher than the
abuse liability of MDMA). These results together suggest that a reduction
in the SERT may confer increased susceptibility for developing drug ad-
diction to certain types of drugs but perhaps not to others. That is, regard-
less of SERT function animals were equally as likely to administer heroin
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and become “addicted” whereas MDMA self-administration was signif-
icantly facilitated for animals with reduced SERT above levels for those
with intact SERT function. However, it must be noted that the qRT-PCR
analysis of the striatal brain tissue revealed that MDMA significantly in-
creased BDNF expression in total BDNF and select transcripts but it did
so equally across the three genotypes. This may be due to a variety of fac-
tors including small samples sizes, inability to detect small shifts in gene
expression or that BDNF gene expression is more readily influenced by
reduced SERT function in other portions of the brain (e.g. nucleus accum-
bens, frontal cortex, or prefrontal cortex). Conversely when the effect of
heroin self-administration on BDNF expression was evaluated via qRT-
PCR the data were consistent with our behavioural findings; that is, no
differences emerged when heroin treated subjects were compared to un-
treated controls. Taken together the current qRT-PCR experiments indi-
cate that BDNF may play a role in drug addiction; however, at this time
we cannot conclude that this relationship is direct and explicit.
It should also be noted that there is a great deal of literature supporting
the idea that a complex relationship exists between the serotonergic sys-
tem and disparate types of drugs. As described previously psychostim-
ulants (e.g. cocaine, amphetamine) and opioids (e.g. morphine, heroin)
ultimately act on a common neurological substrate (the mesolimbic dopa-
mine pathway) which can lead to cognitive impairments in the prefrontal
cortex. Interestingly, studies have shown that self-administration of co-
caine or morphine does not predict self-administration of the other drug;
these results reinforce the idea that psychostimulants and opioids operate
by differing mechanisms (Lenoir, Guillem, Koob, & Ahmed, 2012). More
specifically, research has demonstrated that impulsivity, which is related
to changes in the serotonergic system (Kirby et al., 2011) and is implicated
in drug addiction, may provide insight into important differences between
behavioural changes from the use of psychostimulants and opioids. For
example, studies in human drug addicts revealed that compulsive am-
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phetamine use resulted in robust increases in measures of impulsivity (e.g.
impairments in memory, decision making) whereas heroin use did not (Er-
sche, Clark, London, Robbins, & Sahakian, 2006; Ersche et al., 2005). Sim-
ilarly, animal studies demonstrated that cocaine withdrawal was accom-
panied by increased impulsivity (i.e. inhibitory control) whereas heroin
withdrawal did not lead to changes in impulsivity (McNamara, Dalley,
Robbins, Everitt, & Belin, 2010; Winstanley et al., 2009).
Additionally, there is a body of research to support the differential
role of specific serotonin receptors in the development of psychostimulant
and opioid addiction (see Table 5.1). For example, one study investigated
the role of 5-HT3 receptors when amphetamine or morphine was self-
administered. They found that using specific 5-HT3 antagonists, ICS 205-
930 and MDL 72222, effectively eliminated morphine induced conditioned
place preference whereas they had no effect on amphetamine induced con-
ditioned placed preference (Carboni, Acquas, Leone, & Dichiara, 1989).
Another study demonstrated that heroin induced DA release in the stria-
tum was effectively inhibited when 5-HT4 antagonists, GR 125487 and
SB 204070, were administered. Interestingly, striatal dopamine release
induced by both amphetamine and cocaine were unaffected by admin-
istration of these 5-HT4 antagonists (Porras, Di Matteo, De Deurwaerdere,
Esposito, & Spampinato, 2002). This same group also elegantly demon-
strated that antagonism of 5-HT2A and 5-HT2B/2C receptors led to drug
specific changes in DA release in the nucleus accumbens and striatum.
Specifically, the administration of 5-HT2A antagonist, SR 46349B, inhibited
amphetamine induced DA release whereas it had no effect on DA release
produced by morphine. However, the 5-HT2B/2C antagonist, SB 206553, in-
hibited morphine induced DA release but failed to alter amphetamine in-
duced DA release (Porras, Di Matteo, Fracasso, et al., 2002). These studies
provide compelling evidence that disparate drugs of abuse, psychostim-
ulants and opioids, have differential relationships with the serotonergic
system. The results from the present thesis further emphasise the differ-
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5-HT Receptors in Psychostimulant and Opioid Addiction
Target Receptor: 5-HT1A Reference: Mosner et al. 1997
5-HT1A receptor agonism increased morphine but not cocaine intake
Target Receptor: 5-HT2A/2C Reference: Willins & Meltzer 1998
5-HT2A/2C receptor agonism prevented an increase in morphine but not
cocaine NAc DA release
Target Receptor: 5-HT2A, 5-HT2C/2B Reference: Porras et al. 2002(a)
5-HT2A receptor antagonism reduced amphetamine but not morphine
NAc DA release; 5-HT2C/2B antagonsim increased morphine but not
amphetamine NAc DA release
Target Receptor: 5-HT3 Reference: Carboni et al. 1989
5-HT3 receptor antagonism reduced morphine but not amphetamine
induced CPP
Target Receptor: 5-HT4 Reference: Porras et al. 2002
5-HT4 receptor antagonism reduced morphine but not amphetamine
or cocaine strital DA release
Target Receptor: 5-HT2C Reference: Schmidt et al. 1992
5-HT2C receptor antagonism attenuated MDMA induced increases in
extracellular striatal DA
Target Receptor: 5-HT2C Reference: Gudelsky et al. 1994
5-HT2C receptor agonism facilitated MDMA induced increases in ex-
tracellular striatal DA
Table 5.1: Specific 5-HT receptor interactions with psychostimulants and
opioids.
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ential role 5-HT plays in the reinforcing properties of drugs of abuse. Al-
though the previous studies focused predominantly on morphine versus
amphetamine, our experiments show that differences also exist between
heroin and MDMA. While it is well known that a genetic reduction in the
SERT leads to downregulation of 5-HT receptors most of this evidence has
come from investigation of the 5-HT1A receptor. Given that MDMA is sig-
nificantly more reinforcing for HOM and HET animals (compared to the
WT), the current results point to the crucial involvement of 5-HT and pos-
sibly specific 5-HT receptors. As discussed in previous chapters, heroin
only indirectly stimulates release of DA in the mesolimbic pathway via
inhibition of GABA interneurons. The data from Chapter 2 showed that
there were no differences between the genotypes in relation to heroin self-
administration behaviour; this suggests that the 5-HT receptors involved
in MDMA self-administration do not play an important role when her-
oin is self-administered. The crucial question is: Of the various serotonin
receptors, which ones are predominantly involved in the reinforcing prop-
erties of MDMA? At present we cannot answer this question as the role of
many of these receptors has yet to be determined. Additionally, specific
5-HT receptor downregulation in the SERT KO model has not been fully
elucidated.
Furthermore, studies to date investigating heroin addiction in humans
fail to provide a consistent account of how reduced SERT influences the
development of addictive behaviours. Some studies indicate that reduced
SERT function does indeed represent a risk factor in the development of
heroin addiction (Gerra et al., 2004; Saiz et al., 2008; Tan et al., 1999; Yang
et al., 2012); however other studies have failed to find such a relationship
(Kotler et al., 1999; T. Li et al., 2002; Saiz et al., 2009). The current data
does not provide support for this relationship; these mixed results may
reflect a variety of factors. As described in Chapter 2 there are several
potential confounding variables that may explain the disparate results in
the human data. Additionally, the parameters of the current heroin self-
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administration experiment (2 hour sessions) may have limited the scope of
responding for the drug. It is possible that with longer access to the drug a
genotype difference may have emerged; an investigation into responding
for heroin with longer access to the drug may provide a useful comparison
to the current data and elucidate a genotype effect if indeed one exists.
The BDNF gene expression analysis suggests that MDMA exposure fa-
cilitates gene expression for total BDNF and, in the current experiment, it
does so equally for the three genotypes. As described in Chapter 4 this
effect mirrors previously described research where the administration of
duloxetine led to an increase in hippocampal and prefrontal cortex BDNF
expression in both HOM and WT animals (Calabrese et al., 2010). Both du-
loxetine and MDMA target the SERT and NET but HOM and HET animals
either completely lack or have reduced SERT therefore this may suggest
an important role of the NET in the MDMA induced changes in BDNF
expression. These results are a direct contrast to the lack of effect in any
of the BDNF targets for subjects treated with heroin. Previous research
investigating the relationship between BDNF expression and opioid ad-
diction is less clear, focusing on changes associated with drug withdrawal
and craving. At this time it would be premature to conclude that heroin
does not change BDNF expression; it is possible that changes may be con-
centrated in other areas of the brain or that heroin exposure more readily
influences BDNF expression after drug abstinence. Only additional stud-
ies will effectively elucidate the relationship between heroin and BDNF
gene expression.
5.4 Limitations
While the research described in this thesis forms a coherent set of experi-
ments that can inform understanding of human drug addiction there are
some important limitations that must be acknowledged. Each behavioural
and molecular paradigm is discussed in turn followed by a discussion of
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the challenges of translating animal research to inform outcomes for hu-
mans.
5.4.1 Novelty Suppressed Feeding
It is widely accepted that the mechanisms that underlie drug addiction are
highly complex. Additionally, the high incidence of comorbidity between
drug addiction and anxiety disorders complicates studying and under-
standing this phenomenon in the laboratory. Therefore, in an effort to
tease apart the relationship between anxiety and self-administration be-
haviour subjects first completed novelty suppressed feeding to evaluate
differences in anxiety between groups. This paradigm had been used pre-
viously by colleagues who found robust and reliable results; namely, that
reduced SERT function corresponded to higher levels of anxiety (Olivier
et al., 2008). For this reason we selected it as a measure of anxiety be-
fore subjects went on to drug self-administration. Unexpectedly, we failed
to find a reliable difference in anxiety between the genotypes. As con-
sistent methodology was employed this result may reflect a degree of
natural variation between different groups of animals. Alternatively, it
may suggest that small differences in experimental variables may have
affected the measured behaviour in these particular experiments. Practi-
cally, it should be noted that a large number of subjects underwent nov-
elty suppressed feeding, self-administration surgery and testing. There-
fore, smaller groups were staggered across the process instead of taking
the entire lot through each individual step before starting the next one.
In short, when the results from the novelty suppressed feeding paradigm
were completed a large number of subjects had already undergone catheter
implantation and started self-administration testing. Therefore, while it
would have interesting to attempt another paradigm to measure anxiety it
would have been highly impractical at this stage of the experimental pro-
cedures. For these reasons a single test of anxiety was used in the current
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set of experiments.
5.4.2 Drug Self-Administration
As discussed previously, drug self-administration is a powerful tool for
evaluating drug addiction in humans and animals and is used widely in
laboratories around the world. However, it carries its own limitations.
Drug addiction, as described in the General Introduction, is currently de-
fined as a set of behaviours described in the DSM-5: namely, difficulty
limiting use of the drug, increasing motivation to acquire the drug and
lastly continued use despite negative consequences. Now the current drug
self-administration experiments demonstrated that animals were increas-
ingly motivated to acquire the drug (MDMA) as evidenced by increasing
breakpoints on a progressive ratio schedule. However, these experiments
did not model continued drug use despite negative consequences. At no
point were animals punished for their drug taking behaviour (as with a
foot shock or other aversive stimulus) and for this reason it should be
acknowledged that these experiments did not model all aspects of drug
addiction as set forth in the DSM-5. Some of these indices could be evalu-
ated using extended access sessions (6 hours) or exposure to schedules of
reinforcement where drug associated cues or stimuli are presented to the
animal (Everitt et al., 2008).
Additionally, drug self-administration experiments rarely provide an
animal with an alternative choice to the drug. This has prompted the in-
vestigation of choice within a drug self-administration experiment. Inter-
estingly, results have shown that when rats are given a choice between
cocaine and an alternative reward they seldom choose cocaine even when
the dose is increased. However, these studies did discover a small group
of rats that would forgo the alternative reward and self-administer co-
caine; these particular animals may prove to be a more accurate model
of the small group of individuals who make the transition to addiction
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(Ahmed, 2012). Considering that drug self-administration in the labora-
tory is meant to mirror drug self-administration in humans it should re-
flect the fact that humans often face a variety of choices when it comes
to drug taking. Therefore, this aspect of drug self-administration cannot
be ignored and should be incorporated into laboratory paradigms of drug
self-administration.
Also, it should be noted that the current MDMA and heroin self-admini-
stration experiments in the SERT KO rat model are some of the first of
their kind. While the results reported in this thesis are compelling they are
far from complete. As such it will be imperative to incorporate a full set
of dose response curves into future drug self-administration experiments.
This will help to elucidate the specific effects of dose and how they relate
to the reinforcing properties of these drugs of abuse.
Lastly, there is increasing discussion regarding the use of both male
and female subjects to study a variety of psychiatric illness, including drug
addiction, in the laboratory. Before the current set of experiments was un-
dertaken a pilot study was conducted by our group to evaluate MDMA
self-adminstration in HOM and WT subjects (Oakly et al., 2014). Initially,
we wanted to compare our results with those from another group that has
been intensively studying MDMA self-administration in male Sprague-
Dawley rats (Schenk, 2009, 2011). To make the direct comparison we used
male subjects and found that the HOM animals were significantly more
sensitive to the effects of MDMA compared to the WT. Moving forward,
we began the set of experiments outlined in this thesis. As a small labo-
ratory we maintain our own breeding colony and at the time were strug-
gling to produced a sufficient number of male subjects for each genotype.
For this reason an MDMA self-administration experiment with HOM and
HET subjects (both male and female) was undertaken. Surgical proce-
dures commenced and when subjects had recovered they began MDMA
self-administration. On their first day in the self-administration chamber
three females rapidly administered 30+ infusions within the first twenty
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minutes of the session. Considering these subjects had no prior experi-
ence with MDMA such a large amount administered so quickly was lethal.
This effect was not seen in any of the males in this experiment. It was de-
cided that it would be unethical to subject the remaining female subjects to
a potential drug overdose and therefore the experiment was terminated.
From there animals were bred until there was a sufficient number of male
subjects for each genotype.
5.4.3 Locomotor Activity
Drug influenced locomotion is an important adjunct to drug self-administ-
ration experiments. Locomotor activity is a relatively straightforward way
to quantify levels of activity after drug exposure. For example, heroin is
classified as a narcotic and produces drowsiness after consumption. High
levels of sedation could run counter to and prevent drug self-administrati-
on behaviour (lever pressing) and therefore it was important to evalu-
ate levels of locomotor activity under a variety of heroin doses. In this
way the heroin locomotor activity experiments demonstrated that across
genotypes animals demonstrated largely stable levels of locomotor activ-
ity. Therefore, while heroin can produce sedation this was not the rea-
son for reduced drug self-administration behaviour compared to that seen
with MDMA.
MDMA induced locomotion highlighted the fact that not all drugs of
abuse produce the same pattern of locomotor activity. That is, drugs of
abuse lead to a common downstream effect, dopamine release and this
dopaminergic activity is thought to underlie the reinforcing effects of drugs
of abuse as well as locomotor activity. Interestingly, according to the cur-
rent data MDMA induced locomotor activity is not driven by dopamin-
ergic activity but is much more contingent upon 5-HT release. For this
reason utilising locomotor activity as a measure of the reinforcing proper-
ties of drugs like MDMA may not be accurate.
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5.4.4 Conditioned Taste Aversion
Traditionally, conditioned taste aversion has been used to evaluate the
negative consequences of drugs of abuse. This idea was initially posited
when conditioned taste aversion was demonstrated in animals; specifi-
cally, drugs that were readily self-administered also caused conditioned
taste aversion and this suggested that drugs of abuse may have both pos-
itive and negative properties (Hunt & Amit, 1987). In the current experi-
ments conditioned taste aversion developed after sucrose was paired with
MDMA and while it would fit with some historical data suggesting that
the negative properties of MDMA were driving the effect there is addi-
tional research to suggest an alternative explanation. There is growing
support for the idea that conditioned taste aversion does not reflect the
negative properties of drugs of abuse but rather the positive, reinforcing
properties (Grigson, 1997). Proponents of this revised theory suggest that
the decreased consumption of the palatable solution is due to the fact that
the powerful reinforcing effects of the drug outweigh, effectively devalue,
the desirability of this natural reinforcer. It is this devaluation of the palat-
able solution that drives decreased consumption; in contrast to the highly
desirable drug effect the gustatory reward is greatly diminished.
Other researchers have argued that reduced consumption of the palat-
able solution merely reflects an uncertainty where an animal associates
the drug effect, a change the normal physiological state, with the palat-
able solution. Since avoiding ingestion of potential toxins lies at the core
of conditioned taste aversion it follows that a fluctuation in the normal
physiological state may be interpreted as a toxin and therefore becomes
associated with the palatable solution (Lin, Arthurs, & Reilly, 2014).
If these explanations are accurate the current MDMA conditioned taste
aversion results suggest that the positive, reinforcing properties of MDMA
devalue the palatable solution and this is evidenced by reduced sucrose
consumption. Alternatively, the MDMA drug effects may have been in-
terpreted as a potential toxin, whether they were or not, and conditioned
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taste aversion developed in an effort to avoid this potentially harmful sub-
stance.
Considering the current heroin conditioned taste aversion data the afor-
ementioned explanations fail to account for the lack of affect when heroin
was paired with the sucrose solution. If the devaluation hypothesis was
correct then the powerful reinforcing properties of heroin would be ex-
pected to unequivocally inhibit sucrose consumption. Considering there
was no effect, not even a trend, for either drug dose this argues against
the devaluation hypothesis. Additionally, the idea that changes in the
physiological state may be enough to elicit a conditioned taste aversion
does not provide a compelling explanation for the current data. If this
idea were correct it would be expected that the heroin induced physio-
logical change, that may be considerably stronger than that of MDMA,
would have caused a marked decrease in sucrose consumption. Consid-
ering the current data and the ongoing debate that surrounds conditioned
taste aversion it is obvious that additional research is needed to fully un-
derstand the mechanism driving this behavioural phenomenon.
5.4.5 Quantitative Reverse Transcription Polymerase Chain
Reaction
Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
has become the “go-to” technique for evaluating gene expression and has
significant advantages. Most notably qRT-PCR is a sensitive technique and
can be used to quantify relatively small amounts of RNA in a sample. Ad-
ditionally, qRT-PCR has high throughput where multiple samples can be
processed simultaneously as well as the evaluation of multiple genes in a
single sample. With this said qRT-PCR also has some limitations that must
be addressed. One potential pitfall lies in the amplification process; that
is, each cycle produces a doubling of amplification products. If a portion
of these products are erroneous (e.g. genomic DNA) this will lead to mul-
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tifold amplification of errors which will add large variability to a sample
and make interpretation difficult (Zimmermann & Mannhalter, 1996).
More specifically, the reverse transcription portion of a qRT-PCR exper-
iment has the potential to increase variability. This is due to the sensitivity
of the reverse transcriptase enzyme; it can be influenced by even small
amounts of salt, alcohol and/or phenol leading to varying efficiency in
the reverse transcription reaction. It is for this reason that precise RNA
isolation is absolutely essential; clean RNA will ensure higher efficiency
when reverse transcribed into the cDNA template (Freeman, Walker, &
Vrana, 1999).
Lastly, the qRT-PCR experiments described in this thesis focus on brain
tissue taken from the striatum. The entire structure was excised and pro-
cessed due to a small degree of variability/imprecision in the slicing tech-
nique. As discussed in the General Introduction there are important func-
tional differences within the various portions of the striatum; for example,
habitual drug taking is accompanied by a ventral to dorsal and then a
dorsomedial to dorsolateral shift. Therefore, in subsequent experiments it
would be prudent to implement a different slicing technique where indi-
vidual subsections could be isolated.
5.4.6 Translating Animal Outcomes to Humans
An inherent limitation to the whole of this thesis is the fact that all ex-
periments were performed in animals with a goal to inform human drug
addiction. It must be acknowledged that animal models, at their core, are
approximations of pathophysiology that is seen in humans and for this
reason interpreting these data and what they may mean for human drug
addiction must be done with caution (Ahmed, 2010; McGonigle & Rug-
geri, 2014).
With that said animal models can be powerful tools for the systematic
study of behavioural and neurochemical changes in the laboratory. It is
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for this reason that we chose to utilise the SERT KO rat model to ask spe-
cific questions regarding genetic risk and drug addiction. Considering the
complex interplay of changes in behaviour and the brain that accompany
drug addiction it would have been impossible to conduct these experi-
ments in vitro or using non-biological methods like computer modelling.
While non animal alternatives are being developed for many types of lab-
oratory research none have been developed to date that would entirely
replace the use of an animal model for the suite of experiments described
in this thesis.
5.5 Future Directions
This thesis set out to ask and answer several questions regarding genetic
risk and drug addiction. While the results as a whole will serve to inform
the body of research regarding drug addiction they also beg several ad-
ditional questions. Therefore, the following sections outline several ideas
for future research questions and how to go about answering them.
5.5.1 Microdialysis and In Vivo Voltammetry
The SERT KO rat model is a relatively new tool for investigating the in-
fluence of genetic risk on the development of drug addiction. While there
is ongoing research to understand the complete behavioural and neuro-
chemical profile of this particular model there are still questions to be
answered. Recent research has evaluated DA and 5-HT release in target
brain structures after administration of cocaine and found that DA re-
lease was largely similar in HOM and WT animals (Verheij et al., 2014).
Moving forward it would prove useful to directly measure extracellular
concentrations of both 5-HT and DA after MDMA self-administration us-
ing microdialysis and high performance liquid chromatography (HPLC)
(Benveniste & Httemeier, 1990; Ungerstedt, 1991). Initially, we had hy-
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pothesised that animals with reduced SERT function may have a sensi-
tised dopaminergic system however we were unable to definitively as-
certain if this were true. Measuring DA and 5-HT release may provide
insight into the complex relationship of these two neurotransmitter sys-
tems and how they interact when a drug like MDMA is administered. It
should be noted that microdialysis measures changes in analytes (chem-
ical constituents) over several minutes; therefore, this technique may not
provide the resolution necessary to detect small changes that likely occur
after exposure to a drug. To better investigate small changes in neurotrans-
mitter levels a technique with more precise sampling may be useful. One
such technique, in vivo voltammetry, provides a measure of neurotrans-
mitter concentration by quantifying molecule oxidation near an inserted
electrode (Greco & Garris, 2003; Justice, Michael, & Neill, 1985; Salvatore,
Hoffman, Burmeister, & Gerhardt, 2003). Measurements taken from in
vivo voltammetry describe rapidly changing neurotransmitter levels and
may provide insight into the complex, transient changes that occur when
a drug of abuse is applied to the system.
5.5.2 Ambiguous Cue Interpretation
Considering the discussion of locomotor activity and conditioned taste
aversion given above it is clear that further investigation into the positive
and negative properties of drugs of abuse is needed. To this end a new be-
havioural paradigm, ambiguous cue interpretation, has been developed;
this test provides an opportunity to investigate the positive and negative
effects of drugs of abuse simultaneously. That is, rats are trained to press a
lever when they hear a specific tone to receive a food reward; additionally,
they are also trained to press a lever when they hear a different tone in or-
der to avoid a foot shock. After training to a level of stable responding rats
are presented with an intermediate tone; responding on one lever or the
other would indicate that the rat perceives the ambiguous tone as a posi-
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tive or negative event (Enkel et al., 2010; Papciak, Popik, Fuchs, & Rygula,
2013). It is suggested that this procedure could be utilised to evaluate the
positive and negative effects of drugs of abuse; after drug treatment rats
could then “self-report” by selecting the lever that most closely matches
the drug effect they experience.
5.5.3 Emulsion PCR
As discussed above a potential limitation of qRT-PCR is the precision in
quantifying amplification products. This is particularly problematic when
there are very small amounts of the target gene in a selected sample; re-
sulting CT values will often approach the maximum number of cycles in
the reaction. It is in these last few cycles where amplification of errors
would be most exaggerated. To increase precision particularly when sam-
ples contain very few target sequences methods beyond qRT-PCR must be
utilised. There is growing support for a technique called emulsion poly-
merase chain reaction (ePCR). Recently developed, ePCR allows for ab-
solute quantification of amplification products; using PCR amplification
on individual water-in-oil droplets allows for high precision in detecting
whether a target sequence is present in a sample or not (Williams et al.,
2006; Zhu et al., 2012). ePCR provides a useful and increasingly elegant
alternative to qRT-PCR for evaluating target gene expression.
5.6 Final Conclusion
The current body of work set out to address this question: Is the serotonin
transporter a risk factor in the development of drug addiction? Consider-
ing the data gleaned from this series of behavioural and molecular experi-
ments it is clear that to fully answer this question additional research must
be undetaken. Limitations of the current research have been acknowl-
edged and discussed above; additionally, ideas for future research have
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also been outlined. However, it is insufficient to conclude that the current
work cannot be interpreted and would only be valid with additional ex-
perimental data sets. Therefore, a preliminary conclusion is provided for
consideration and is based solely on the data presented in this thesis. The
combined results point to a potentially compelling relationship between
the serotonin transporter and specific drugs of abuse that target this pro-
tein. In the end, the scientific community is trying to understanding why
some individuals become addicted to drugs of abuse whereas others do
not. While it is readily ackowledged that this is no simple line of inquiry
new data like what is presented in this thesis can provide a fundamen-
tal, essential foundation for the research that will ultimately answer this
question.
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Appendix A
Supplemental qRT-PCR Analysis
Supplemental information for the qRT-PCR experiments described in Chap-
ter 4 is given in this Appendix.
• Section 1: Housekeeping Genes
• Section 2: Total BDNF
• Section 3: BDNF transcript III
• Section 4: BDNF transcript IV
• Section 5: BDNF transcript VI
• Section 6: BDNF transcript IXa
A.1 Section 1: Housekeeping Genes
Relative expression of HPRT against Cyclophilin A is described in Chapter
4. ∆CT values were calculated for each sample (∆CT = (CT HPRT) - (CT
Cyc A)) (see Figure A.1). Each ∆CT value was converted into the negative
binary log (2−∆CT) (see Figure A.2). Raw datum values are given in Tables
A.1, A.2 and A.3.
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Figure A.1: ∆CT values for HPRT against Cyc A across treatment groups
and genotypes.
Figure A.2: 2−∆CT values for HPRT against Cyc A across treatment groups
and genotypes.
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HOM
Clean
Animal HPRT CT Cyc A CT ∆CT 2−∆CT
117 23.23 28.23 -5 32
119 23.07 27.46 -4.39 20.97
122 23.7 28.18 -4.48 22.32
123 22.72 26.98 -4.26 19.16
121 23.65 27.51 -3.86 14.52
MDMA
Animal HPRT CT Cyc A CT ∆CT 2−∆CT
210 22.43 25.77 -3.34 10.13
223REP 22.43 26.78 -4.36 20.46
249REP 23.14 27.43 -4.29 19.56
415 23.09 27.44 -4.35 20.39
423 21.66 25.94 -4.28 19.43
Heroin
Animal HPRT CT Cyc A CT ∆CT 2−∆CT
710 22.07 25.12 -3.05 8.28
719 22.74 26.3 -3.56 11.79
720 22.99 25.79 -2.8 6.96
742REP 21.11 25.08 -3.97 15.67
Table A.1: Comparison of housekeeping gene expression: HOM subjects
across treatment groups.
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HET
Clean
Animal HPRT CT Cyc A CT ∆CT 2−∆CT
110 24.34 30.74 -6.4 84.45
111 23.09 27.45 -4.36 20.53
112 21.97 26.33 -4.36 20.55
114 22.25 26.2 -3.95 15.45
116 22.76 26.28 -3.52 11.47
MDMA
Animal HPRT CT Cyc A CT ∆CT 2−∆CT
217 22.82 26.83 -4.01 16.11
231 21.78 25.36 -3.58 11.96
232 22.83 27.23 -4.4 21.11
246 21.62 26.5 -4.88 29.45
247 24.3 31.05 -6.75 107.63
Heroin
Animal HPRT CT Cyc A CT ∆CT 2−∆CT
704 23.75 26.43 -2.68 6.41
715 22.69 25.78 -3.09 8.51
723 23.97 28.25 -4.28 19.43
732 21.92 24.97 -3.05 8.28
733 23.44 26.18 -2.74 6.68
Table A.2: Comparison of housekeeping gene expression: HET subjects
across treatment groups.
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WT
Clean
Animal HPRT CT Cyc A CT ∆CT 2−∆CT
102 22.33 28.83 -6.5 90.51
103 22.79 27.5 -4.71 26.17
104 21.59 25.59 -4 16
106 23.09 26.67 -3.58 11.96
108REP 21.99 26.42 -4.44 21.63
MDMA
Animal HPRT CT Cyc A CT ∆CT 2−∆CT
203 23.04 30.03 -6.99 127.12
216 23.31 29.01 -5.7 51.98
240 23.44 29.09 -5.65 50.21
401 21.93 26.52 -4.59 24.08
417 23.12 27.41 -4.29 19.56
Heroin
Animal HPRT CT Cyc A CT ∆CT 2−∆CT
701 23.78 27.39 -3.61 12.21
711 22.29 25.26 -2.97 7.84
721 22.51 26.69 -4.18 18.13
730 22.43 26.32 -3.89 14.83
739 22.81 26.76 -3.96 15.51
Table A.3: Comparison of housekeeping gene expression: WT subjects
across treatment groups.
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A.2 Section 2: Total BDNF
Relative expression of total BDNF (against Cyclophilin A and HPRT) was
described in Chapter 4.
• ∆CT values were calculated for each sample against Cyclophilin A,
(∆CT = (CT total BDNF) - (CT Cyc A)) (see Figure A.3), and HPRT
(∆CT = (CT total BDNF) - (CT HPRT)) (see Figure A.4); raw datum
values are given in Table A.4.
• Each ∆CT value was converted into the negative binary log (2−∆CT)
(see Figures A.5 and A.6); raw datum values are given in Table A.5.
Figure A.3: ∆CT values for total BDNF against Cyc A.
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Cyclophilin A
Clean
HOM HET WT
1.57 2.41 1.69
1.84 2.67 -0.24
1.38 3.28 4.49
3.99 -1.36 1.66
1.68 2.04 2.51
MDMA
HOM HET WT
-2.59 1.1 -4.93
-2.06 1.5 -3.67
1.23 -3.15 -2.83
-2.93 -2.17 -1.84
2.24 -3.43 -3.18
Heroin
HOM HET WT
2.79 -2.79 -2.90
3.29 3.63 4.07
-0.14 2.22 0.9
1.15 4.00 0.34
- 0.93 2.59
(a)
HPRT
Clean
HOM HET WT
5.43 6.36 6.39
6.83 7.04 6.26
5.65 6.8 8.08
8.39 5.04 5.67
6.16 6.4 6.94
MDMA
HOM HET WT
1.69 4.68 0.77
2.30 5.51 1.99
4.57 1.26 1.46
1.42 4.59 5.15
6.52 1.45 1.42
Heroin
HOM HET WT
6.35 1.49 1.06
7.26 6.31 7.68
2.91 5.32 3.87
3.95 6.73 4.23
- 3.98 6.77
(b)
Table A.4: ∆CT values for total BDNF against Cyclophilin A (a) and HPRT
(b).
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Figure A.4: ∆CT values for total BDNF against HPRT.
Figure A.5: 2−∆CT values for total BDNF against Cyclophilin A.
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Cyclophilin A
Clean
HOM HET WT
-2.96 -5.31 -3.22
-3.57 -6.34 1.18
-2.60 -9.71 -22.47
-15.90 2.57 -3.16
-3.20 -4.11 -5.68
MDMA
HOM HET WT
6.02 -2.14 30.48
4.17 -2.83 12.73
-2.34 8.88 7.11
7.62 4.50 3.58
-4.71 10.78 9.03
Heroin
HOM HET WT
-6.92 6.92 7.44
-9.75 -12.38 -16.74
1.10 -4.66 -1.87
-2.22 -15.94 -1.27
- -1.90 -6.00
(a)
HPRT
Clean
HOM HET WT
-42.96 -82.14 -83.87
-113.77 -131.60 -76.64
-50.04 -111.43 -269.66
-334.30 -32.90 -50.74
-71.51 -84.45 -122.79
MDMA
HOM HET WT
-3.22 -25.55 -1.70
-4.91 -45.41 -3.96
-23.67 -2.39 -2.75
-2.67 -24.00 -35.51
-91.77 -2.72 -2.68
Heroin
HOM HET WT
-81.29 -2.80 -2.08
-152.75 -79.34 -205.07
-7.52 -39.81 -14.62
-15.45 -106.15 -18.77
- -15.78 -108.76
(b)
Table A.5: 2−∆CT values for total BDNF against Cyclophilin A (a) and
HPRT (b).
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Figure A.6: 2−∆CT values for total BDNF against HPRT.
A.3 Section 3: BDNF Transcript III
Relative expression of BDNF transcript III (against Cyclophilin A and HPRT)
was described in Chapter 4.
• ∆CT values were calculated for each sample (∆CT = (CT BDNF III) -
(CT Cyc A)) (see Figure A.7), and (∆CT = (CT BDNF III) - (CT HPRT))
(see Figure A.8); raw datum values are given in Table A.6.
• Each ∆CT value was converted into the negative binary log (2−∆CT)
(see Figures A.9 and A.10); raw datum values are given in Table A.7.
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Figure A.7: ∆CT values for BDNF transcript III against Cyc A.
Figure A.8: ∆CT values for BDNF transcript III against HPRT.
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Cyclophilin A
Clean
HOM HET WT
6.27 7.16 7.15
6.58 7.29 5.76
6.55 8.06 9.59
9.84 3.78 6.50
6.25 6.99 7.16
MDMA
HOM HET WT
1.85 5.78 -0.8
1.91 5.88 0.35
6.07 0.86 1.83
1.91 2.35 2.68
7.35 0.50 1.54
Heroin
HOM HET WT
7.07 1.35 1.23
7.66 8.32 9.05
4.12 6.21 4.96
5.58 8.36 4.56
- 5.19 7.36
(a)
HPRT
Clean
HOM HET WT
10.13 11.11 11.85
11.58 11.67 12.26
10.81 11.58 13.17
14.24 10.18 10.5
10.73 11.35 11.59
MDMA
HOM HET WT
6.12 9.35 4.9
6.26 9.88 6.01
9.41 5.26 6.12
6.26 9.1 3.71
11.64 5.37 6.13
Heroin
HOM HET WT
10.62 5.62 5.18
11.63 11 12.66
7.17 9.31 7.93
8.38 11.09 8.45
- 8.25 11.54
(b)
Table A.6: ∆CT values for BDNF transcript III against Cyclophilin A (a)
and HPRT (b).
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Figure A.9: 2−∆CT values for BDNF transcript III against Cyc A.
Figure A.10: 2−∆CT values for BDNF transcript III against HPRT.
146 APPENDIX A. SUPPLEMENTAL QRT-PCR ANALYSIS
Cyclophilin A
Clean
HOM HET WT
-76.90 -142.52 -141.53
-95.67 -156.50 -54.19
-93.38 -265.95 -768.02
-916.51 -13.74 -90.20
-75.85 -127.12 -142.52
MDMA
HOM HET WT
-3.59 -54.76 1.74
-3.75 -58.69 -1.27
-66.95 -1.81 -3.54
-3.76 -5.08 -6.41
-163.14 -1.41 -2.90
Heroin
HOM HET WT
-133.90 -2.54 -2.34
-201.55 -319.57 -528.22
-17.39 -74.03 -31.02
-47.84 -327.42 -23.59
- -36.50 -163.71
(a)
HPRT
Clean
HOM HET WT
-1116.68 -2202.61 -3691.52
-3050.86 -3247.24 -4904.87
-1795.29 -3050.86 -9216.48
-19282.44 -1160.07 -1448.15
-1692.57 -2610.30 -3082.75
MDMA
HOM HET WT
-69.55 -652.58 -29.75
-76.64 -942.27 -64.22
-677.93 -38.32 -69.31
-76.37 -548.75 -13.04
-3180.42 -41.36 -70.03
Heroin
HOM HET WT
-1573.76 -49.18 -36.13
-3158.45 -2048 -6472.02
-143.51 -632.53 -243.03
-333.14 -2179.83 -349.71
- -303.38 -2967.43
(b)
Table A.7: 2−∆CT values for BDNF transcript III against Cyclophilin A (a)
and HPRT (b).
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A.4 Section 4: BDNF Transcript IV
Relative expression of BDNF transcript IV (against Cyclophilin A and HPRT)
was described in Chapter 4.
• ∆CT values were calculated for each sample (∆CT = (CT BDNF IV) -
(CT Cyc A)) (see Figure A.11), and (∆CT = (CT BDNF IV) - (CT HPRT))
(see Figure A.12); raw datum values are given in Table A.8.
• Each ∆CT value was converted into the negative binary log (2−∆CT)
(see Figures A.13 and A.14); raw datum values are given in Table
A.9.
Figure A.11: ∆CT values for BDNF transcript IV against Cyc A.
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Cyclophilin A
Clean
HOM HET WT
9.38 7.93 7.2
9.31 8.28 6.34
8.58 11.19 11.54
12.31 9.3 8.51
9.9 10.21 9.79
MDMA
HOM HET WT
1.4 5.3 -0.72
2.57 5.87 0.35
6.17 1.88 2.28
1.74 3.81 4.26
6.07 0.62 1.14
Heroin
HOM HET WT
10.01 6.07 5.02
11.57 11.42 11.89
6.26 9.21 8.07
8.58 11.05 11.51
- 7.68 10.09
(a)
HPRT
Clean
HOM HET WT
13.24 11.88 11.91
14.3 12.66 12.84
12.84 14.71 15.12
16.71 15.7 12.52
14.38 14.57 14.22
MDMA
HOM HET WT
5.68 8.88 4.98
6.92 9.87 6.01
9.51 6.29 6.57
6.08 10.57 11.25
10.35 5.49 5.73
Heroin
HOM HET WT
13.57 10.35 8.97
15.54 14.1 15.51
9.31 12.3 11.04
11.38 13.79 15.4
- 10.74 14.27
(b)
Table A.8: ∆CT values for BDNF transcript IV against Cyclophilin A (a)
and HPRT (b).
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Figure A.12: ∆CT values for BDNF transcript IV against HPRT.
Figure A.13: 2−∆CT values for BDNF transcript IV against Cyc A.
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Cyclophilin A
Clean
HOM HET WT
-666.29 -243.03 -147.03
-632.53 -310.83 -81.01
-381.36 -2328.20 -2967.43
-5077.84 -628.17 -364.56
-955.43 -1184.45 -882.22
MDMA
HOM HET WT
-2.64 -39.4 1.64
-5.92 -58.28 -1.27
-71.75 -3.68 -4.86
-3.33 -14.03 -19.16
-66.95 -1.53 -2.2
Heroin
HOM HET WT
-1031.12 -67.18 -32.45
-3029.79 -2730.6 -3795.30
-76.64 -590.18 -267.8
-382.68 -2120.22 -2916.45
- -205.07 -1086.14
(a)
HPRT
Clean
HOM HET WT
-9674.69 -3756.05 -3834.97
-20171.07 -6449.63 -7332.05
-7332.05 -26708.29 -35610.13
-106833.16 -53047.61 -5853.16
-21321.18 -24322.43 -19083
MDMA
HOM HET WT
-51.09 -469.51 -31.56
-121.1 -935.76 -64.22
-726.59 -77.98 -95.01
-67.65 -1514.89 -2435.5
-1305.15 -44.94 -53.08
Heroin
HOM HET WT
-12119.14 -1300.63 -501.46
-47478.94 -17499.18 -46501.83
-632.53 -5042.77 -2098.29
-2665.15 -14115.57 -43237.64
- -1704.34 -19687.61
(b)
Table A.9: 2−∆CT values for BDNF transcript IV against Cyclophilin A (a)
and HPRT (b).
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Figure A.14: 2−∆CT values for BDNF transcript IV against HPRT.
A.5 Section 5: BDNF Transcript VI
Relative expression of BDNF transcript VI (against Cyclophilin A and HPRT)
was described in Chapter 4.
• ∆CT values were calculated for each sample (∆CT = (CT BDNF VI) -
(CT Cyc A)) (see Figure A.15), and (∆CT = (CT BDNF VI) - (CT HPRT))
(see Figure A.16); raw datum values are given in Table A.10.
• Each ∆CT value was converted into the negative binary log (2−∆CT)
(see Figures A.17 and A.18); raw datum values are given in Table
A.11.
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Figure A.15: ∆CT values for BDNF transcript VI against Cyc A.
Figure A.16: ∆CT values for BDNF transcript VI against HPRT.
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Cyclophilin A
Clean
HOM HET WT
6.71 6.21 5.65
6.51 7.01 4.04
6.28 8.1 9.07
8.22 4.79 6.26
6.01 6.25 8.53
MDMA
HOM HET WT
2.84 6.8 7.23
5.47 8.74 7.99
8.98 4.15 5.71
5.37 9.52 8.72
10.98 4.53 4.81
Heroin
HOM HET WT
7.13 1.23 1.6
8.64 8.03 8.19
4.74 7.00 5.8
6.2 8.79 5.11
- 5.3 7.92
(a)
HPRT
Clean
HOM HET WT
10.57 10.16 10.36
11.51 11.39 10.54
10.54 11.62 12.66
12.61 11.19 10.26
10.49 10.61 12.96
MDMA
HOM HET WT
7.12 10.38 12.92
9.82 12.74 13.65
12.32 8.56 10.00
9.71 16.27 15.71
15.27 9.4 9.4
Heroin
HOM HET WT
10.69 5.51 5.55
12.61 10.71 11.81
7.78 10.09 8.77
9.00 11.52 9.00
- 8.36 12.10
(b)
Table A.10: ∆CT values for BDNF transcript VI against Cyclophilin A (a)
and HPRT (b).
154 APPENDIX A. SUPPLEMENTAL QRT-PCR ANALYSIS
Figure A.17: 2−∆CT values for BDNF transcript VI against Cyc A.
Figure A.18: 2−∆CT values for BDNF transcript VI against HPRT.
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Cyclophilin A
Clean
HOM HET WT
-104.33 -73.77 -50.21
-91.14 -128.89 -16.39
-77.44 -273.42 -537.45
-297.14 -27.57 -76.37
-64.22 -76.11 -368.37
MDMA
HOM HET WT
-7.16 -111.43 -149.60
-44.17 -426.09 -254.23
-503.20 -17.75 -52.35
-41.21 -731.64 -421.68
-2019.80 -23.023 -27.95
Heroin
HOM HET WT
-140.07 -2.35 -3.03
-397.55 -261.38 -292.04
-26.63 -127.56 -55.52
-73.26 -441.11 -34.42
- -39.4 -241.35
(a)
HPRT
Clean
HOM HET WT
-1514.89 -1140.14 -1309.68
-2906.36 -2674.40 -1483.72
-1488.87 -3136.63 -6449.63
-6251.56 -2328.20 -1226.22
-1433.18 -1562.89 -7967.99
MDMA
HOM HET WT
-138.62 -1327.96 -7750.10
-903.89 -6841.04 -12810.15
-5095.47 -376.11 -1024
-837.53 -79023.82 -53602.03
-39375.21 -675.59 -675.59
Heroin
HOM HET WT
-1646.29 -45.41 -46.85
-6229.93 -1675.06 -3578.15
-219.79 -1089.92 -435.04
-510.23 -2936.74 -510.23
- -327.42 -4374.8
(b)
Table A.11: 2−∆CT values for BDNF transcript VI against Cyclophilin A (a)
and HPRT (b).
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A.6 Section 6: BDNF Transcript IXa
Relative expression of BDNF transcript IXa (against Cyclophilin A and
HPRT) was described in Chapter 4.
• ∆CT values were calculated for each sample (∆CT = (CT BDNF IXa)
- (CT Cyc A)) (see Figure A.19), and (∆CT = (CT BDNF IXa) - (CT
HPRT)) (see Figure A.20); raw datum values are given in Table A.12.
• Each ∆CT value was converted into the negative binary log (2−∆CT)
(see Figures A.21 and A.22); raw datum values are given in Table
A.13.
Figure A.19: ∆CT values for BDNF transcript IXa against Cyc A.
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Cyclophilin A
Clean
HOM HET WT
9.26 10.51 8.63
8.80 9.52 6.21
8.84 10.48 12.33
12.01 9.05 9.3
9.02 11.27 8.82
MDMA
HOM HET WT
7.1 10.82 7.47
8.92 10.90 5.94
10.16 7.09 8.13
8.38 8.81 8.58
10.28 5.93 7.48
Heroin
HOM HET WT
10.18 7.47 7.42
12.56 12.00 11.95
9.83 12.92 9.87
9.89 12.01 8.3
- 9.5 12.25
(a)
HPRT
Clean
HOM HET WT
13.12 14.46 13.34
13.79 13.89 12.71
13.1 14.00 15.92
16.41 15.45 13.31
13.50 15.63 13.25
MDMA
HOM HET WT
11.38 14.39 13.16
13.28 14.9 11.6
13.5 11.5 12.42
12.72 15.56 15.57
14.57 10.8 12.08
Heroin
HOM HET WT
13.74 11.74 11.37
16.53 14.68 15.57
12.87 16.02 12.84
12.69 14.75 12.19
- 12.56 16.43
(b)
Table A.12: ∆CT values for BDNF transcript IXa against Cyclophilin A (a)
and HPRT (b).
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Figure A.20: ∆CT values for BDNF transcript IXa against HPRT.
Figure A.21: 2−∆CT values for BDNF transcript IXa against Cyc A.
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Cyclophilin A
Clean
HOM HET WT
-610.99 -1458.23 -396.18
-444.18 -731.64 -73.77
-456.67 -1423.28 -5148.73
-4124.49 -530.06 -630.35
-517.35 -2469.49 -450.38
MDMA
HOM HET WT
-137.19 -1801.52 -176.68
-484.38 -1904.24 -61.39
-1140.14 -136.24 -279.17
-332 -447.27 -381.36
-1243.34 -60.76 -178.53
Heroin
HOM HET WT
-1160.07 -176.68 -171.25
-6038.61 -4081.83 -3956.48
-907.03 -7750.10 -932.53
-945.54 -4124.49 -315.17
- -724.08 -4854.14
(a)
HPRT
Clean
HOM HET WT
-8871.73 -22536.88 -10333.20
-14164.58 -15181.22 -6677.07
-8779.97 -16327.32 -61786.33
-86775.49 -44762.41 -10120.55
-11545.16 -50710.61 -9741.98
MDMA
HOM HET WT
-2655.93 -21469.49 -9152.82
-9912.27 -30573.63 -3093.45
-11545.16 -2886.29 -5461.19
-6746.86 -48308.85 -48476.57
-24238.28 -1782.89 -4314.57
Heroin
HOM HET WT
-13634.74 -3420.52 -2646.74
-94629.34 -26158.64 -48476.57
-7486.10 -66220.95 -7306.68
-6585.15 -27459.16 -4672.57
- -6017.71 -87986.83
(b)
Table A.13: Converted 2−∆CT values for BDNF transcript IXa against Cy-
clophilin A (a) and HPRT (b).
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Figure A.22: 2−∆CT values for BDNF transcript IXa against HPRT.
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